Fortress Biotech (FBIO) 10-K 16 Mar 18 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 13, 2018	Jun. 30, 2017
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Entity Registrant Name	Fortress Biotech, Inc.
Entity Central Index Key	1,429,260
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 144,508,462
Trading Symbol	FBIO
Entity Common Stock, Shares Outstanding		51,342,513

Consolidated Balance Sheets

Consolidated Balance Sheets $ in Thousands, € in Millions	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)
Current assets
Cash and cash equivalents	$ 113,915	$ 88,294
Accounts receivable	7,758	1,830
Short-term investments (certificates of deposit)	36,002	0
Cash deposits with clearing organizations	1,041	1,030
Receivables from broker-dealers and clearing organizations	7,395	3,357
Forgivable loans receivable	1,616	1,712
Securities owned, at fair value	1,985	2,357
Inventory	171	203
Other receivables - related party	618	1,790
Prepaid expenses and other current assets	12,680	9,061
Total current assets	183,181	109,634
Property and equipment, net	9,513	7,376
Restricted cash	17,387	15,860
Long-term investments, at fair value	1,390	1,414
Intangible assets	15,223	17,408
Goodwill	18,645	18,645
Other assets	611	394
Total assets	245,950	170,731
Current liabilities
Accounts payable and accrued expenses	36,127	24,295
Accounts payable and accrued expenses - related party	222	0
Accrued commissions and payroll payable	10,065	11,940
Deferred clearing and marketing credits	786	995
Securities sold, not yet purchased, at fair value	151	298
Warrants issued in 2017 and issuable in 2016 - National	5,597	14,359
Interest payable	315	88
Interest payable - related party	669	77
Notes payable, short-term (net of debt discount of $973 and $0 at December 31, 2017 and December 31, 2016, respectively)	8,528	1,000
Subsidiary convertible note, short-term, at fair value	4,700	1,031
Contingently issuable liabilities	0	1,682
Derivative warrant liability	87	481
Other current liabilities	181	319
Total current liabilities	67,428	56,565
Notes payable, long-term (net of debt discount of $62 and $2,009 at December 31, 2017 and December 31, 2016, respectively)	43,222	22,528
Subsidiary convertible note, long-term, at fair value	10,059	3,656
Other long-term liabilities	4,739	5,014
Total liabilities	125,448	87,763
Commitments and contingencies
Stockholders' equity
Preferred stock, $.001 par value, 15,000,000 authorized, 5,000,000 designated Series A shares 1,000,000 and 0 shares issued and outstanding as of December 31, 2017 and December 31, 2016, respectively	1	0
Common Stock, $.001 par value, 100,000,000 shares authorized, 50,991,285 and 48,932,023 shares issued and outstanding as of December 31, 2017 and December 31, 2016, respectively	51	49
Common stock issuable, 158,015 and 0 shares as of December 31, 2017 and December 31, 2016, respectively	500	0
Additional paid-in-capital	364,148	283,697
Accumulated deficit	(312,127)	(245,251)
Total stockholders' equity attributed to the Company	52,573	38,495
Non-controlling interests	67,929	44,473
Total stockholders' equity	120,502	82,968
Total liabilities and stockholders' equity	$ 245,950	$ 170,731

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument, Unamortized Discount, Current	$ 973	$ 0
Debt Instrument, Unamortized Discount, Noncurrent	$ 62	$ 2,009
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	15,000,000	15,000,000
Preferred Stock Shares Designated	5,000,000	5,000,000
Preferred Stock, shares issued	1,000,000	0
Preferred Stock, shares outstanding	1,000,000	0
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	50,991,285	48,932,023
Common Stock, shares outstanding	50,991,285	48,932,023
Common Stock, Shares Subscribed but Unissued	158,015	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenue
Total National revenue	$ 187,584	$ 16,480	$ 863
Net revenue	187,584	16,480	863
Operating expenses
Cost of goods sold - product revenue	3,658	790	0
Research and development	52,486	35,134	29,810
Research and development - licenses acquired	4,164	5,532	11,408
General and administrative	40,487	28,229	18,734
Total operating expenses	288,792	82,190	51,394
Loss from operations	(101,208)	(65,710)	(50,531)
Other income (expenses)
Interest income	819	298	245
Interest expense and financing fee	(5,860)	(3,690)	(1,484)
Change in fair value of derivative liabilities	8,391	(1,039)	(438)
Change in fair value of subsidiary convertible note	(457)	(78)	0
Change in fair value of investments	226	(1,071)	(1,675)
Other loss	(234)	0	0
Total other income (expenses)	2,885	(5,580)	(3,352)
Loss before Income Taxes	(98,323)	(71,290)	(53,883)
Income tax expense	1,513	0	0
Net loss	(99,836)	(71,290)	(53,883)
Less: net loss attributable to non-controlling interests	32,960	16,195	5,455
Net loss attributable to common stockholders	$ (66,876)	$ (55,095)	$ (48,428)
Basic and diluted net loss per common share	$ (1.61)	$ (1.38)	$ (1.24)
Weighted average common shares outstanding—basic and diluted	41,658,733	39,962,657	39,146,589
Parent Company [Member]
Revenue
Product revenue, net	$ 15,520	$ 3,587	$ 273
Revenue - from a related party	1,725	2,570	590
Total National revenue	17,245	6,157	863
Operating expenses
Cost of goods sold - product revenue	3,658	790	0
Research and development	48,322	29,602	18,402
Research and development - licenses acquired	4,164	5,532	11,408
General and administrative	50,897	34,003	21,584
Total operating expenses	107,041	69,927	51,394
National Holdings Corporation [Member]
Revenue
Commissions	96,807	5,388	0
Net dealer inventory gains	15,108	253	0
Investment banking	25,064	2,829	0
Investment advisory	14,528	904	0
Interest and dividends	2,764	155	0
Transfer fees and clearing services	7,393	386	0
Tax preparation and accounting	7,439	338	0
Other	1,236	70	0
Total National revenue	170,339	10,323	0
Operating expenses
Commissions, compensation and fees	155,187	10,414	0
Clearing fees	2,343	144	0
Communications	2,767	177	0
Occupancy	4,286	193	0
Licenses and registration	1,726	147	0
Professional fees	4,531	327	0
Interest	14	1	0
Depreciation and amortization	2,089	545	0
Other administrative expenses	8,808	315	0
Total operating expenses	$ 181,751	$ 12,263	$ 0

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Series A Preferred Stock [Member]	Common Stock [Member]	Common Shares Issuable [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit	Non-Controlling Interests [Member]
Balance at Dec. 31, 2014	$ 70,523	$ 0	$ 46	$ 0	$ 212,205	$ (141,728)	$ 0
Balance (in shares) at Dec. 31, 2014			46,494,034
Exercise of options	216	0	$ 0	0	216	0	0
Exercise of options (in shares)			100,000
Stock-based compensation expense	14,291	0	$ 0	0	14,291	0	0
Issuance of restricted stock	0	0	$ 1	0	(1)	0	0
Issuance of restricted stock (in shares)			525,000
Issuance of subsidiaries' common shares for license expenses	958	0	$ 0	0	958	0	0
Issuance of common stock under ESPP	59	0	$ 0	0	59	0	0
Issuance of common stock under ESPP (in shares)			27,998
Subsidiaries' offering, net	51,496	0	$ 0	0	51,496	0	0
Issuance of warrants by subsidiary in connection with NSC note	613	0	0	0	613	0	0
Non-controlling interest in subsidiaries	0	0	0	0	(32,882)	0	32,882
Net loss attributable to non-controlling interest	(5,455)	0	0	0	0	0	(5,455)
Net loss attributable to common stockholders	(48,428)	0	$ 0	0	0	(48,428)	0
Balance (in shares) at Dec. 31, 2015			47,147,032
Balance at Dec. 31, 2015	$ 84,273	0	$ 47	0	246,955	(190,156)	27,427
Exercise of options (in shares)	20,000
Stock-based compensation expense	$ 12,128	0	0	0	12,128	0	0
Issuance of restricted stock	0	0	$ 2	0	(2)	0	0
Issuance of restricted stock (in shares)			1,568,408
Cashless exercise of warrants	0	0	$ 0	0	0	0	0
Cashless exercise of warrants (in shares)			12,633
Issuance of subsidiaries' common shares for license expenses	53	0	$ 0	0	53	0	0
Issuance of common stock for at-the-market offering	434	0	$ 0	0	434	0	0
Issuance of common stock for at-the-market offering (in shares)			150,556
At-the-market offering cost	(79)	0	$ 0	0	(79)	0	0
Cancellation of restricted stock	0	0	$ 0	0	0	0	0
Cancellation of restricted stock (in shares)			(33,333)
Issuance of common stock under ESPP	189	0	$ 0	0	189	0	0
Issuance of common stock under ESPP (in shares)			86,727
Subsidiaries' offering, net	36,818	0	$ 0	0	36,818	0	0
Issuance of warrants by subsidiary in connection with NSC note	793	0	0	0	793	0	0
Conversion of subsidiary’s notes payable	2,006	0	0	0	2,006	0	0
Non-controlling interest in subsidiaries	0	0	0	0	(15,598)	0	15,598
Non-controlling interest in National Holdings Corp.	17,643	0	0	0	0	0	17,643
Net loss attributable to non-controlling interest	(16,195)	0	0	0	0	0	(16,195)
Net loss attributable to common stockholders	(55,095)	0	$ 0	0	0	(55,095)	0
Balance (in shares) at Dec. 31, 2016			48,932,023
Balance at Dec. 31, 2016	82,968	0	$ 49	0	283,697	(245,251)	44,473
Exercise of options	27	0	$ 0	0	27	0	0
Exercise of options (in shares)			20,000
Stock-based compensation expense	14,005	0	$ 0	0	14,005	0	0
Issuance of restricted stock	0	0	$ 2	0	(2)	0	0
Issuance of restricted stock (in shares)			1,796,270
Issuance of Series A preferred stock for cash, net of offering cost of $2,804	22,196	$ 1	$ 0	0	22,195	0	0
Issuance of Series A preferred stock for cash, net of offering cost of $2,804 (in shares)		1,000,000	0
Issuance of subsidiaries' common shares for license expenses	1,727	$ 0	$ 0	0	1,727	0	0
Issuance of subsidiaries' common shares for research and development expenses	50	0	0	0	50	0	0
Issuance of subsidiaries' common shares for settlement	2,062	0	0	0	2,062	0	0
Issuance of common stock under ESPP	191	0	$ 0	0	191	0	0
Issuance of common stock under ESPP (in shares)			67,733
Issuance of common stock for research and development expenses	200	0	$ 0	0	200	0	0
Issuance of common stock for research and development expenses (in shares)			43,292
Acquisition of business - NHLD	(211)	0	$ 0	0	(211)	0	0
Subsidiaries' offering, net	95,116	0	0	0	95,116	0	0
Debt discount related to Opus Credit Facility	201	0	0	0	201	0	0
Issuance of warrants by subsidiary in connection with NSC note	750	0	0	0	750	0	0
Conversion of subsidiary’s notes payable	314	0	0	0	314	0	0
Common shares issuable for PIK interest expense	500	0	0	500	0	0	0
Common shares issued for PIK interest expense	541	$ 0	$ 0	0	541	0	0
Common shares issued for PIK interest expense (in shares)		0	131,967
Preferred A dividends declared and paid	(299)	$ 0	$ 0	0	(299)	0	0
Non-controlling interest in subsidiaries	0	0	0	0	(56,416)	0	56,416
Net loss attributable to non-controlling interest	(32,960)	0	0	0	0	0	(32,960)
Net loss attributable to common stockholders	(66,876)	$ 0	$ 0	0	0	(66,876)	0
Balance (in shares) at Dec. 31, 2017		1,000,000	50,991,285
Balance at Dec. 31, 2017	$ 120,502	$ 1	$ 51	$ 500	$ 364,148	$ (312,127)	$ 67,929

Consolidated Statements of Cha6

Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)
Series A Preferred Stock [Member]
Issuance of Net of Offering Cost	$ 2,804

Consolidated Statements of Cash

Consolidated Statements of Cash Flows $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Cash Flows from Operating Activities:
Net Loss	$ (99,836)	$ (71,290)	$ (53,883)
Reconciliation of net loss to net cash used in operating activities:
Depreciation expense	1,165	944	26
Noncash interest expense	0	0	167
Amortization of intangible asset	1,651	0	0
Amortization of debt discount	1,314	1,466	314
Amortization of product revenue license fee	534	183	0
Amortization of forgivable loans to registered representatives	693	176	0
Amortization of deferred clearing credit	(209)	(13)	0
Stock-based compensation expense	14,005	12,128	14,291
Issuance of common stock for research and development expenses	200	0	0
Issuance of subsidiaries' common shares for research and development expenses	50	0	0
Recovery for doubtful accounts	(191)	(47)	0
Deferred tax benefit	0	(73)	0
Common shares issuable for license expenses	0	1,682	0
Common shares issuable for PIK interest expense	500	0	0
Common shares issued for PIK interest expense	541	0	0
Change in fair value of investments	(226)	1,071	1,675
Change in fair value of derivative liabilities	(8,391)	1,039	438
Change in fair value of subsidiary convertible note	457	78	0
Loss on write off of investment	250	0	0
Research and development-licenses acquired, expense	4,164	3,838	11,406
Change in fair value of subsidiaries' assets and liabilities	132	1,034	0
Increase (decrease) in cash and cash equivalents resulting from changes in operating assets and liabilities:
Cash deposits with clearing organizations	(11)	0	0
Accounts receivable	(5,928)	(1,830)	0
Receivables from broker-dealers and clearing organizations	(4,038)	(4,048)	0
Forgivable loans receivable	(597)	(84)	0
Securities owned, at fair value	372	(179)	0
Inventory	32	(203)	0
Other receivables - related party	1,172	(1,634)	(156)
Prepaid expenses and other current assets	(3,481)	(204)	(739)
Other assets	0	(12)	0
Accounts payable and accrued expenses	9,727	5,395	5,889
Accounts payable and accrued expenses - related party	172	0	0
Securities sold, but not yet purchased, at fair value	(147)	298	0
Interest payable	176	61	(1)
Interest payable - related party	602	66	0
Other long-term liabilities	(284)	4,346	195
Net cash used in operating activities	(85,430)	(45,812)	(20,378)
Cash Flows from Investing Activities:
Purchase of marketable securities, at fair value	0	0	(79,947)
Sale of marketable securities	0	0	99,949
Purchase of research and development licenses	(3,365)	(3,785)	(10,448)
Purchase of property and equipment	(2,080)	(6,370)	(283)
Purchase of license	0	(350)	(1,250)
Purchase of short-term investment (certificates of deposit)	(56,091)	0	0
Redemption of short-term investment (certificates of deposit)	20,089	0	0
Security deposits paid	(251)	(6)	0
Security deposits refund	42	0	22
Acquisition of business - National	(19)	4,626	0
Collection on notes receivable - disposal of Gilman branches	46	0	0
Investment in Origo Acquisition Corp.	0	(175)	(158)
Net cash (used in) provided by investing activities	(41,629)	(6,060)	7,885
Cash Flows from Financing Activities:
Proceeds from issuance of Series A preferred stock	25,000	0	0
Payment of costs related to the issuance of Series A preferred stock	(2,804)	0	0
Proceeds from exercise of stock options	27	0	216
Proceeds from issuance of common stock under ESPP	191	189	59
Proceeds from subsidiaries’ offering	95,116	39,662	57,817
Payment of costs related to subsidiaries’ offering	0	(2,844)	(6,321)
Proceeds from at-the-market offering	0	434	0
Payment of cost related to at-the-market offering	0	(79)	0
Payment of NSC note	(3,608)	(6,392)	0
Proceeds from NSC note	0	0	10,000
Payment of debt issuance costs associated with NSC Note	0	0	(855)
Proceeds from 2017 Subordinated Note Financing	28,355	0	0
Payment of debt issuance costs associated with 2017 Subordinated Note Financing	(81)	0	0
Proceeds from subsidiaries' Convertible Note	9,914	4,609	0
Payment of debt issuance costs associated with subsidiaries’ Convertible Note	(104)	(594)	0
Proceeds from IDB Note	0	920	0
Proceeds from Opus Credit Facility	2,500	7,000	0
Payment of Preferred A dividends	(299)	0
Net cash provided by financing activities	154,207	42,905	60,916
Net increase (decrease) in cash, cash equivalents, and restricted cash	27,148	(8,967)	48,423
Cash, cash equivalents, and restricted cash at beginning of period	104,154	112,768
Cash, cash equivalents and restricted cash at end of period	131,302	104,154	112,768
Acquisition of National Holdings Corp.
Goodwill	0	(18,645)	0
Accounts receivable	0	(4,889)	0
Cash deposits with clearing organizations	0	(1,030)	0
Receivables from broker-dealers and clearing organizations	0	(1,607)	0
Securities owned, at fair value	0	(2,178)	0
Prepaid expenses and other current assets	0	(1,985)	0
Property and equipment, net	0	(1,132)	0
Restricted cash	0	(353)	0
Accounts payable and accrued expenses	0	6,079	0
Accrued commissions and payroll payable	0	14,029	0
Deferred clearing and marketing credits	0	1,007	0
Warrants issuable	0	13,406	0
Other current liabilities	0	707	0
Non-controlling interests	0	17,717	0
Net cash acquired in acquisition of National Holdings Corp.	0	4,626	0
Fortress [Member]
Supplemental disclosure of non-cash financing and investing activities:
Issuance of restricted stock	2	2	2
Issuance of warrants by subsidiary in conjunction with NSC debt	750	634	114
Issuance of subsidiaries’ common shares for settlement	2,062	0	0
Debt discount related to Opus Credit Facility	201	0	0
Beneficial conversion feature related to Opus Credit Facility	0	2,006	0
Unpaid debt offering cost	58	0	0
Common shares issuable for license acquired	1,682	0	0
Conversion of subsidiaries notes payable	314	0	0
Property, plant and equipment included in accounts payable and accrued liabilities	982	0	0
National [Member]
Supplemental disclosure of cash flow information:
Cash paid for interest	14	51	0
Cash paid for income taxes	2,399	104	0
Acquisition of National Holdings Corp.
Fixed assets (acquired but not paid)	0	512	0
Dividend payable in warrants	0	14,055	0
Business acquired	(192)	0	0
Customer Lists [Member]
Acquisition of National Holdings Corp.
Intangible assets	0	(13,500)	0
Trademarks [Member]
Acquisition of National Holdings Corp.
Intangible assets	0	(3,000)	0
non-related party [Member] | Fortress [Member]
Supplemental disclosure of cash flow information:
Cash paid for interest	675	349	80
related party [Member] | Fortress [Member]
Supplemental disclosure of cash flow information:
Cash paid for interest	1,839	0	0
Restricted Stock [Member] | Fortress [Member]
Supplemental disclosure of non-cash financing and investing activities:
Issuance of warrants in conjunction with NSC debt	$ 0	$ 793	$ 175

Organization and Description of

Organization and Description of Business	12 Months Ended
	Dec. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Description of Business	Fortress Biotech, Inc. (“Fortress” or the “Company”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through certain of its subsidiary companies, also referred to as the “Fortress Companies.” Additionally, the Company maintains a controlling interest in National Holdings Corporation, a diversified independent brokerage company (together with its subsidiaries, referred to as “NHLD” or “National”). In addition to its internal development programs, the Company leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies achieve their goals. The Company and the Fortress Companies may seek licenses, acquisitions, partnerships, joint ventures and/or public and private financings to accelerate and provide additional funding to support their research and development programs. As of December 31, 2017, in addition to National, the Company has several consolidated Fortress Companies, some of which contain product licenses, including. (“Aevitas”), Avenue Therapeutics, Inc. (“Avenue”), Caelum Biosciences, Inc. (“Caelum”), Cellvation, Inc. (“Cellvation”), Checkpoint Therapeutics, Inc. (“Checkpoint”), Cyprium Therapeutics, Inc. (“Cyprium”), Helocyte, Inc. (formerly known as DiaVax Biosciences, Inc., “Helocyte”), Journey Medical Corporation (“Journey” or “JMC”), and Mustang Bio, Inc. (formerly known as Mustang Therapeutics, Inc., “Mustang”). Caelum Biosciences, Inc. (“Caelum”), Cyprium Biosciences, Inc. (“Cyprium”) and Tamid Biosciences, Inc. ("Tamid). The Company also maintains exclusive ownership positions in operational subsidiaries CB Securities Corporation (“CB Securities”), Innmune Limited and FBIO Acquisition, Inc. (the acquisition vehicle we used to obtain National) and majority ownership positions in acquisition companies for which the Company is actively seeking product candidate licenses, including Coronado SO Co. (“Coronado SO”), Escala Therapeutics, Inc. (“Escala”), GeneXion Oncology, Inc. (“GeneXion”), FBIO Acquisition Corp. IV and FBIO Acquisition Corps. VI – XIV. Liquidity and Capital Resources Since inception, the Company’s operations have been financed primarily through the sale of equity and debt securities and the proceeds from the exercise of warrants and stock options. The Company has incurred losses from operations and negative cash flows from operating activities since inception and expects to continue to incur substantial losses for the next several years as it continues to fully develop and prepare regulatory filings and obtain regulatory approvals for its existing and new product candidates. The Company’s current cash and cash equivalents are sufficient to fund operations through March 2019. However, the Company will need to raise additional funding through strategic relationships, public or private equity or debt financings, grants or other arrangements to fully develop and prepare regulatory filings and obtain regulatory approvals for our existing and new product candidates, fund operating losses, and, if deemed appropriate, establish or secure through third parties manufacturing for our potential products, sales and marketing capabilities. If such funding is not available or not available on terms acceptable to the Company, the Company’s current development plan and plans for expansion of its general and administrative infrastructure will be curtailed. The Company also has the ability, subject to limitations imposed by Rule 144 of the Securities Act of 1933 and other applicable laws and regulations, to raise money from the sale of common stock of the public companies in which it has ownership. National On September 9, 2016, the Company, purchased approximately 56.6 0.02 3.25 22.9 56.6

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The Company’s consolidated financial statements include the accounts of the Company and the accounts of the Company’s subsidiaries, listed above. All intercompany balances and transactions have been eliminated. The accompanying consolidated financial statements include the accounts of the Company’s subsidiaries. For consolidated entities where the Company owns less than 100% of the subsidiary, the Company records net loss attributable to non-controlling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. The Company also consolidates subsidiaries in which it owns less than 50% of the subsidiary but maintains voting control. The National assets acquired, and liabilities assumed and revenues and expenses are reported on a one quarter lag. Therefore, the National assets acquired and liabilities assumed included in these consolidated financial statements as of December 31, 2017 are actually the assets acquired and liabilities assumed as of September 30, 2017 and the revenues and expenses included in these consolidated financial statements for the year ended December 31, 2017 are actually the revenues and expenses for the period from October 1, 2016 through September 30, 2017. National provides the company and certain Fortress Companies with investment banking services in connection with debt or equity raises. The company records the fees as expense, debt discount or equity. All such fees are eliminated in consolidation. The Company’s consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value of stock options and warrants, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates. The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories: Level 1 Level 2 Level 3 The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Certain of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable, accrued expenses and other current liabilities. The carrying value of the amount owed to Ovamed GmbH (“Ovamed”) upon the acquisition of certain manufacturing rights has been recorded at its net present value, which approximates its fair value, due to the short-term nature of the liability. The amount due to Ovamed is included in current liabilities at December 31, 2016 in the Consolidated Balance Sheets (see Note 12) and was paid in 2017. Debt carried at cost approximates fair value. Consistent with the increase in Journey’s operations as of April 1, 2016 and the investment in National as of September 9, 2016, the Company now operates in three operating and reportable segments, Dermatology Product Sales, Pharmaceutical and Biotechnology Product Development and National. The Company evaluates the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes. The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at December 31, 2017 and at December 31, 2016 consisted of cashand certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities. The company classifies its certificates of deposit as cash and cash equivalents or held to maturity in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification (“ASC”) 320, Investments - Debt and Equity Securities At December 31, 2017, the Company had approximately $50.0 million in certificates of deposit. The Company classified $ 14.0 36.0 Office equipment is recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset. Leasehold improvements are amortized over the shorter of the estimated useful lives or the term of the respective leases. The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. The Company records cash held in trust or pledged to secure certain debt obligations as restricted cash. As of December 31, 2017, and 2016, the Company has $ 17.4 15.9 14.9 2.5 1.0 Inventories comprise finished goods, which are valued at the lower of cost or market, on a first-in, first-out basis. The Company evaluates the carrying value of inventories on a regular basis, taking into account anticipated future sales compared with quantities on hand, and the remaining shelf life of goods on hand. Accounts receivable consists of amounts due to the Company for product sales from JMC. The Company’s accounts receivable reflects discounts for estimated early payment and for product estimated returns. Accounts receivable are stated at amounts due from customers, net of an allowance for doubtful accounts. Accounts that are outstanding longer than the contractual payment terms are considered past due. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time trade accounts receivable are past due and the customer’s current ability to pay its obligation to the Company. The Company writes off accounts receivable when they become uncollectible. Accounts receivable are net of allowance for product estimated returns of $ 1.3 0.1 1.2 0.1 The Company elects the fair value option for its long-term investments at fair value (see Note 7). The decision to elect the fair value option, which is irrevocable once elected, is determined on an instrument by instrument basis and applied to an entire instrument. The net gains or losses, if any, on an investment for which the fair value option has been elected are recognized as a change in fair value of investments on the Consolidated Statements of Operations. The Company has various processes and controls in place to ensure that fair value is reasonably estimated. While the Company believes its valuation, methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. As permitted under the FASB, ASC 825, Financial Instruments, The Company classifies as liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The fair value of warrants that include price protection reset provision features are deemed to be “down-round protection” and, therefore, do not meet the scope exception for treatment as a derivative under ASC 815, Derivatives and Hedging The Company assessed the classification of warrants issued, in connection with the 2016 convertible note financings for Helocyte and Avenue, and Caelum’s convertible note financing in 2017 (the “Helocyte, Avenue and Caelum Warrants”), and determined that the Helocyte, Avenue and Caelum Warrants met the criteria for liability classification. Accordingly, the Company classified the Helocyte, Avenue and Caelum Warrants as a liability at their fair value and adjusts the instruments to fair value at each balance sheet date until the warrants are exercised or expired. Any change in the fair value of the Helocyte, Avenue and Caelum Warrants is recognized as “change in the fair value of warrant liabilities” in the Consolidated Statements of Operations. Also in accordance with ASC 815, the Company classified the fair value of the warrants granted in connection with the note in favor of National Security Corporations’s NSC Biotech Venture Fund I, LLC (“the NSC Note”) that was transferred to Avenue effective February 2015 (the “Contingently Issuable Warrants”) as a derivative liability. The Company valued these Contingently Issuable Warrants using an option pricing model and used estimates for an expected dividend yield, a risk-free interest rate, and expected volatility together with management’s estimate of the probability of issuance of the Contingently Issuable Warrants. At each reporting period, as long as the Contingently Issuable Warrants are potentially issuable and there is a potential for an insufficient number of authorized shares available to settle the Contingently Issuable Warrants, these Contingently Issuable Warrants will be revalued, and any difference from the previous valuation date will be recognized as a change in fair value of derivative liabilities in the Consolidated Statements of Operations. The Company accounts for the Opus Credit Facility with detachable warrants in accordance with ASC 470, Debt The Company recorded the related issue costs and value ascribed to the warrants as a debt discount of the Opus Credit Facility. The discount is amortized utilizing the effective interest method over the term of the Opus Credit Facility. The unamortized discount, if any, upon repayment of the Opus Credit Facility will be expensed to interest expense. In accordance with ASC Subtopic 470-20, the Company determined the weighted average effective interest rate of the debt was approximately 28 Derivatives and Hedging The Company issues complex financial instruments which include both equity and debt features. The Company analyzes each instrument under ASC 480, Distinguishing Liabilities from Equity, Derivatives and Hedging Debt Acquired assets and assumed liabilities are recognized in a business combination on the basis of their fair values at the date of acquisition. The Company assesses fair value, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, using a variety of methods including income approaches such as present value techniques or cost approaches such as the estimation of current selling prices and replacement values. Fair value of the assets acquired, and liabilities assumed, including intangible assets, are measured based on the assumptions and estimations with regards to the variable factors such as the amount and timing of future cash flows for the asset or liability being measured, appropriate risk-adjusted discount rates, nonperformance risk, or other factors that market participants would consider. Upon acquisition, the Company determines the estimated economic lives of the acquired intangible assets for amortization purposes, which are based on the underlying expected cash flows of such assets. Goodwill represents the excess acquisition cost over the fair value of net tangible and intangible assets acquired. Goodwill is not amortized and is subject to annual impairment testing on October 1st or between annual tests if an event or change in circumstance occurs that would more likely than not reduce the fair value of a reporting unit below its carrying value. In testing for goodwill impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances lead to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events and circumstances, the Company concludes that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is not required. If the Company concludes otherwise, it is required to perform the two-step impairment test. The goodwill impairment test is performed at the reporting unit level by comparing the estimated fair value of a reporting unit with its respective carrying value. If the estimated fair value exceeds the carrying value, goodwill at the reporting unit level is not impaired. If the estimated fair value is less than carrying value, further analysis is necessary to determine the amount of impairment, if any, by comparing the implied fair value of the reporting unit’s goodwill to the carrying value of the reporting unit’s goodwill. The fair value of reporting units is based on widely accepted valuation techniques that the Company believes market participants would use, although the valuation process requires significant judgment and often involves the use of significant estimates and assumptions. The Company utilizes a market cap approach in estimating the fair value of reporting units. The estimates and assumptions used in determining fair value could have a significant effect on whether or not an impairment charge is recorded and the magnitude of such a charge. Adverse market or economic events could result in impairment charges in future periods. Intangible assets deemed to have finite lives are amortized on a straight line basis over their estimated useful lives, where the useful life is the period over which the asset is expected to contribute directly, or indirectly, to its future cash flows. Intangible assets are reviewed for impairment on an interim basis when certain events or circumstances exist. For amortizable intangible assets, impairment exists when the carrying amount of the intangible asset exceeds its fair value. At least annually, the remaining useful life is evaluated. An intangible asset with an indefinite useful life is not amortized but assessed for impairment annually, or more frequently, when events or changes in circumstances occur indicating that it is more likely than not that the indefinite-lived asset is impaired. Impairment exists when the carrying amount exceeds its fair value. In testing for impairment, the Company has the option to first perform a qualitative assessment to determine whether it is more likely than not that an impairment exists. If it is determined that it is not more likely than not that an impairment exists, a quantitative impairment test is not necessary. If the Company concludes otherwise, it is required to perform a quantitative impairment test. To the extent an impairment loss is recognized, the loss establishes the new cost basis of the asset that is amortized over the remaining useful life of that asset, if any. Subsequent reversal of impairment losses is not permitted. Long-lived assets, primarily fixed assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company will perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company would recognize an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value. The Company recognizes revenue for the performance of services or the shipment of products when each of the following four criteria is met: (i) persuasive evidence of an arrangement exists; (ii) products are delivered or as services are rendered; (iii) the sales price is fixed or determinable; and (iv) collectability is reasonably assured. Collaborative Arrangements Checkpoint is paid by TGTX, a related party, a share of the cost of the license and future milestone payments that are payable to Dana-Farber Cancer Institute pursuant to the license agreement (see Note 8). Checkpoint is also paid by TGTX for the Sponsored Research Agreement between Checkpoint and NeuPharma (see Note 8). The gross amounts of these payments are reported as revenue in the accompanying Statements of Operations. Checkpoint acts as a principal, bears credit risk and may perform part of the services required in the transactions. Consistent with ASC 605-45-15 Revenue Recognition - Principal Agent Considerations The Company follows ASC 605-25, Revenue Recognition - Multiple-Element Arrangements Collaborative Arrangements ASC 605-25 provides guidance relating to the separability of deliverables included in an arrangement into different units of accounting and the allocation of arrangement consideration to the units of accounting. The evaluation of multiple-element arrangements requires management to make judgments about (i) the identification of deliverables, (ii) whether such deliverables are separable from the other aspects of the contractual relationship, (iii) the estimated selling price of each deliverable, and (iv) the expected period of performance for each deliverable. To determine the units of accounting under a multiple-element arrangement, management evaluates certain separation criteria, including whether the deliverables have stand-alone value, based on the relevant facts and circumstances for each arrangement. Management then estimates the selling price for each unit of accounting and allocates the arrangement consideration to each unit utilizing the relative selling price method. The allocated consideration for each unit of accounting is recognized over the related obligation period in accordance with the applicable revenue recognition criteria. If there are deliverables in an arrangement that are not separable from other aspects of the contractual relationship, they are treated as a combined unit of accounting, with the allocated revenue for the combined unit recognized in a manner consistent with the revenue recognition applicable to the final deliverable in the combined unit. Payments received prior to satisfying the relevant revenue recognition criteria are recorded as deferred revenue in the Consolidated Balance Sheets and recognized as revenue in the Consolidated Statements of Operations when the related revenue recognition criteria are met. Revenue Recognition – Milestone Method The Company follows ASC 605-28, Revenue Recognition-Milestone Method JMC Product Revenue JMC sells its products directly to wholesalers and specialty pharmacies. JMC recognizes product sales revenue when delivery has occurred, collectability is reasonably assured, and the price to the buyer is fixed or determinable, (in accordance with the specific contractual terms). Delivery occurs when title has transferred to the customer, and the customer has assumed the risks and rewards of ownership. Revenue from product sales is recognized net of provisions for estimated cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to certain of JMC’s wholesale customers. JMC establishes these provisions concurrently with the recognition of product sales revenue. JMC offers cash discounts for prompt payment and allowances are recorded at the time of sale. JMC allows customers to return product within a specified period of time before and after its expiration date. Provisions for returns are estimated based on historical levels for like products from external data sources, taking into account additional available information such as historical return and exchange levels, and inventory levels in the wholesale distribution channel through its partners. Although the company has limited history with these product sales, the Company believes based on its current level of sales that it can make reasonable estimates of returns based upon external data sources. JMC reviews its methodology and adequacy of the provision for returns on a quarterly basis, adjusting for changes in assumptions, historical internal and external results and business practices, as necessary. JMC’s co-promotion revenue for Dermasorb HC is based upon prescription volume over an established baseline. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company’s behalf will be expensed as services are rendered or when the milestone is achieved. Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third parties for license and milestone costs related to in-licensed products and technology, payments made to third party contract research organizations for preclinical and clinical studies, investigative sites for clinical trials, consultants, the cost of acquiring and manufacturing clinical trial materials, and costs associated with regulatory filings, laboratory costs and other supplies. In accordance with ASC 730-10-25-1, Research and Development The Company records accruals for contingencies and legal proceedings expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated. If a loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. The Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards and forfeiture rates. For stock-based compensation awards to non-employees, the Company remeasures the fair value of the non-employee awards at each reporting period prior to vesting and finally at the vesting date of the award. Changes in the estimated fair value of these non-employee awards are recognized as compensation expense in the period of change. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model or 409A valuations, as applicable. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if management believes it is more likely than not that the deferred tax assets will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50 On December 22, 2017, “H.R.1”, formerly known as the “Tax Cuts and Jobs Act”, was signed into law. Among other items, H.R.1 reduces the federal corporate tax rate to 21 35 Non-controlling interests in consolidated entities represent the component of equity in consolidated entities held by third parties. Any change in ownership of a subsidiary while the controlling financial interest is retained is accounted for as an equity transaction between the controlling and non-controlling interests. The Company’s comprehensive loss is equal to its net loss for all periods presented. Certain prior period amounts may have been reclassified to conform to the current year presentation. National’s Summary of Significant Accounting Policies The consolidated financial statements include the accounts of National and its wholly owned and majority owned subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation. Further National’s results for 2015 are not included in the Company’s Consolidated Financial Statements. In addition, National may consolidate entities which meet the definition of a variable interest entity for which National is the primary beneficiary. The primary beneficiary is the party who has the power to direct the activities of a variable interest entity that most significantly impact the entity’s economic performance and who has an obligation to absorb losses of the entity or a right to receive benefits from the entity that could potentially be significant to the entity. As of December 31, 2017, and 2016, National did not consolidate any variable interest entities. Fees attributable to such arrangements were $ 16.5 17.0 The preparation of these financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Commission revenue represents commissions generated by National’s financial advisors for their clients’ purchases and sales of mutual funds, variable annuities, general securities and other financial products, most of which is paid to the advisors as commissions for initiating the transactions. Commission revenue is generated from front-end sales commissions that occur at the point of sale, as well as trailing commissions. National recognizes front-end sales commission revenue and related clearing and other expenses on transactions introduced to its clearing brokers on a trade date basis. National also recognizes front-end sales commissions and related expenses on transactions initiated directly between the financial advisors and product sponsors upon receipt of notification from sponsors of the commission earned. Commission revenue also includes 12b-1 fees, and variable product trailing fees, collectively considered as trailing fees, which are recurring in nature. These trailing fees are earned by National based on a percentage of the current market value of clients’ investment holdings in trail eligible assets. Because trail commission revenues are generally paid in arrears, management estimates commission revenues earned during each period. These estimates are based on a number of factors including investment holdings and the applicable commission rate and the amount of trail commission revenue received in prior periods. Estimates are subsequently adjusted to actual based on notification from the sponsors of trail commissions earned. Net dealer inventory gains, which are recorded on a trade-date basis, include realized and unrealized net gains and losses resulting from the National’s principal trading activities. Investment banking revenues consist of underwriting revenues, advisory revenues and private placement fees. Underwriting revenues arise from securities offerings in which National acts as an underwriter and include management fees, selling concessions and underwriting fees, net of related syndicate expenses. Underwriting revenues are recorded at the time the underwriting is completed and the income is reasonably determined. Management estimates National’s share of the transaction-related expenses incurred by the syndicate, and recognizes revenues net of such expense. On final settlement, typically within 90 days from the trade date of the transaction, these amounts are adjusted to reflect the actual transaction-related expenses and the resulting underwriting fee. Investment advisory fees are derived from account management and investment advisory services. These fees are determined based on a percentage of the customers assets under management, may be billed monthly or quarterly and are recognized when earned. Interest is recorded on an accrual basis and dividends are recorded on the ex-dividend date. Transfer fees and fees for clearing services, which are recorded on a trade date basis, are principally charged to the broker on customer security transactions. Tax preparation and accounting fees are recognized upon completion of the services. Securities owned and securities sold, but not yet purchased, are recorded at fair value. Authoritative accounting guidance defines fair value, establishes a framework for measuring fair value, and establishes a fair value hierarchy which prioritizes the inputs to valuation techniques. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A fair value measurement assumes that the transaction to sell the asset or transfer the liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market. Valuation techniques that are consistent with the market, income or cost approach are used to measure fair value. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value are classified and disclosed in one of the following three categories: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 Inputs other than quoted market prices that are observable, either directly or indirectly, and reasonably available. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of National. Level 3 Unobservable inputs which reflect

National Holdings Corporation

National Holdings Corporation	12 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
National Holdings Corporation	3. National Holdings Corporation On September 9, 2016, the Company, purchased approximately 56.6 0.02 3.25 On April 27, 2016, the Company entered into an Agreement and Plan of Merger with National and a wholly owned subsidiary of the Company, providing for the acquisition of National (the “Merger Agreement”). Pursuant to the Merger Agreement, and upon the terms and subject to the conditions described therein, the Company agreed to cause its wholly owned subsidiary to commence a tender offer for all the issued and outstanding shares of National’s common stock, par value $ 0.02 3.25 7 56 22.9 Assets Cash and cash equivalents $ 27,498 Accounts receivable 4,889 Cash deposits with clearing organizations 1,030 Receivable from brokers, dealers and clearing agencies 1,607 Securities owned, at fair value 2,178 Prepaid expenses and other current assets 1,985 Property and equipment 1,132 Restricted cash 353 Intangible assets - trademark 3,000 Intangible assets - customer list 13,500 Goodwill 18,645 Total assets 75,817 Liabilities Accrued compensation payable $ 14,029 Accounts payable and accrued expenses 6,079 Deferred clearing and marketing credits 1,007 Warrants issuable 13,406 Other current liabilities 707 Total liabilities assumed 35,228 Non-controlling interests (17,717) Net assets acquired $ 22,872 Cash and cash equivalents from National $ 27,498 Cash to NHLD Shareholders (Tender Offer) (22,872) Net cash acquired in acquisition of National $ 4,626 The Company recognized $ 18.6 Intangible assets consist of trademark and customer lists acquired in the merger under the purchase method of accounting are recorded at fair value net of accumulated amortization since the purchase date. Useful Trademark 10 Customer lists 6 Intangible assets at September 9, 2016 $ 16,500 Amortization expense (509) Intangible assets at December 31, 2016 $ 15,991 Amortization expense (1,651) Intangible assets at December 31, 2017 $ 14,340 Trademark Customer Total Year Ended December 31, 2018 $ 300 $ 2,250 $ 2,550 Year Ended December 31, 2019 300 2,250 2,550 Year Ended December 31, 2020 301 2,250 2,551 Year Ended December 31, 2021 300 2,250 2,550 Year Ended December 31, 2022 300 2,250 2,550 Thereafter 1,107 482 1,589 Total $ 2,608 $ 11,732 $ 14,340 The Company reviews its finite-lived intangible assets for impairment when events or changes in circumstances indicate that the carrying amount of finite-lived intangible asset may not be recoverable. Recoverability of a finite-lived intangible asset is measured by a comparison of its carrying amount to the undiscounted future cash flows expected to be generated by the asset. If the asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were no indicators of impairment during the periods ended September 30, 2017 and 2016, respectively

Broker-Dealers and Clearing Org

Broker-Dealers and Clearing Organizations and Other Receivables	12 Months Ended
	Dec. 31, 2017
Brokers and Dealers [Abstract]
Broker-Dealers and Clearing Organizations and Other Receivables	4. Broker-Dealers and Clearing Organizations and Other Receivables At September 30, 2017 and 2016, National’s receivables of $ 7.4 3.4 5.2 , which 0.5 5.4 and 0.7

Forgivable Loans Receivable

Forgivable Loans Receivable	12 Months Ended
	Dec. 31, 2017
Forgivable Loans Receivable [Abstract]
Forgivable Loans Receivable	5. Forgivable Loans Receivable From time to time, National's operating subsidiaries may make loans, evidenced by promissory notes, primarily to newly recruited independent financial advisors as an incentive for their affiliation. The notes receivable balance is comprised of unsecured non-interest-bearing and interest-bearing loans (interest ranging up to 9 At September 30, 2017 and 2016 National Forgivable loans totaled $ 1.6 1.7 National provides an allowance for doubtful accounts on the notes based on historical collection experience and continually evaluates the receivables for collectability and possible write-offs where a loss is deemed probable. As of September 30, 2017, and 2016, no allowance for doubtful accounts was required. There were no unamortized forgivable loans outstanding at September 30, 2017 and 2016 attributable to registered representatives who ended their affiliation with National’s subsidiaries prior to the fulfillment of their obligation.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2017
Property Plant And Equipment [Abstract]
Property and Equipment	6. Property and Equipment Useful Life As of December 31, ($ in thousands) (Years) 2017 2016 Computer equipment 3 $ 543 $ 440 Furniture and fixtures 5 1,009 821 Machinery and Equipment 5 143 – Leasehold improvements 5 - 15 5,351 5,396 Construction in progress (1) NA 1,241 – Total property and equipment 8,287 6,657 Less: Accumulated depreciation (1,171) (445) Property and equipment, net $ 7,116 $ 6,212 (1) For build-out of Mustang’s cell processing 3.5 2.5 Depreciation expenses of Fortress’ property and equipment for the years ended December 31, 2017, 2016, and 2015 was $ 0.7 0.4 26,000 Estimated Useful September 30, ($ in thousands) Lives (in years) 2017 2016 Equipment 5 $ 1,306 $ 600 Furniture and fixtures 5 284 65 Leasehold improvements Lesser of useful life 1,006 259 Capital Leases (Primarily composed of computer equipment) 5 276 276 Total property and equipment 2,872 1,200 Less: Accumulated depreciation (475) (36) Property and equipment, net $ 2,397 $ 1,164 Depreciation expense of National's property and equipment for the fiscal year ended September 30, 2017 and the period from September 10, 2016 through September 30, 2016 was $ 0.4 36,000

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	7. Fair Value Measurements Certain of the Company’s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable, accrued expenses and other current liabilities. Laser Device for Treatment of Migraine Headaches On March 17, 2014, the Company invested $ 250,000 35 13,409,962 83 16,091,954 0.3 0.3 Origo Acquisition Corporation (formerly CB Pharma Acquisition Corporation) On June 10, 2016, CB Pharma Acquisition Corp (“CB Pharma”) held an extraordinary general meeting of shareholders (the “Meeting”). At the Meeting, the shareholders approved each of the following items: (i) an amendment to the CB Pharma’s Amended and Restated Memorandum and Articles of Association (the “Charter”) to extend the date by which CB Pharma has to consummate a business combination from June 12, 2016 to December 12, 2016 (the “ Extension ”), (ii) an amendment to the Charter to allow the holders of the CB Pharma’s ordinary shares issued in the their initial public offering to elect to convert their shares into their pro rata portion of the funds held in trust, if the Extension is approved, and (iii) the change of CB Pharma’s name from “CB Pharma Acquisition Corp.” to “Origo Acquisition Corporation” (“Origo”). In connection with the Meeting, the Company transferred 1,050,000 265,000 On July 24, 2017, Origo entered into a Merger Agreement with High Times Holding Corp. (“HTH”), which was later amended on September 27, 2017 (“Amended Merger Agreement”). Pursuant to the terms of the Amended Merger Agreement, the Merger Sub will merge with and into HTH, with HTH continuing as the surviving entity (the “Merger”) and all holders of HTH equity securities and warrants, options and rights to acquire or securities that convert into HTH equity securities (collectively, “HTH Securities”) will convert into Origo common shares and, with respect to options, options to acquire Origo common shares. On September 11, 2017, Origo’s shareholders approved a second amendment to the Articles of Association and extended the date by which to consummate a business combination to March 12, 2018. A shareholder meeting was held on March 12, 2018, at which the Origo shareholders approved the extension of the date by which to consummate a business combination to June 12, 2018. As of December 31, 2017, and 2016, the Company valued its investment in Origo, a publicly traded company, utilizing the following assumptions: probability of a successful business combination of 46.53 51.53 10.65 8.16 1.28 0.85 11.50 1.06 0.82 1.07 0.58 0.2 1.1 1.4 1.2 0.3 Contingently Issuable Warrant Pursuant to the Amended NSC Note (see Note 11), if a Fortress Company has the proceeds of the NSC Note transferred to it, such Fortress Company will issue a note to NSC and NSC will also receive a warrant to purchase a number of shares of the Fortress Company’s stock equal to 25 10 Derivatives and Hedging. Avenue Avenue classified the fair value of the Contingently Issuable Warrants that may have been granted in connection with Avenue’s $ 3.0 December 31, 2017 2016 Risk-free interest rate - % 2.45 % Expected dividend yield - - Expected term in years - 10.00 Expected volatility - % 87 % Probability of issuance of the warrant - 50 % On June 26, 2017, Avenue closed on an Initial Public Offering (“IPO”) raising gross proceeds of $ 38.0 6.3 6.00 3.0 125,000 ($ in thousands) Avenue’s Beginning balance at January 1, 2016 $ 114 Additions - Change in fair value 188 Ending balance at December 31, 2016 302 Conversion into common shares (750) Change in fair value 448 Ending balance at December 31, 2017 $ - Mustang Mustang classified the fair value of the Contingently Issuable Warrants that may have been granted in connection with Mustang’s $ 3.6 138,462 0.8 Issuance Risk-free interest rate 1.37 % Expected dividend yield - Expected term in years 10.00 Expected volatility 76.70 % Probability of issuance of the warrant 100 % ($ in thousands) Mustang’s Beginning balance at January 1, 2016 $ - Additions 634 Change in fair value 159 Issuance of Warrants (October 25, 2016) (793) Ending balance at December 31, 2016 $ - Checkpoint On October 30, 2015, Checkpoint issued 139,592 ($ in thousands) Checkpoint’s Beginning balance at January 1, 2015 $ - Additions 175 Change in fair value 438 Issuance of Warrants (October 30, 2015) (613) Ending balance at December 31, 2015 $ - 0.2 0.6 Issuance October 30, Risk-free interest rate 2.26 % 2.16 % Expected dividend yield - - Expected term in years 10.00 10.00 Expected volatility 83 % 100.86 % Probability of issuance of the warrant 25 % 100 % Warrant Liabilities Avenue On December 30, 2016, Avenue held a closing of the sale of convertible promissory notes. In the closing, WestPark Capital, Inc., (“WestPark”) the placement agent, received a warrant (“WestPark Warrant”) to purchase the number of shares of Avenue’s common stock equal to $ 10,000 December 31, Risk-free interest rate 2.45 % Expected dividend yield - % Expected term in years 10.00 Expected volatility 87 % Additionally, on June 26, 2017, in connection with its IPO, Avenue issued 2,488 4.02 33 6.00 ($ in thousands) Fair Value of Beginning balance at January 1, 2016 $ - Additions 12 Change in fair value of derivative liabilities - Ending balance at December 31, 2016 $ 12 Conversion into common shares (15) Change in fair value 3 Ending balance at December 31, 2017 $ - Helocyte The fair value of Helocyte’s warrant liability was measured at fair value using a Monte Carlo simulation valuation methodology. December 31 2017 2016 Risk-free interest rate 2.04% - 2.08 % 1.82% - 1.91 % Expected dividend yield - % - % Expected term in years 3.50 – 3.92 4.50 - 4.92 Expected volatility 70.0 % 70.0 % Strike price $ 0.46 $ 0.44 ($ in thousands) Fair Value of Beginning balance at January 1, 2016 $ - Additions 428 Change in fair value of derivative liabilities (261) Ending balance at December 31, 2016 $ 167 Change in fair value of derivative liabilities (80) Ending balance at December 31, 2017 $ 87 Caelum The fair value of Caelum's warrant liability, which was issued in connection with Caelum’s convertible note, was measured using a Monte Carlo simulation valuation methodology. December 31, Risk-free interest rate 2.154% - 2.168 % Expected dividend yield - % Expected term in years 4.58 - 4.71 Expected volatility 70.0 % Strike price $ 1.01 ($ in thousands) Fair Value of Derivative Beginning balance at January 1, 2017 $ - Additions 226 Change in fair value of derivative liabilities (3) Ending balance at December 31, 2017 $ 223 Convertible Notes at Fair Value Helocyte Helocyte’s convertible debt is measured at fair value using the Monte Carlo simulation valuation methodology. December 31 2017 2016 Risk-free interest rate 1.53% - 1.72 % 0.74% - 1.17 % Expected dividend yield - % - % Expected term in years 0.50 – 0.911 0.75 - 1.91 Expected volatility 52.4 % 61.7 % Convertible Note ($ in thousands) At Fair Value Beginning balance at January 1, 2016 $ - Additions 4,409 Change in fair value of convertible notes 78 Ending balance at December 31, 2016 4,487 Change in fair value of convertible notes 213 Ending balance at December 31, 2017 $ 4,700 Avenue Avenue’s convertible debt is measured at fair value using the Monte Carlo simulation valuation methodology. December 31, 2016 Risk-free interest rate 0.62% - 1.20 % Expected dividend yield - % Expected term in years 0.50 - 2.00 Expected volatility 63.1 % On June 26, 2017, upon completion of Avenue’s IPO, Avenue’s convertible debt automatically converted into approximately 49,749 4.02 33 ($ in thousands) Convertible Beginning balance at January 1, 2016 $ - Additions 200 Ending balance at December 31, 2016 200 Conversion into common shares (299) Change in fair value of convertible notes 99 Ending balance at December 31, 2017 $ - Caelum Caelum’s convertible debt is measured at fair value using the Monte Carlo simulation valuation methodology. December 31, Risk-free interest rate 1.506%- 1.851 % Expected dividend yield - % Expected term in years 0.46 - 1.70 Expected volatility 70.0 % ($ in thousands) Convertible Beginning balance at January 1, 2017 $ - Additions 9,914 Change in fair value of convertible notes 145 Ending balance at December 31, 2017 $ 10,059 Fair Value Measurement as of December 31, 2017 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Long-term investments, at fair value $ - $ - $ 1,390 $ 1,390 Total $ - $ - $ 1,390 $ 1,390 Liabilities Warrant liabilities $ - $ - $ 87 $ 87 Caelum Convertible Note, at fair value - - 10,059 10,059 Helocyte Convertible Note, at fair value - - 4,700 4,700 Total $ - $ - $ 14,846 $ 14,846 Fair Value Measurement as of December 31, 2016 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Long-term investments, at fair value $ - $ - $ 1,414 $ 1,414 Total $ - $ - $ 1,414 $ 1,414 Liabilities Contingently Issuable Warrants $ - $ - $ 302 $ 302 Warrant liabilities - - 179 179 Helocyte Convertible Note, at fair value - - 4,487 4,487 Avenue Convertible Note, at fair value - - 200 200 Total $ - $ - $ 5,168 $ 5,168 The following tables show the fair values hierarchy of National’s financial instruments measured at fair value on a recurring basis on the Consolidated Balance Sheets as of September 30, 2017 and 2016: Fair Value Measurement as of September 30, 2017 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Securities owned, at fair value Corporate stock $ 116 $ - $ - $ 116 Municipal bonds - 1,239 - 1,239 Restricted stock - 82 - 82 Warrants - - 5,665 5,665 Total $ 116 $ 1,321 $ 5,665 $ 7,102 Liabilities Securities sold, but not yet purchased at fair value Contingent consideration $ - $ - $ 311 $ 311 Municipal bonds - 151 - 151 Warrants issued - - 5,597 5,597 Total $ - $ 151 $ 5,908 $ 6,059 Fair Value Measurement as of September 30, 2016 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Corporate stock 101 - 101 Municipal bonds - 2,111 - 2,111 Restricted stock - 145 - 145 Total $ 101 $ 2,256 $ - $ 2,357 Liabilities Corporate stock 298 - - 298 Warrants issuable 14,359 14,359 Total $ 298 $ - $ 14,359 $ 14,657 Warrants Issued In accordance with the Merger Agreement, since less than 80 3.25 At September 30, 2016 net cash settlement of the warrant was assumed since National did not have the ability to settle the warrants with unregistered shares and did not have an effective registration statement making settlement outside of National’s control. Accordingly, National was obligated to issue the warrants. The fair value of the 5.4 44 September 30 2017 2016 Dividend yield - % - % Expected volatility 91.0 % 118.85 % Risk-free interest rate 1.890 % 1.14 % Life (in years) 4.20 5 The table below provides a roll forward of the changes in fair value of Level 3 financial instruments for the years ended December 31, 2017 and 2016: Convertible Notes, at fair value ($ in thousands) Investment in Investment in Helocyte Avenue Caelum Issued Warrant Total Balance at December 31, 2016 $ 1,164 $ 250 $ 4,487 $ 200 $ - $ 14,661 $ 179 $ 20,941 Additions during the period - - - - 9,914 - - 9,914 Conversion into common shares - - - (299) - (750) (15) (1,064) Loss on write off investment - (250) - - - - - (250) Change in fair value of investments 226 - - - - - - 226 Change in fair value of convertible notes - - 213 99 145 - - 457 Change in fair value of derivative liabilities - - - - - 448 (8,839) (8,391) Balance at December 30, 2017 $ 1,390 $ - $ 4,700 $ - $ 10,059 $ 14,359 $ (8,675) $ 21,833 Convertible Notes, at Fair Value ($ in thousands) Investment in Investment in Contingently Helocyte Avenue Warrant Total Balance at December 31, 2015 $ 2,235 $ 250 $ 114 $ - $ - $ - $ 2,599 Additions during the period - - 14,040 4,409 200 440 19,089 Issuance of warrants - - (793) - - - (793) Change in fair value of investments (1,071) - - - - - (1,071) Change in fair value of convertible notes - - - 78 - 78 Change in fair value of derivative liabilities - - 1,300 - (261) 1,039 Balance at December 31, 2016 $ 1,164 $ 250 $ 14,661 $ 4,487 $ 200 $ 179 $ 20,941

Licenses Acquired

Licenses Acquired	12 Months Ended
	Dec. 31, 2017
Licenses Acquired [Abstract]
Licenses Acquired	8. Licenses Acquired In accordance with ASC 730-10-25-1, Research and Development 4.2 5.5 11.4 For the Years Ended December 31, ($ in thousands) 2017 2016 2015 Fortress $ 300 $ 325 $ - Fortress Companies: Avenue - - 3,000 Caelum 219 - - Cellvation - 312 - Checkpoint 400 3,160 3,159 Coronado SO - - 1,607 Cyprium 100 - - Escala - - 1,295 Helocyte - 53 200 Mustang 2,875 1,682 2,147 Tamid 270 - - Total $ 4,164 $ 5,532 $ 11,408 Fortress Biotech, Inc. In July 2016, Fortress entered into a License Agreement with GeneMedicine, Inc. (“GeneMedicine”) to develop products using Gene Medicine’s oncolytic adenovirus technology. In connection with the license agreement, Fortress agreed to provide GeneMedicine $ 0.3 0.1 19.3 In September 2016, Fortress entered into a Development and License Agreement with Effcon Laboratories, Inc. (“Effcon”) for the extended release formulation of methazolamide. Fortress made an upfront payment to Effcon of $ 0.2 5.3 1.6 Avenue License Agreement with Revogenex Ireland Ltd In February 2015, the Company purchased an exclusive license to IV Tramadol for the U.S. market from Revogenex, a privately held company in Dublin, Ireland. Fortress made an upfront payment of $ 2.0 1.0 The Company transferred the Revogenex license and all other rights and obligations of Fortress under the License Agreement to Avenue pursuant to the Avenue Founders Agreement effective as of February 17, 2015. Per the terms of the agreement, Avenue assumed $ 3.0 Caelum License Agreement with Columbia University In January 2017, Caelum entered into an exclusive license agreement with Columbia University (“Columbia”) to secure worldwide license rights to CAEL-101 (11-1F4), a chimeric fibril-reactive monoclonal antibody (mAb) being evaluated in a Phase 1a/1b study for the treatment of amyloid light chain (“AL”) amyloidosis. This transaction was accounted for as an asset acquisition pursuant to ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, . 0.2 1,050,000 10 29,000 0.028 70 1.93 5 49.5 5.5 Cellvation In October 2016, Cellvation entered into a license agreement with the University of Texas Health Science Center at Houston (“University of Texas”) for the treatment of traumatic brain injury using Autologous Bone Marrow Mononuclear Cells (the “Initial TBI License”) for an upfront fee of approximately $ 0.3 500,000 5 6.2 6.0 50,000 0.2 In addition, Cellvation entered into a secondary license with the University of Texas for a method and apparatus for conditioning cell populations for cell therapies (the “Second TBI License”). Cellvation paid an upfront fee of $ 50,000 0.1 0.3 are due for the completion of certain development milestones and single digit royalties upon the achievement of net sales. In connection with the two University of Texas licenses, Cellvation granted each of two University of Texas researchers acting as consultants to Cellvation 500,000 shares of Cellvation common stock. 40.2 30 0.024 12,000 12,000 Checkpoint Dana-Farber Cancer Institute In March 2015, Checkpoint entered into an exclusive license agreement with Dana-Farber Cancer Institute (“Dana-Farber”) to develop a portfolio of fully human immuno-oncology targeted antibodies. The portfolio of antibodies licensed from Dana-Farber include antibodies targeting PD-L1, GITR and CAIX. Under the terms of the agreement, Checkpoint paid Dana-Farber an up-front licensing fee of $ 1.0 500,000 32,500 0.065 5 10.0 136,830 0.6 21.5 60.0 In connection with the license agreement with Dana-Farber, Checkpoint entered into a collaboration agreement with TGTX, a related party, to develop and commercialize the anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies, while Checkpoint retains the right to develop and commercialize these antibodies in the field of solid tumors. Michael Weiss, Chairman of the Board of Directors of Checkpoint is also the Executive Chairman, President and Chief Executive Officer and a stockholder of TGTX. Under the terms of the agreement, TGTX paid Checkpoint $ 0.5 21.5 7.0 14.5 60.0 84,000 42,000 0.6 NeuPharma, Inc. In March 2015, the Company entered into an exclusive license agreement with NeuPharma, Inc. (“ NeuPharma 1.0 40.0 22.5 40.0 1.0 Also, in connection with the license agreement with NeuPharma, Checkpoint entered into a Sponsored Research Agreement with NeuPharma for certain research and development activities. Effective January 11, 2016, TGTX, a related party, agreed to assume all costs associated with this agreement and paid Checkpoint for all amounts previously paid by Checkpoint. The company recognized approximately $ 0.6 1.0 Teva Pharmaceutical Industries Ltd. (through its subsidiary, Cephalon, Inc.) In December 2015, the Company entered into a license agreement with Teva Pharmaceutical Industries Ltd. through its subsidiary, Cephalon, Inc. (“Cephalon”), which agreement was assigned to Checkpoint by the Company on the same date. Under the terms of the license agreement, Checkpoint obtained an exclusive, worldwide license to Cephalon’s patents relating to CEP-8983 and its small molecule prodrug, CEP-9722, a PARP inhibitor, which Checkpoint now refers to as CK-102. Checkpoint paid Cephalon an up-front licensing fee of $ 0.5 220.0 206.5 Jubilant Biosys Limited In May 2016, Checkpoint entered into a license agreement with Jubilant Biosys Limited (“Jubilant”), whereby Checkpoint obtained an exclusive, worldwide license (the “Jubilant License”) to Jubilant’s family of patents covering compounds that inhibit BRD4, a member of the BET domain for cancer treatment, including CK-103. Under the terms of the Jubilant License, Checkpoint paid Jubilant an up-front licensing fee of $ 2.0 89.0 59.5 89.0 2.0 research and development-licenses acquired In connection with the Jubilant License, Checkpoint entered into a sublicense agreement with TGTX (the “Sublicense Agreement”), a related party, to develop and commercialize the compounds licensed in the field of hematological malignancies, with Checkpoint retaining the right to develop and commercialize these compounds in the field of solid tumors. Michael Weiss, Chairman of the Board of Directors of Checkpoint and the Company’s Executive Vice Chairman, Strategic Development, is also the Executive Chairman, President and Chief Executive Officer and a stockholder of TGTX. Under the terms of the Sublicense Agreement, TGTX paid Checkpoint $ 1.0 87.2 25.5 61.7 89.0 50 1.0 1.5 Coronado SO Co. License Agreement In February 2015, Coronado SO entered into an exclusive license agreement and other arrangements with third parties to acquire development and commercialization rights to a topical product used in the treatment of hand-foot syndrome, a common painful side effect of chemotherapeutics. Coronado SO paid $ 0.9 150,000 0.5 10.7 26.2 44.8 30 1.19 0.2 In October 2017, Coronado SO transferred its proprietary interests and rights in its lead product candidate to a third party. In exchange for this assignment, Fortress made a $ 50,000 43,292 0.2 4.6197 0.3 1.8 Cyprium License Agreement with the Eunice Kennedy Shriver In March 2017, Cyprium and the Eunice Kennedy Shriver Business Combinations (Topic 805): Clarifying the Definition of a Business, . 0.1 Escala On July 16, 2015, Escala acquired from New Zealand Pharmaceuticals Limited (“NZP”) a license from the NIH and cooperative research and development agreements for the development of oral ManNAc, a key compound in the sialic biosynthetic pathway, for the treatment of hyposialylation disorders, including GNE myopathy and various forms of nephropathy. As part of this agreement, Escala provided NZP and NIH an upfront payment of approximately $ 1.3 0.7 0.6 1.3 Seven milestones totaling approximately $ 22.0 7.0 In July 2017, Escala discontinued its development of ManNAc and as such returned the license to NIH and discontinued its funding of cooperative research and development of ManNAc. No expense was incurred in connection with the discontinuation of this development program. Helocyte License Agreement with the City of Hope In March 2016, Helocyte entered into amended and restated license agreements for each of its PepVax and Triplex immunotherapies programs with its licensor City of Hope National Medical Center (“COH”). The amended and restated licenses expand the intellectual property and other rights granted to Helocyte by COH in the original license agreement. The financial terms of the original license have not been modified, and if Helocyte successfully develops and commercializes PepVax and Triplex, COH will receive milestones, royalties and other payments. Helocyte entered into the original license agreement with COH on March 31, 2015, to secure: (i) an exclusive worldwide license for two immunotherapies for CMV control in the post-transplant setting (known as Triplex and PepVax); and (ii) an option for an exclusive worldwide license to an immunotherapy for the prevention of congenital CMV (known as Pentamer). In consideration for the license and option, Helocyte made an upfront payment of $ 150,000 45,000 1.5 13.0 0.2 9.0 26.0 0.75 5.5 26.0 0.75 As further consideration for the licenses, in March and May 2016, Helocyte granted COH 500,000 8,333 44.5 30 0.097 48,500 Mustang License Agreement with the City of Hope In March 2015, Mustang entered into an exclusive license agreement with COH to acquire intellectual property rights pertaining to CAR-T (the “COH License”). Pursuant to the COH License, Mustang paid COH an upfront fee of $ 2.0 research and development-licenses acquired expenses 1.0 10 2.0 14.5 1.0 44.8 30 0.147 0.1 0.1 Effective October 2016, Mustang closed on gross proceeds of $ 10.0 293,588 5.73 1.7 1.0 CD123 License Pursuant to the CD123 License, Mustang and COH acknowledge that an upfront fee was paid under the Original License. In addition, an annual maintenance fee will continue to apply. COH is eligible to receive up to approximately $ 14.5 IL13R2 License Pursuant to the IL13R2 License, Mustang and COH acknowledge that an upfront fee was paid under the Original License. In addition, an annual maintenance fee will continue to apply. COH is eligible to receive up to approximately $ 14.5 0.5 Spacer License Pursuant to the Spacer License, Mustang and COH acknowledge that an upfront fee was paid under the Original License. In addition, an annual maintenance fee will continue to apply. No royalties are due if the Spacer technology is used in conjunction with a CD123 CAR or an IL13R2 CAR, and royalty payments in the low single digits are due on net sales of licensed products if the Spacer technology is used in conjunction with other intellectual property. Mustang is obligated to pay COH a percentage (in the mid-thirties) of certain revenues received in connection with a sublicense. In addition, equity grants made under the Original License were acknowledged, and the anti-dilution provisions of the Original License were carried forward. IV/ICV Agreement On February 17, 2017, Mustang entered into an exclusive license agreement (the “IV/ICV Agreement”) with COH to acquire intellectual property rights in patent applications related to the intraventricular and intracerebroventricular methods of delivering T cells that express CARs. Pursuant to the IV/ICV Agreement, Mustang paid COH an upfront fee of $ 0.1 0.1 HER2 Technology License On May 31, 2017, Mustang entered into an exclusive license agreement with the COH for the use of human epidermal growth factor receptor 2 (HER2) CAR T technology (HER2 Technology), which will initially be applied in the treatment of glioblastoma multiforme. Pursuant to the Agreement, Mustang paid an upfront fee of $ 0.6 50,000 14.9 CS1 Technology License On May 31, 2017, Mustang entered into an exclusive license agreement with the COH for the use of CS1 specific CAR T technology (CS1 Technology) to be directed against multiple myeloma. Pursuant to the Agreement, Mustang paid an upfront fee of $ 0.6 50,000 14.9 PSCA Technology License On May 31, 2017, Mustang entered into an exclusive license agreement with the COH for the use of prostate stem cell antigen (PSCA) CAR T technology (PSCA Technology) to be used in the treatment of prostate cancer. Pursuant to the Agreement, Mustang paid an upfront fee of $ 0.3 50,000 14.9 License with University of California On March 17, 2017, Mustang entered into an exclusive license agreement with the Regents of the University of California (“UCLA License”) to acquire intellectual property rights in patent applications related to the engineered anti-prostate stem cell antigen antibodies for cancer targeting and detection. Pursuant to the UCLA Agreement, Mustang paid UCLA an upfront fee of $ 0.2 14.3 Fred Hutchinson Cancer Research Center License On July 3, 2017, Mustang entered into an exclusive, worldwide licensing agreement with Fred Hutchinson Cancer Research Center (“Fred Hutch”) for the use of a CAR T therapy related to autologous T cells engineered to express a CD20-specific chimeric antigen receptor (“CD 20 Technology License”). Pursuant to the CD 20 Technology License, Mustang paid Fred Hutch an upfront fee of $ 0.3 50,000 39.1 Harvard College License In December 2017, Mustang entered into a license agreement with the President and Fellows of Harvard College (“Harvard”) for the development of CRISPR/Cas9-enhanced CAR T therapies for the treatment of cancer. Pursuant to the Harvard Agreement, Mustang paid Harvard in January 2018 an upfront fee of $ 0.2 2.7 14.0 Tamid Licenses with the University of North Carolina On November 30, 2017, Tamid entered into three exclusive AAV gene therapies licensing arrangements with the University of North Carolina at Chapel Hill (“UNC”). The preclinical product candidates acquired through these licenses target ocular manifestations of Mucopolysaccharidosis type 1 (MPS1), dysferlinopathies and corneal transplant rejections. The three therapies were developed in the lab of Matthew Hirsch, Ph.D., Assistant Professor, Ophthalmology at the UNC Gene Therapy center. MPS1 License As consideration for the exclusive rights to the MPS1 license Tamid paid an up-front fee paid in January 2018 of $ 85,000 5.5 7.5 Nanadysferlin License As consideration for the exclusive rights to Nanadysferlin license Tamid paid an up-front fee paid in January 2018 of $ 85,000 5.4 33 Extension for such milestones is $10,000 per milestone for the first year and $20,000 per milestone thereafter. HLA-G License As consideration for the exclusive rights to HLA-G license Tamid paid an up-front fee paid in January 2018 of $ 85,000 5.4 42 As additional consideration for the three licenses, UNC, UNC received 1.0 10 40.5 75 0.015 15,000

Milestones and Sponsored Resear

Milestones and Sponsored Research Agreements	12 Months Ended
	Dec. 31, 2017
Research and Development [Abstract]
Research, Development, and Computer Software Disclosure	9. Milestones and Sponsored Research Agreements Fortress The Company has a license agreement with the University College London Business PLC (“UCLB”) under which the Company received an exclusive, worldwide license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions. In consideration for the license, the Company made upfront payments totaling $ 0.1 22.0 0.4 3 5 Checkpoint NeuPharma, Inc. Sponsored Research Agreement In connection with its license agreement with NeuPharma, Inc. (“NeuPharma”), Checkpoint entered into a Sponsored Research Agreement with NeuPharma for certain research and development activities. Effective January 11, 2016, TGTX, a related party, agreed to assume all costs associated with this Sponsored Research Agreement and paid Checkpoint for all amounts previously paid by the Company. For the year ended December 31, 2017 and 2016, approximately $ 0.6 1.0 Cellvation In October 2016, Cellvation entered research funding agreement with the University of Texas in connection with the license for a method and apparatus for conditioning cell populations for cell therapies. In connection with this agreement Cellvation agreed to fund $ 0.8 0.1 0.2 Helocyte PepVax and Triplex Clinical Research and Support Agreements In March 2016, Helocyte entered into an Investigator-Initiated Clinical Research Support Agreement, as amended, with the COH, to support a Phase 2 clinical study of its PepVax immunotherapy for CMV control in allogeneic stem cell transplant recipients (“PepVax Research Agreement”). The Phase 2 study is additionally supported by grants from the National Institutes of Health/National Cancer Institute (“NCI”). Under the terms of the agreement, Helocyte made an upfront payment to COH of $ 1.0 2.0 In February 2016, Helocyte entered into an Investigator-Initiated Clinical Research Support Agreement, as amended, with the COH, to support a Phase 2 clinical study of its Triplex immunotherapy for CMV control in allogeneic stem cell transplant recipients (“Triplex Research Agreement”). The Phase 2 study is additionally supported by grants from the NCI. Under the terms of the agreement, Helocyte made an upfront payment to COH of $ 1.0 3.4 For the years ended December 31, 2017, 2016 and 2 0 3.7 4.3 2.6 1.8 1.1 2.5 Pentamer Sponsored Research Agreement On May 1, 2017, Helocyte and COH entered in a Sponsored Research Agreement for preclinical studies in connection with the development of Pentamer. In June 2017, Helocyte made an upfront payment of $ 1.5 0.2 Mustang In March 2015, in connection with Mustang’s license with COH for the development of CAR-T, Mustang entered into a Sponsored Research Agreement in which Mustang will fund continued research in the amount of $ 2.0 2.0 2.0 1.5 CD 123 Clinical Research Support Agreement On February 17, 2017, Mustang entered into a Clinical Research Support Agreement for CD123. Pursuant to the terms of this agreement Mustang made an upfront payment of approximately $ 20,000 0.1 0.2 1.1 IL13Rα2 Clinical Research Support Agreement Also, on February 17, 2017, Mustang entered into a Clinical Research Support Agreement for IL13R2 (“IL13R2 CRA”). Pursuant to the terms of this agreement Mustang made an upfront payment of approximately $ 9,300 0.1 0.2 1.4 CD20 Clinical Trial Agreement Also, on July 3, 2017, in conjunction with the CD20 Technology License from Fred Hutch, Mustang entered into an investigator-initiated clinical trial agreement (“CD20 CTA”) to provide partial funding for a Phase 1/2 clinical trial at Fred Hutch evaluating the safety and efficacy of the CD20 Technology in patients with relapsed or refractory B-cell non-Hodgkin lymphomas. In connection with the CD20 CTA, Mustang agreed to fund up to $ 5.3 0.6 CRISPR Sponsored Research Agreement On November 28, 2017, Mustang entered into a Sponsored Research Agreement with Beth Israel Deaconess Medical Center Inc. (“BIDMC”) to perform research relating to gene editing, via the use of CRISPR/Cas9, to be used in enhancing the efficacy of chimeric antigen receptor T (CAR-T) cell therapies for solid tumor indications and to generate universal off the shelf CAR-T cell therapies for both liquid and solid tumor indications. The Company agreed to fund approximately $ 0.8 0.1

Intangibles

Intangibles	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangibles	10. Intangibles Journey In January 2016, JMC entered into a licensing agreement with a third party to distribute its prescription wound cream Luxamend ® and paid an upfront fee of $ 50,000 0.3 In March 2015, JMC entered into a license and supply agreement to acquire the rights to distribute Targadox® a dermatological product for the treatment of acne. JMC made an upfront payment of $ 1.3 For the years ended December 31, 2017 and 2016, JMC recognized expense of approximately $ 0.5 0.2 , respectively National For the years ended December 31, 2017 and 2016, National recognized license amortization expense of approximately $ 1.7 0.5

Debt and Interest

Debt and Interest	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Debt and Interest	Debt and Interest Debt December 31, ($ in thousands) 2017 2016 Interest rate Maturity IDB Note $ 14,929 $ 14,929 2.25 % Aug - 2020 NSC Note - 3,608 8.00 % Sep - 2018 2017 Subordinated Note Financing 3,254 - 8.00 % March - 2020 2017 Subordinated Note Financing 13,893 - 8.00 % May - 2020 2017 Subordinated Note Financing 1,820 - 8.00 % June - 2020 2017 Subordinated Note Financing 3,018 - 8.00 % August - 2020 2017 Subordinated Note Financing 6,371 - 8.00 % September - 2020 Opus Credit Facility 9,500 7,000 12.00 % Sep - 2018 Helocyte Convertible Note, at fair value 1,000 1,031 5.00% - 8.00 % December 2017 Helocyte Convertible Note, at fair value 2,194 2,051 5.00% - 8.00 % March - 2018 Helocyte Convertible Note, at fair value 1,062 991 5.00% - 8.00 % April - 2018 Helocyte Convertible Note, at fair value 444 414 5.00% - 8.00 % May - 2018 Avenue Convertible Note, at fair value - 200 5.00% - 8.00 % June - 2018 Caelum Convertible Note, at fair value 1,017 - 8.00 % January - 2019 Caelum Convertible Note, at fair value 6,900 - 8.00 % February - 2019 Caelum Convertible Note, at fair value 2,142 - 8.00 % June - 2019 Total notes payable 67,544 30,224 Less: Discount on notes payable 1,035 2,009 Total notes payable $ 66,509 $ 28,215 IDB Note On February 13, 2014, the Company executed a promissory note in favor of IDB in the amount of $ 15.0 14.0 0.1 2.25 The obligations of the Company under the IDB Note are collateralized by a security interest in, a general lien upon, and a right of set-off against the Company’s money market account of $ 15.0 The Company will default on the IDB Note if, among other things, it fails to pay outstanding principal or interest when due. Following the occurrence of an event of default under the IDB Note, the Bank may: (i) declare the entire outstanding principal balance of the IDB Note, together with all accrued interest and other sums due under the IDB Note, to be immediately due and payable; (ii) exercise its right of setoff against any money, funds, credits or other property of any nature in possession of, under control or custody of, or on deposit with IDB; (iii) terminate the commitments of IDB; and (iv) liquidate the money market account to reduce the Company’s obligations to IDB. During 2016, the Company and IDB extended the maturity date of the IDB Note to February 27, 2018. On September 18, 2017, the maturity on the IDB Note was extended to August 1, 2020. The Company applied the 10 At December 31, 2017 and 2016, the Company had approximately $ 14.9 NSC Note In March 2015, the Company closed a private placement of a promissory note for $ 10.0 8 0.9 17.83 14.00 The NSC Note was amended and restated on July 29, 2015 to provide that any time a Fortress subsidiary receives from the Company any proceeds from the NSC Note, the Company may, in its sole discretion, cause the Fortress Company to issue to NSC Biotech Venture Fund I LLC a new promissory note (the “Amended NSC Note”) on identical terms as the NSC Note, giving effect to the passage of time with respect to maturity. The Amended NSC Note will equal the dollar amount of the Fortress Company’s share of the NSC Note and reduce the Company’s obligations under the NSC Note by such amount. The Company will guarantee the Amended NSC Note until the Fortress Company either completes an initial public offering of its securities or raises sufficient equity capital so that it has cash equal to five times the Amended NSC Note. As of December 31, 2015, the Company transferred $ 2.8 3.0 3.6 In connection with the transfer of NSC Note proceeds to a Fortress Company, NSC will receive a warrant to purchase the Fortress Company’s common stock equal to 25 10 On October 30, 2015, Checkpoint granted 139,592 0.0001 0.6 0.2 0.4 On October 31, 2015, Avenue recorded approximately $ 0.1 In February 2016, Checkpoint repaid its NSC Debt of $ 2.8 0.3 0.2 In July 2016, Fortress transferred $ 3.6 25 0.6 On October 25, 2016, Mustang issued 138,462 0.0001 0.8 As of December 31, 2016, Avenue recorded approximately $ 0.4 0.1 In January 2017, the Company and Avenue notified NSC of their intention to extend the maturity date of the NSC Notes by six months, to September 2018. On July 5, 2017, the Company repaid it NSC Note in the amount of $ 3.6 Helocyte Convertible Notes During 2016 Helocyte entered into an agreement with Aegis Capital Corp. (“Aegis”) to raise up to $ 5.0 18 5 8 10.0 As of December 31, 2016, Helocyte realized net proceeds in its four separate closings of $3.9 million after paying Aegis, its placement fee of $0.4 million, or approximately 10% of the net proceeds, and legal fees of approximately $ 0.1 0.4 110 Due to the complexity and number of embedded features within each convertible note, and as permitted under accounting guidance, the Company elected to account for the convertible notes and all the embedded features under the fair value option (see note 7). On January 1, 2018, the first $ 1.0 Opus Credit Facility Agreement On September 14, 2016, Fortress entered into a Credit Facility Agreement (the “Opus Credit Facility”) with Opus Point Healthcare Innovations Fund, LP (“OPHIF”). Since Fortress’s Chairman, President and Chief Executive Officer (Lindsay A. Rosenwald) and Fortress’s Executive Vice President, Strategic Development (Michael S. Weiss), are Co-Portfolio Managers and Partners of Opus Point Partners Management, LLC (“Opus”), an affiliate of OPHIF, all of the disinterested directors of Fortress’s board of directors approved the terms of the Credit Facility Agreement and accompanying Pledge and Security Agreement and forms of Note and Warrant (collectively, the “Financing Documents”). Pursuant to the Opus Credit Facility, Fortress may borrow up to a maximum aggregate amount of $ 25.0 September 14, 2018 Pursuant to the Opus Credit Facility and form of Note, each Note will bear interest at 12 10.00 Fortress may terminate the Opus Credit Facility upon notice to the Lenders and payment of all outstanding obligations under the Credit Facility Agreement. Notwithstanding any early termination of the Credit Facility Agreement, within 15 days after termination of the Commitment Period, Fortress will issue each Lender warrants (each a “Warrant”) pursuant to the terms of the Credit Facility Agreement and form of Warrant to purchase their pro rata share of (a) 1,500,000 3.00 As of December 31, 2017 and 2016, $ 9.5 7.0 Avenue Convertible Notes On December 31, 2016, Avenue held the first closing of the sale of convertible promissory notes (the “Avenue Notes”). The Avenue Notes have an initial term of 18 5 10.0 (a) the lowest price per share at which equity securities of Avenue are sold in such sale less a 33% discount and (b) a per share price based on a pre-offering valuation of $30.0 million divided by the number of common shares outstanding on a fully-diluted basis. (a) a discount to the price per share being paid in the Sale of Avenue equal to 33% or (b) a conversion price per share based on a pre-sale valuation of $30.0 million divided by the fully-diluted common stock of Avenue immediately prior to the Sale of Avenue (excluding the Avenue Notes). Gross proceeds from this offering totaled $ 0.2 0.1 58,000 10,000 10 44,000 4,000 10,000 Due to the complexity and number of embedded features within each convertible note, and as permitted under accounting guidance, the Company elected to account for the convertible notes and all the embedded features (collectively, the “hybrid instrument “) under the fair value option. At December 31, 2017 and 2016 Avenue had nil and $ 0.2 IDB Letters of Credit The Company has several letters of credit (“LOC”) with IDB securing rent deposits for lease facilities totaling approximately $ 2.0 2 2017 Subordinated Note Financing On March 31, 2017, the Company entered into Note Purchase Agreements (the “Purchase Agreements”) with NAM Biotech Fund II, LLC I (“NAM Biotech Fund”) and NAM Special Situations Fund I QP, LLC (“NAM Special Situations Fund”), both of which are accredited investors, and sold subordinated promissory notes (the “Notes”) of the Company (the “2017 Subordinated Note Financing”) in the aggregate principal amount of $ 3.25 8 7 Each Note is due on the third anniversary of its issuance, provided that the Company may extend the maturity date for two one-year periods in its sole discretion. 40.0 50.0 National Securities Corporation (“NSC”), a subsidiary of National and a related party, (see Note 18), pursuant to a Placement Agency Agreement entered into between the Company, NAM Biotech Fund and NSC (the “NAM Placement Agency Agreement”) and a Placement Agency Agreement entered into between the Company, NAM Special Situations Fund and NSC (together with the NAM Placement Agency Agreement, the “Placement Agency Agreements”) acts as placement agent in the 2017 Subordinated Note Financing. Pursuant to the terms of the Placement Agency Agreements, NSC receives (in addition to reimbursement of certain expenses) an aggregate cash fee equal to 10 10 On March 31, 2017, held its first closing of the 2017 Subordinated Note Financing and received gross proceeds of $ 3.2 0.3 87,946 3.70 On May 1, 2017, the Company held a second closing of the 2017 Subordinated Note Financing and received gross proceeds of $ 8.6 0.9 234,438 3.65 On May 31, 2017, the Company held a third closing of the 2017 Subordinated Note Financing and received gross proceeds of $ 5.3 0.5 147,806 3.61 On June 30, 2017, the Company held a fourth closing of the 2017 Subordinated Note Financing and received gross proceeds of $ 1.8 0.2 38,315 4.75 On August 31, 2017, the Company held a fifth closing of the 2017 Subordinated Note Financing and received gross proceeds of $ 3.0 0.3 63,526 4.75 On September 30, 2017, the Company held a sixth closing of the 2017 Subordinated Note Financing and received gross proceeds of $ 6.4 0.6 144,149 4.42 Caelum Convertible Notes On July 31, 2017 Caelum through National Securities Corporation (“NSC” or “Placement Agent”), a subsidiary of National offered up to $ 10 10 During the year ended December 31, 2017, Caelum raised $ 9.9 10 0.9 10 110 the exercise price will be $75 million dollars divided by the total number of fully-diluted shares of Common Stock outstanding immediately prior to exercise of the warrant, giving effect to the assumed conversion of all options, warrants, and convertible securities of the Company . The notes convert upon a qualified financing in which Caelum raises gross proceeds of at least $10 million as follows: the lesser of (a) a discount to the price per common share being paid in the Sale of the Company equal to 20% or (b) a conversion price per share based on a pre-sale valuation of $75,000,000 divided by the number of common shares outstanding at that time assuming the hypothetical conversion or exercise of any convertible securities, options, warrants and other rights to acquire common shares of the Company. Interest Expense For the Years Ended December 31, ($ in thousands) 2017 2016 2015 IDB Note Interest $ 340 $ 328 $ 314 Amortization of fees - 1 5 Total IDB Note 340 329 319 NSC Debt Interest 147 599 690 Amortization of fees 201 1,270 309 Total NSC Debt 348 1,869 999 2017 Subordinated Note Interest 2,234 - - Amortization of fees 76 - - Total 2017 Subordinated Note 2,310 - - Opus Credit Facility Interest 1,087 192 - Amortization of fees 1,037 195 - Total Opus Note 2,124 387 - Ovamed Interest - - 166 Total Ovamed - - 166 LOC Fees Interest 36 11 - Total LOC 36 11 - Helocyte Convertible Note Interest 261 61 - Financing fee 1 962 - Total Helocyte Convertible Note 262 1,023 - Avenue Convertible Note Interest 5 - - Financing fee 3 70 - Total Avenue Convertible Note 8 70 - Caelum Convertible Note Interest 265 - - Financing fee 100 - - Total Caelum Convertible Note 365 - - Falk CSR Interest 64 - - Total Falk CSR 64 - - D&O Insurance Interest 3 1 - Total D&O Insurance 3 1 - Total Interest Expense and Financing Fee $ 5,860 $ 3,690 $ 1,484

Accrued Liabilities and other L

Accrued Liabilities and other Long-Term Liabilities	12 Months Ended
	Dec. 31, 2017
Payables and Accruals [Abstract]
Accrued Liabilities and other Long-Term Liabilities	12. Accrued Liabilities and other Long-Term Liabilities December 31, 2017 2016 Accrued expenses: Professional fees $ 1,625 $ 1,253 Salaries, bonuses and related benefits 5,279 2,846 Accrued expenses – related party 95 - Accrued severance - 53 Ovamed manufacturing rights - short term component - 900 Research and development 4,046 394 Dr. Falk Pharma milestone (See Note 16) 3,059 2,634 Accrued royalties payable 1,411 263 Accrued coupon expense 1,087 463 Lease impairment - 128 Other 1,030 1,148 Total accrued expenses $ 17,632 $ 10,082 Other long-term liabilities: Deferred rent and long-term lease abandonment charge 4,739 5,014 Total other long-term liabilities $ 4,739 $ 5,014 September 30, 2017 2016 Legal $ 877 $ 1,346 Audit 176 198 Telecommunications 205 209 Data Services 464 425 Regulatory 540 444 Settlements 2,403 832 Deferred rent 497 65 Other 3,242 3,223 Total $ 8,404 $ 6,742

Non-Controlling Interests

Non-Controlling Interests	12 Months Ended
	Dec. 31, 2017
Noncontrolling Interest [Abstract]
Non-Controlling Interests	13. Non-Controlling Interests As of December 31, 2017 NCI equity share Net gain/(loss) attributable to Non-controlling Non-controlling Aevitas $ (126) $ (168) $ (294) 35.4 % Avenue 2 17,454 (4,646) 12,808 66.1 % Caelum (815) (1,262) (2,077) 34.7 % Cellvation (259) (96) (355) 21.5 % Checkpoint 1 21,635 (12,314) 9,321 62.0 % Coronado SO (236) (54) (290) 13.0 % Cyprium (143) (15) (158) 11.1 % Helocyte (1,907) (1,193) (3,100) 20.0 % JMC (469) 7 (462) 6.3 % Mustang 2 48,740 (11,911) 36,829 61.6 % National Holdings 17,021 (1,216) 15,805 43.4 % Tamid (6) (92) (98) 24.0 % Total $ 100,889 $ (32,960) $ 67,929 As of December 31, 2016 NCI equity share Net loss attributable to Non-controlling Non-controlling Avenue (494) (349) (843) 10.2 % Cellvation 4 (158) (154) 22.0 % Checkpoint 1 32,160 (11,733) 20,427 62.9 % Coronado SO (217) (19) (236) 13.0 % Helocyte (612) (1,155) (1,767) 20.5 % JMC (192) (355) (547) 7.0 % Mustang 12,376 (1,805) 10,571 26.7 % National Holdings 17,643 (621) 17,022 43.4 % Total $ 60,668 $ (16,195) $ 44,473 As of December 31, 2015 NCI equity share Net loss attributable to Non-controlling Non-controlling Avenue $ 6 $ (567) $ (561) 11.5 % Checkpoint 1 32,760 (3,855) 28,905 62.3 % Coronado SO 23 (240) (217) 13.0 % JMC 79 (420) (341) 8.8 % Mustang 14 (373) (359) 10.0 % Total $ 32,882 $ (5,455) $ 27,427 (1) Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights. (2) Avenue and Mustang are consolidated with Fortress’ operations because Fortess maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights.

Net Loss per Common Share

Net Loss per Common Share	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Net Loss Per Common Share	14. Net Loss per Common Share The Company calculates loss per share using the two-class method, which is an earnings allocation formula that determines earnings per share for Common Stock and participating securities, if any, according to dividends declared and non-forfeitable participation rights in undistributed earnings. Under this method, all earnings (distributed and undistributed) are allocated to Common Stock and participating securities, if any, based on their respective rights to receive dividends. Holders of restricted Common Stock were entitled to all cash dividends, when and if declared, and such dividends are non-forfeitable. The participating securities do not have a contractual obligation to share in any losses of the Company. As a result, net losses are not allocated to the participating securities for any periods presented. Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of Common Stock outstanding during the period, without consideration for Common Stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of Common Stock and Common Stock equivalents outstanding for the period. Included in Common Stock issued and outstanding as of December 31, 2017, 2016 and 2015 were 9,840,614 8,749,052 6,816,321 The Company’s potential dilutive securities which consist of unvested restricted stock, unvested restricted stock units, options, and warrants have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average Common Stock outstanding used to calculate both basic and diluted net loss per share is the same. The following shares of potentially dilutive securities, weighted during the years ended December 31, 2017, 2016, and 2015 have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive: For the Years Ended December 31, 2017 2016 2015 Warrants to purchase Common Stock 745,285 456,150 685,061 Opus warrants to purchase Common Stock 628,383 1,780,000 - Options to purchase Common Stock 1,093,283 1,604,214 1,960,443 Series A Preferred Stock 2,740 - - Unvested Restricted Stock 9,840,614 8,749,052 6,816,321 Unvested Restricted Stock Units 1,390,799 1,087,563 427,627 Total 13,701,104 13,676,979 9,889,452

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2017
Stockholders' Equity Note [Abstract]
Stockholders’ Equity	15. Stockholders’ Equity Common Stock The Company’s Certificate of Incorporation, as amended, authorizes the Company to issue 100,000,000 0.001 50,991,285 48,932,023 The terms, rights, preference and privileges of the Common Stock are as follows: Voting Rights Each holder of Common Stock is entitled to one vote per share of Common Stock held on all matters submitted to a vote of the stockholders, including the election of directors. The Company’s certificate of incorporation and bylaws do not provide for cumulative voting rights. Dividends Subject to preferences that may be applicable to any then outstanding preferred stock, the holders of the Company’s outstanding shares of Common Stock are entitled to receive dividends, if any, as may be declared from time to time by the Company’s Board of Directors out of legally available funds. Liquidation In the event of the Company’s liquidation, dissolution or winding up, holders of Common Stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of the Company’s debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any outstanding shares of Preferred Stock. Rights and Preference Holders of the Company’s Common Stock have no preemptive, conversion or subscription rights, and there is no redemption or sinking fund provisions applicable to our Common Stock. The rights, preferences and privileges of the holders of Common Stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of the Company’s preferred stock that are or may be issued. Fully Paid and Nonassessable All of the Company’s outstanding shares of Common Stock are fully paid and nonassessable. Series A Preferred Stock On October 26, 2017, the Company designated 5,000,000 25.0 1,000,000 Voting Rights Except as may be otherwise required by law, the voting rights of the holders of the Series A Preferred Stock are limited to the affirmative vote or consent of the holders of at least two-thirds of the votes entitled to be cast by the holders of the Series A Preferred Stock outstanding at the time in connection with the: (1) authorization or creation, or increase in the authorized or issued amount of, any class or series of capital stock ranking senior to the Series A Preferred Stock with respect to payment of dividends or the distribution of assets upon liquidation, dissolution or winding up or reclassification of any of the Company’s authorized capital stock into such shares, or creation, authorization or issuance of any obligation or security convertible into or evidencing the right to purchase any such shares; or (2) amendment, alteration, repeal or replacement of the Company’s certificate of incorporation, including by way of a merger, consolidation or otherwise in which the Company may or may not be the surviving entity, so as to materially and adversely affect and deprive holders of Series A Preferred Stock of any right, preference, privilege or voting power of the Series A Preferred Stock. Dividends Dividends on Series A Preferred Stock accrue daily and will be cumulative from, and including, the date of original issue and shall be payable quarterly every March 31, June 30, September 30, and December 31, at the rate of 9.375 2.34375 0.299479 0.3 No Maturity Date or Mandatory Redemption The Series A Preferred Stock has no maturity date, and the Company is not required to redeem the Series A Preferred Stock. Accordingly, the Series A Preferred Stock will remain outstanding indefinitely unless the Company decides to redeem it pursuant to its optional redemption right or its special optional redemption right in connection with a Change of Control (as defined below), or under the circumstances set forth below under “Limited Conversion Rights Upon a Change of Control” and elect to convert such Series A Preferred Stock. The Company is not required to set aside funds to redeem the Series A Preferred Stock. Optional Redemption The Series A Preferred Stock may be redeemed in whole or in part (at the Company’s option) any time on or after December 15, 2022, upon not less than 30 days nor more than 60 days’ written notice by mail prior to the date fixed for redemption thereof, for cash at a redemption price equal to $25.00 per share, plus any accumulated and unpaid dividends to, but not including, the redemption date. Special Optional Redemption Upon the occurrence a Change of Control (as defined below), the Company may redeem the shares of Series A Preferred Stock, at its option, in whole or in part, within one hundred twenty (120) days of any such Change of Control, for cash at $25.00 per share, plus accumulated and unpaid dividends (whether or not declared) to, but excluding, the redemption date. If, prior to the Change of Control conversion date, the Company has provided notice of its election to redeem some or all of the shares of Series A Preferred Stock (whether pursuant to the Company’s optional redemption right described above under “Optional Redemption” or this special optional redemption right), the holders of shares of Series A Preferred Stock will not have the Change of Control conversion right with respect to the shares of Series A Preferred Stock called for redemption. If the Company elects to redeem any shares of the Series A Preferred Stock as described in this paragraph, the Company may use any available cash to pay the redemption price. A “Change of Control” is deemed to occur when, after the original issuance of the Series A Preferred Stock, the following have occurred and are continuing: · the acquisition by any person, including any syndicate or group deemed to be a “person” under Section 13(d)(3) of the Exchange Act of beneficial ownership, directly or indirectly, through a purchase, merger or other acquisition transaction or series of purchases, mergers or other acquisition transactions of the Company’s stock entitling that person to exercise more than 50% of the total voting power of all the Company’s stock entitled to vote generally in the election of the Company’s directors (except that such person will be deemed to have beneficial ownership of all securities that such person has the right to acquire, whether such right is currently exercisable or is exercisable only upon the occurrence of a subsequent condition); and · following the closing of any transaction referred to in the bullet point above, neither the Company nor the acquiring or surviving entity has a class of common equity securities (or American Depositary Receipts representing such securities) listed on the NYSE, the NYSE American LLC or the Nasdaq Stock Market, or listed or quoted on an exchange or quotation system that is a successor to the NYSE, the NYSE American LLC or the Nasdaq Stock Market. Conversion, Exchange and Preemptive Rights Except as described below under “Limited Conversion Rights upon a Change of Control,” the Series A Preferred Stock is not subject to preemptive rights or convertible into or exchangeable for any other securities or property at the option of the holder. Limited Conversion Rights upon a Change of Control Upon the occurrence of a Change of Control, each holder of shares of Series A Preferred Stock will have the right (unless, prior to the Change of Control Conversion Date, the Company has provided or provides irrevocable notice of its election to redeem the Series A Preferred Stock as described above under “Optional Redemption,” or “Special Optional Redemption”) to convert some or all of the shares of Series A Preferred Stock held by such holder on the Change of Control Conversion Date, into the Common Stock Conversion Consideration, which is equal to the lesser of: · the quotient obtained by dividing (i) the sum of the $ 25.00 · 13.05483 shares of common stock, subject to certain adjustments. In the case of a Change of Control pursuant to which the Company’s common stock will be converted into cash, securities or other property or assets, a holder of Series A Preferred Stock will receive upon conversion of such Series A Preferred Stock the kind and amount of Alternative Form Consideration which such holder would have owned or been entitled to receive upon the Change of Control had such holder held a number of shares of the Company’s common stock equal to the Common Stock Conversion Consideration immediately prior to the effective time of the Change of Control. Notwithstanding the foregoing, the holders of shares of Series A Preferred Stock will not have the Change of Control Conversion Right if the acquiror has shares listed or quoted on the NYSE, the NYSE American LLC or Nasdaq Stock Market or listed or quoted on an exchange or quotation system that is a successor to the NYSE, the NYSE American LLC or Nasdaq Stock Market, and the Series A Preferred Stock becomes convertible into or exchangeable for such acquiror’s listed shares upon a subsequent Change of Control of the acquiror. Liquidation Preference In the event the Company liquidates, dissolves or is wound up, holders of the Series A Preferred Stock will have the right to receive $25.00 per share, plus any accumulated and unpaid dividends to, but not including, the date of payment, before any payment is made to the holders of the Company’s common stock. Ranking The Series A Preferred Stock will rank, with respect to rights to the payment of dividends and the distribution of assets upon the Company’s liquidation, dissolution or winding up, (1) senior to all classes or series of the Company’s common stock and to all other equity securities issued by the Company other than equity securities referred to in clauses (2) and (3); (2) on a par with all equity securities issued by the Company with terms specifically providing that those equity securities rank on a par with the Series A Preferred Stock with respect to rights to the payment of dividends and the distribution of assets upon the Company’s liquidation, dissolution or winding up; (3) junior to all equity securities issued by the Company with terms specifically providing that those equity securities rank senior to the Series A Preferred Stock with respect to rights to the payment of dividends and the distribution of assets upon the Company liquidation, dissolution or winding up; and (4) junior to all of the Company’s existing and future indebtedness. As of December 31, 2017 and 2016, 1,000,000 and nil shares, respectively, of Series A Preferred Stock were issued and outstanding. Stock-Based Compensation including National As of December 31, 2017, the Company had four equity compensation plans: the Fortress Biotech, Inc. 2007 Stock Incentive Plan (the “2007 Plan”), the Fortress Biotech, Inc. 2013 Stock Incentive Plan, as amended (the “2013 Plan”), the Fortress Biotech, Inc. 2012 Employee Stock Purchase Plan (the “ESPP”) and the Fortress Biotech, Inc. Long Term Incentive Plan (“LTIP”). In 2007, the Company’s Board of Directors adopted and stockholders approved the 2007 Plan authorizing the Company to grant up to 6,000,000 2,300,000 7,700,000 10,000,000 16,000,000 12,506,679 3,493,321 Fortress Companies have their own equity compensation plan under which shares are granted to eligible employees, directors and consultants in the form of restricted stock, stock options, and other types of grants of stock of the respective Fortress Company. Fortress Company Stock Plan Shares Authorized Shares Avenue Avenue Therapeutics, Inc. 2015 Stock Plan 2,000,000 1,115,000 Caelum Caelum Biosciences Inc. 2017 Incentive Plan 2,000,000 125,002 Cellvation Cellvation Inc. 2016 Incentive Plan 2,000,000 300,000 Checkpoint Checkpoint Therapeutics, Inc. Amended and Restated 2015 Stock Plan 5,000,000 2,961,697 Cyprium Cyprium Therapeutics, Inc. 2017 Stock Plan 2,000,000 2,000,000 Helocyte DiaVax Biosciences, Inc. 2015 Incentive Plan 2,000,000 341,667 Journey Journey Medical Corporation 2015 Stock Plan 3,000,000 614,792 Mustang Mustang Bio, Inc. 2016 Incentive Plan 2,000,000 444,325 Tamid FBIO Acquisition Corp. V 2017 Incentive Plan 2,000,000 1,600,000 The purpose of the Company’s and the Fortress Companies’ equity compensation plans is to provide for equity awards as part of an overall compensation package of performance-based rewards to attract and retain qualified personnel. Such awards include, without limitation, options, stock appreciation rights, sales or bonuses of restricted stock, restricted stock units or dividend equivalent rights, and an award may consist of one such security or benefit, or two or more of them in any combination or alternative. Vesting of awards may be based upon the passage of time, the occurrence of one or more events, or the satisfaction of performance criteria or other conditions. Incentive and non statutory stock options are granted pursuant to option agreements adopted by the plan administrator. Options generally have 10-year contractual terms and vest in three equal annual installments commencing on the grant date. The Company estimates the fair value of stock option grants using a Black-Scholes option pricing model. In applying this model, the Company uses the following assumptions: · Risk-Free Interest Rate: · Volatility: · Expected Term: · Expected Dividend Rate: The fair value of each option award was estimated on the grant date using the Black-Scholes option-pricing model and expensed under the straight line method. Journey and Mustang issued stock options during the years ended December 31, 2017, 2016 and 2015. The fair value for non-employee stock based awards are marked-to-market on each valuation date until vested using the Black-Scholes pricing model. For the Years Ended December 31, ($ in thousands) 2017 2016 2015 Employee awards $ 6,606 $ 7,386 $ 8,130 Executive awards of Fortress Companies’ stock - - 2,228 Non-employee awards 83 33 33 Fortress Companies: Avenue 604 28 51 Caelum 595 - - Cellvation 31 7 - Checkpoint 3,118 3,867 3,252 Helocyte 128 250 - JMC 224 515 597 Mustang 2,013 - - Tamid 1 - - National 602 42 - Total stock-based compensation expense $ 14,005 $ 12,128 $ 14,291 For the years ended December 31, 2017, 2016 and 2015, $ 4.0 4.7 5.8 10.0 7.4 8.5 Options Number of Weighted Total Weighted Options vested and expected to vest at December 31, 2015 1,779,365 $ 4.37 $ 666,396 6.32 Forfeited (648,864) 0.51 - - Options vested and expected to vest at December 31, 2016 1,130,501 3.73 602,451 4.93 Exercised (20,000) 1.37 52,400 - Exercisable as of December 31, 2016 1,110,501 $ 3.78 $ 1,351,080 3.95 Options vested and expected to vest at December 31, 2017 1,085,501 $ 3.75 $ 1,351,080 3.93 During the years ended December 31, 2017, 2016 and 2015, exercises of stock options resulted in total proceeds of approximately $ 27,000 0.2 As of December 31, 2017, the Company had unrecognized stock-based compensation expense related to all unvested options and vested options of nil and nil, respectively. Restricted Stock Stock-based compensation expense from restricted stock awards and restricted stock units for the years ended December 31, 2017, 2016, 2015 was $ 11.3 9.9 6.9 Senior Vice President (“SVP”) Grant On July 15, 2015, the Company’s SVP, Biologics Operations, was granted 1.0 50 200,000 3.3 0.4 3.7 150,000 150,000 300,000 0.3 1.2 1.9 , respectively Acceleration of Grants to Former Director On July 15, 2015, the Board of Directors accelerated the vesting of 133,000 0.4 Restricted Stock Unit Grant to a Current Director During 2017, the Company granted 1,325,396 1,128,750 3.6 4.7 During 2016, the Company granted 1,240,868 641,000 3.4 1.8 Restricted Stock Issuance Agreements to Chief Executive Officer and Executive Chair, Strategic Development In December 2017, the Company modified the vesting schedule on the 1.9 0.4 December 2022 2.5 Number of shares Weighted Unvested balance at December 31, 2015 8,757,935 $ 2.47 Restricted stock granted 1,240,868 2.77 Restricted stock cancelled (33,333) 2.69 Restricted stock vested (173,333) 2.73 Restricted stock units granted 641,000 2.93 Restricted stock units cancelled (111,750) 3.58 Restricted stock units vested (227,292) 3.56 Unvested balance at December 31, 2016 10,094,095 $ 2.49 Restricted stock granted 1,325,396 2.70 Restricted stock vested (213,333) 2.75 Restricted stock units granted 1,128,750 4.17 Restricted stock units forfeited (15,000) 2.98 Restricted stock units vested (445,874) 3.50 Unvested balance at December 31, 2017 11,874,034 $ 2.63 As of December 31, 2017, the Company had unrecognized stock-based compensation expense related to all unvested restricted stock and restricted stock unit awards of $ 3.4 3.2 4.6 1.5 Deferred Compensation Plan On March 12, 2015, the Company’s Compensation Committee approved the Deferred Compensation Plan allowing all non-employee directors the opportunity to defer all or a portion of their fees or compensation, including restricted stock and restricted stock units. During the year ended December 31, 2017, 2016, and 2015 certain non-employee directors elected to defer an aggregate of 230,000 230,000 290,000 Employee Stock Purchase Plan Eligible employees can purchase the Company’s Common Stock at the end of a predetermined offering period at 85 On June 1, 2015, the Company issued 14,681 1.80 85 2.12 13,317 2.41 85 2.84 On June 1, 2016, the Company issued 33,958 2.40 85 2.82 52,769 2.03 85 2.39 On June 1, 2017, the Company issued 22,076 1.90 85 2.24 45,657 3.26 85 3.83 As of December 31, 2017, 245,652 154,348 0.2 0.1 45,000 Warrants Number of Weighted Total Weighted Outstanding as of December 31, 2015 569,835 $ 6.31 $ 120,700 1.84 Granted 1,880,000 3.00 - 5.65 Expired (161,382) 6.30 - - Exercised (*) (25,000) 1.37 33,250 - Outstanding as of December 31, 2016 2,263,453 $ 3.62 $ 79,800 4.74 Granted 816,180 3.84 260,380 4.87 Forfeited (305,444) 7.07 - - Outstanding as of December 31, 2017 2,774,189 $ 3.30 $ 2,204,530 4.47 Exercisable as of December 31, 2017 869,189 $ 3.96 $ 318,580 4.05 (*) – cashless All stock-based expense in connection with these warrants has been recognized prior to January 1, 2017. Long-Term Incentive Program (“LTIP”) On July 15, 2015, the stockholders approved the LTIP for the Company’s Chairman, President and Chief Executive Officer, Dr. Rosenwald, and Executive Vice Chairman, Strategic Development, Mr. Weiss. The LTIP consists of a program to grant equity interests in the Company and in the Company’s subsidiaries, and a performance-based bonus program that is designed to result in performance-based compensation that is deductible without limit under Section 162(m) of the Internal Revenue Code of 1986, as amended. 500,000 2015 Warrant Risk Free Volatility Life Exercise Fair Value Mustang 1,000,000 2.36 % 106.11 % 10 $ 0.147 $ 135,000 Checkpoint 1,000,000 2.36 % 106.11 % 10 $ 0.129 $ 118,000 Avenue 1,000,000 2.36 % 106.11 % 10 $ 0.146 $ 134,000 CNDO SO 1,000,000 2.36 % 106.11 % 10 $ 1.190 $ 1,091,000 Helocyte 1,000,000 2.36 % 106.11 % 10 $ 0.097 $ 89,000 JMC 1,000,000 2.36 % 106.11 % 10 $ 0.650 $ 596,000 Escala 1,000,000 2.36 % 106.11 % 10 $ 0.071 $ 65,000 2016 Cellvation 1,000,000 2.86 % 70 % 9 $ 0.024 $ 18,000 The exercise price, which approximates the fair value, was determined by the Company utilizing a discounted cash flow model to determine the weighted market value of invested capital, discounted by a lack of marketability of 44.8 30 $ 18,000 2.2 500,000 5 Risk Free Discount for Exercise 2017 Stock Shares Rate Volatility Marketability price Fair Value Aevitas 1,000,000 1.92 79.8 % 42.6 % $ 0.020 $ 20,000 Caelum 1,000,000 1.93 70.0 % 49.5 % $ 0.028 $ 28,000 Cyprium 1,000,000 1.92 84.3 % 44.2 % $ 0.004 $ 4,000 Acquisition Corp. III 1,000,000 1.92 83.9 % 44.0 % $ 0.007 $ 7,000 Acquisition Corp. IV 1,000,000 1.92 83.9 % 44.0 % $ 0.007 $ 7,000 Tamid 1,000,000 1.92 83.9 % 44.0 % $ 0.007 $ 7,000 Acquisition Corp. VI 1,000,000 1.92 83.9 % 44.0 % $ 0.007 $ 7,000 Acquisition Corp. VII 1,000,000 1.92 83.9 % 44.0 % $ 0.007 $ 7,000 Acquisition Corp. VIII 1,000,000 1.92 83.9 % 44.0 % $ 0.007 $ 7,000 For the year ended December 31, 2017, the Company recorded expense of approximately $ 0.1 On January 1, 2017 and 2016, the Compensation Committee granted 552,698 510,434 1 100.0 $ 1.5 1.4 0.6 0.3 Capital Raise Avenue Therapeutics, Inc. On June 26, 2017, Avenue completed an IPO of its common stock. In connection with the IPO, Avenue issued 6,325,000 825,000 6.00 34.2 2.3 In conjunction with the closing of the IPO, Avenue issued warrants in connection with its NSC Debt and its Convertible Notes. Avenue issued to National warrants for 125,000 0.8 Checkpoint Therapeutics, Inc. On September 18, 2015, Checkpoint entered into a placement agency agreement with National Securities Corporation (the “Placement Agent”) relating to Checkpoint’s offering, issuance and sale (the “Offering”) to select institutional investors (the “Investors”) of units consisting of 10,000 2,500 7.00 50,000 10.0 10 57.8 51.5 10,000 2,500 7.00 50,000 Following this capital raise, the Company’s ownership in Checkpoint decreased to 37.7 On February 23, 2016, Checkpoint closed on gross proceeds of $ 0.6 10,000 3,500 7.00 45,000 126,640 44,324 Mustang Bio, Inc. In third and fourth quarter of 2016, Mustang closed on gross proceeds of $ 39.1 3.9 10 10,000 2,500 8.50 65,000 6.0 1.5 601,486 In 2017, Mustang raised gross proceeds of $ 56.0 8,610,774 2,152,693 5.6 10 861,077 As of December 31, 2017, the Company determined that the warrants still did not meet the definition of a derivative and continued to qualify for equity recognition. At Market Offerings In May 2016, the Company issued 150,556 2.89 0.4 79,000 On August 17, 2016, the Company entered into an Amended and Restated At Market Issuance Sales Agreement, or Sales Agreement, with MLV & Co. LLC, or MLV, and FBR Capital Markets & Co., or FBR. On August 18, 2016, the Company filed a Registration Statement on Form S-3, which became effective on December 1, 2016 and permits the Company to issue and sell shares of its common stock having an aggregate offering price of up to $ 53.0 Perpetual Preferred Offering In November 2017, the Company raised gross proceeds of $ 25.0 9.375 25.0 22.2 2.7 2.1 0.1

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	16. Commitments and Contingencies Fortress In October 2015, the Company entered into a 5 6,100 0.2 On October 3, 2014, the Company entered into a 15 2.7 10 45 0.3 1.1 1.0 1.3 0.2 In December 2012, we assumed a lease from TSO Laboratories, Inc., a wholly owned subsidiary of Ovamed GmbH, for approximately 8,700 February 28, 2018 0.1 In April 2013, the Company entered into a three-year lease for approximately 1,500 0.1 Journey In June 2017 and July 2016, Journey extended its lease for one year for $ 2,295 55,000 53,000 0.1 Mustang On October 27, 2017, Mustang entered into a lease agreement with WCS - 377 Plantation Street, Inc., a Massachusetts nonprofit corporation (“Landlord”). Pursuant to the terms of the lease agreement, Mustang agreed to lease 27,043 0.6 3.6 3.5 The terms of the lease also require that Mustang post an initial security deposit of $ 0.8 0.5 0.3 1.3 1.0 0.3 The Facility is expected to be operational for the production of personalized CAR T therapies in 2018. For the twelve months ended December 31, 2017 Mustang recorded $ 0.1 ($ in thousands) 2018 $ 2,761 2019 2,976 2020 3,203 2021 3,084 2022 3,084 Beyond 26,600 Total minimum lease payments $ 41,708 The Company recognizes rent expense on a straight-line basis over the non-cancellable lease term. Rent expense for the years ended December 31, 2017, 2016 and 2015 was $ 1.2 1.8 0.4 Operating Lease Obligations - National As of September 30, 2017, National leases office space in various states expiring at various dates through August 2025, and is committed under operating leases for future minimum lease payments as follows ($ in thousands): Fiscal Year Ending Rental Less, Sublease Net 2018 $ 3,040 $ 360 $ 2,680 2019 2,481 30 2,451 2020 2,346 — 2,346 2021 2,043 — 2,043 2022 1,331 — 1,331 Thereafter 4,524 — 4,524 Total $ 15,765 $ 390 $ 15,375 Rental expense under all operating leases for the period from September 9, 2016 through September 30, 2016 and for the year ended September 30, 2017 was approximately $ 0.2 4.3 8,200 0.2 As of September 30, 2017, and 2016, National had outstanding three letters of credit, which have been issued in the maximum amount of $ 1.4 0.4 Indemnification In accordance with its certificate of incorporation, bylaws and indemnification agreements, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company’s request in such capacity. There have been no claims to date, and the Company has director and officer insurance to address such claims. Pursuant to agreements with clinical trial sites, the Company provides indemnification to such sites in certain conditions. Legal Proceedings Fortress In the ordinary course of business, the Company and its subsidiaries may be subject to both insured and uninsured litigation. Suits and claims may be brought against the Company by customers, suppliers, partners and/or third parties (including tort claims for personal injury arising from clinical trials of the Company’s product candidates and property damage) alleging deficiencies in performance, breach of contract, etc., and seeking resulting alleged damages. In March 2012, Fortress and Dr. Falk Pharma, GmbH (“ Dr. Falk Pharma 2.5 2.5 2.5 At December 31, 2017 and 2016, the Company recorded a liability of approximately $ 3.0 2.6 2.5 Fortress and Mustang On January 15, 2016, Dr. Winson Tang (“Tang”) filed a Complaint against us in the Superior Court of the State of California, County of Los Angeles. Winson Tang v. Lindsay Rosenwald et al., In connection with the legal settlement, above, the Company delivered 200,000 2.0 0.2 2.2 Litigation and Regulatory Matters – National National is a defendant or respondent in various pending and threatened arbitrations, administrative proceedings and lawsuits seeking compensatory damages. Several cases have no stated alleged damages. Claim amounts are infrequently indicative of the actual amounts National will be liable for, if any. Further, National has a history of collecting amounts awarded in these types of matters from its brokers that are still affiliated, as well as from those that are no longer affiliated. Many of these claimants also seek, in addition to compensatory damages, punitive or treble damages, and all seek interest, costs and fees. These matters arise in the normal course of business. National intends to vigorously defend itself in these actions, and the ultimate outcome of these matters cannot be determined at this time. Liabilities for potential losses from complaints, legal actions, government investigations and proceedings are established where management believes that it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. In making these decisions, management bases its judgments on its knowledge of the situations, consultations with legal counsel and its historical experience in resolving similar matters. In many lawsuits, arbitrations and regulatory proceedings, it is not possible to determine whether a liability has been incurred or to estimate the amount of that liability until the matter is close to resolution. However, accruals are reviewed regularly and are adjusted to reflect management’s estimates of the impact of developments, rulings, advice of counsel and any other information pertinent to a particular matter. Because of the inherent difficulty in predicting the ultimate outcome of legal and regulatory actions, management cannot predict with certainty the eventual loss or range of loss related to such matters. These amounts are included in accounts payable and other accrued expenses in the statements of financial condition. Awards ultimately paid, if any, may be covered by our errors and omissions insurance policy. While National will vigorously defend itself in these matters and will assert insurance coverage and indemnification to the maximum extent possible, there can be no assurance that such matters will not have a material adverse impact on our financial position, results of operations or cash flows. National has included in “Professional fees” litigation and FINRA related expenses of $ 0.2 1.5

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2017
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
Employee Benefit Plans	17. Employee Benefit Plan Fortress Biotech, Inc. On January 1, 2008, the Company adopted a defined contribution 401(k) plan which allows employees to contribute up to a percentage of their compensation, subject to IRS limitations and provides for a discretionary Company match up to a maximum of 4 0.2 0.2 0.1 National Holdings Corporation In September 2011, National created a new defined contribution 401(k) plan (the “Plan”) merging the two plans originally formed prior to the merger of National and vFinance effective October 1, 2011. Under the Plan, employees can elect to defer up to 75

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Note	18. Related Party Transactions Other Related Parties The Company’s Chairman, President and Chief Executive Officer, individually and through certain trusts over which he has voting and dispositive control, beneficially owned approximately 13.0 12.3 12.2 15.2 14.5 14.8 Service Agreement with Opus Point Management Partners, LLC On April 3, 2014, the Company entered into a Shared Services Agreement with OPPM in which the parties agreed to share a rented facility as well as costs for certain services, which they individually require for the operation of their respective entities. The Company’s Chairman, President and Chief Executive Officer and the Company’s Executive Vice President, Strategic Development, are both Co-Portfolio Managers and Partners of OPPM. The Company incurred expense of approximately nil, $ 84,000 24,000 Shared Services Agreement with TGTX In July 2015, TGTX and the Company entered into an arrangement to share the cost of certain research and development employees. The Company’s Executive Vice Chairman, Strategic Development, is Executive Chairman and Interim Chief Executive Officer of TGTX. Under the terms of the Agreement, TGTX will reimburse the Company for the salary and benefit costs associated with these employees based upon actual hours worked on TGTX related projects. For the year ended December 31, 2017 and 2016, the Company invoiced TGTX $ 1.0 0.8 0.9 71,800 Desk Share Agreements with TGTX and OPPM In September 2014, the Company entered into Desk Share Agreements with OPPM and TGTX to occupy 20 40 0.5 1.1 45 10 Each initial Desk Share Agreement has a term of five years. The Company took possession of the New York, NY office space in December 2015, commenced build out of the space shortly thereafter and took occupancy of the space in April 2016. The Company expects the total build out costs to approximate $ 5.1 1.0 95,000 0.4 4.8 2.1 0.5 As of December 31, 2017, the Company had paid $ 2.4 135,000 1.0 163,000 24,000 6,600 Checkpoint Collaborative Agreements with TGTX Checkpoint has entered into various agreements with TGTX to develop and commercialize certain assets in connection with its licenses, including a collaboration agreement for some of the Dana Farber licensed antibodies, an option agreement and sponsored research agreement for compounds licensed from NeuPharma, and a sublicense agreement for the Jubilant family of patents. Checkpoint believes that by partnering with TGTX to develop these compounds in therapeutic areas outside of its business focus, it may substantially offset its preclinical costs and milestone costs related to the development and marketing of these compounds in solid tumor indications. Opus Credit Facility On September 14, 2016, the Company and Opus Point Health Innovations Fund (“OPHIF”) entered into a Credit Facility Agreement (the “Opus Credit Facility”). Fortress’s Chairman, President and Chief Executive Officer (Lindsay A. Rosenwald) and Fortress’s Executive Vice President, Strategic Development (Michael Weiss), are Co-Portfolio Managers and Partners of OPPM, an affiliate of OPHIF. As such, all of the disinterested directors of Fortress’s board of directors approved the terms of the Opus Credit Facility and related agreements. For the years ended December 31, 2017, 2016 and 2015, the Company paid interest expense of $ 1.1 0.2 2017 Subordinated Note Financing On March 17, 2017, the Company and NSC, a subsidiary of National (of which the Company owns 56.6 10 10 For the year ended December 31, 2017, NSC earned a placement agent fee of $ 2.8 716,180 3.61 4.75 Caelum Convertible Notes On July 31, 2017 Caelum through NSC, a subsidiary of National, offered up to $ 10 9.9 10 1.0 10 110 the exercise price will be $75 million dollars divided by the total number of fully-diluted shares of Common Stock outstanding immediately prior to exercise of the warrant, giving effect to the assumed conversion of all options, warrants, and convertible securities of the Company For the year ended December 31, 2017, NSC earned fees of approximately $ 1.0 Avenue IPO On June 26, 2017, Avenue completed an IPO in which NSC acted as co-manager and earned fees and commissions of approximately $ 2.3 Founders Agreement and Management Services Agreement The Company has entered into Founders Agreements with each of the listed in the table below As additional consideration under the Founders Agreement, each Fortress Company with which the Company has entered into a Founders Agreement will also: (i) pay an equity fee in shares of the common stock of such Fortress Company, payable within five (5) business days of the closing of any equity or debt financing for each Fortress Company or any of its respective subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when the Company no longer has majority voting control in such Fortress Company’s voting equity, equal to two and one-half (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to four and one-half percent (4.5%) of such Fortress Company’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a Change in Control, each such Fortress Company will pay a one-time change in control fee equal to five (5x) times the product of (A) net sales for the twelve (12) months immediately preceding the change in control and (B) four and one-half percent (4.5%). Fortress Company Effective Date (1) PIK Dividend as Class of Stock Helocyte March 20, 2015 2.5 % Common Stock Avenue February 17, 2015 2.5 % Common Stock Mustang March 13, 2015 2.5 % Common Stock Checkpoint March 17, 2015 0.0 % (2) Common Stock Cellvation October 31, 2016 2.5 % Common Stock Caelum January 1, 2017 2.5 % Common Stock Cyprium March 13, 2017 2.5 % Common Stock Aevitas July 28, 2017 2.5 % Common Stock Tamid November 30, 2017 (3) 2.5 % Common Stock (1) - Represents the effective date of each subsidiary’s Founders Agreement. Each PIK dividend and equity fee is payable on the annual anniversary of the effective date of the original Founders Agreement. (2) - Instead of a PIK dividend, Checkpoint pays the Company an annual equity fee in shares of Checkpoint’s common stock equal to 2.5 Financing Fees Pursuant to the Founders’ Agreement, Caelum, in connection with each Convertible Note Closing during the three months ended September 30, 2017, issued to Fortress approximately 218,000 2.5 0.2 On June 26, 2017, pursuant to the Founders’ Agreement, Avenue, in connection with its IPO, issued to Fortress approximately 158,000 0.9 2.5 Equity Fees The following table summarizes, by subsidiary, the PIK dividend or equity fee recorded by the Company in accordance with the terms of the Founders Agreements, Exchange Agreements and the subsidiaries’ certificates of incorporation for the year ended December 31, 2017 ($ in thousands): Fortress Company PIK Dividend Year Ended 1 Year Ended Aevitas 2 July 28 $ - $ - Avenue February 17 1,103 49 Caelum January 1 302 - Cellvation October 31 8 - Checkpoint March 17 2,296 3,919 Cyprium January 1 1 - Helocyte March 20 321 - Mustang March 13 9,479 4,396 Tamid3 November 30 - - Fortress (13,510) (8,364) Consolidated (Income)/Expense $ - $ - Note 1: Includes 2018 PIK dividend accrued for the year ended December 31, 2017, as Type 1 subsequent event Note 2: Aevitas PIK dividend wll be recorded during the third quarter of 2018 Note 3: Tamid PIK dividend will be recorded during the fourth quarter of 2018 Management Services Agreements The Company has entered into Management Services Agreements (the “MSAs”) with certain of the Fortress Companies. Pursuant to each MSA, the Company’s management and personnel provide advisory, consulting and strategic services to each Fortress Company that has entered into an MSA with Fortress for a period of five (5) years. Such services may include, without limitation, (i) advice and assistance concerning any and all aspects of each such Fortress Company’s operations, clinical trials, financial planning and strategic transactions and financings and (ii) conducting relations on behalf of each such Fortress Company with accountants, attorneys, financial advisors and other professionals (collectively, the “Services”). Each such Fortress Company is obligated to utilize clinical research services, medical education, communication and marketing services and investor relations/public relation services of companies or individuals designated by Fortress, provided those services are offered at market prices. However, such Fortress Companies are not obligated to take or act upon any advice rendered from Fortress, and the Company shall not be liable to any such Fortress Company for its actions or inactions based upon the Company’s advice. The Company and its affiliates, including all members of Fortress’ Board of Directors, have been contractually exempted from fiduciary duties to each such Fortress Company relating to corporate opportunities. Fortress Company Effective Date R&D G&A Annual MSA Fee Helocyte March 20, 2015 $ 250 $ 250 $ 500 Avenue February 17, 2015 250 250 500 Mustang March 13, 2015 250 250 500 Checkpoint March 17, 2015 250 250 500 Cellvation October 31, 2016 250 250 500 Caelum January 1, 2017 250 250 500 Cyprium March 13, 2017 250 250 500 Aevitas July 28, 2017 250 250 500 Tamid November 30, 2017 (1) 250 250 500 Fortress (2,250) (2,250) (4,500) Consolidated (Income)/Expense $ - $ - $ - (1) – Represents the Trigger Date. Fees and Stock Grants Received by Fortress Fees recorded in connection with the Company’s agreements with its subsidiaries re eliminated in consolidation. These include management services fees, issuance of common shares of Fortress Companies in connection with third party raises and annual stock dividend or issuances on the anniversary date of respective Founders Agreements. Chord Advisors, LLC In May 2015, the Company entered into a full-service consulting agreement with Chord Advisors, LLC (“Chord”) to provide advisory accounting services. Under the terms of the agreement, the Company pays Chord $ 10,000 andHelocyte. Helocyteand 5,000 7,500 in a separate agreement with 65,000 75,000 10,000 , respectively 64,700 15,000 National In September 2016, pursuant to the terms of the Merger Agreement between National and Fortress, the Company acquired 56.6 22.9 September 30, September 30, Fortress Company Description 2017 2016 Fortress Subordinated Financing $ 2,836 $ - Avenue IPO Fees 2,331 - Mustang Private Placement Offering 9,527 1,265 Caelum Convertible Debt Raise 991 - Total Fees per Fortress 15,685 1,265 Less: Mustang fee recorded by National in 2016 1,265 - Total National Fees $ 14,420 $ 1,265 Additionally, the Company’s Chairman, President and Chief Executive Officer and the Company’s Executive Vice Chairman, Strategic Development are both Co-Portfolio Managers and Partners of OPPM which owns approximately 4.6

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	19 Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards. For the years ended December 31, ($ in thousands) 2017 2016 Current Federal $ 1,074 $ - State 439 - Deferred Federal - - State - - Total $ 1,513 $ - The Company has incurred net operating losses since inception. The Company has not reflected any benefit of such net operating loss carryforwards (“NOL”) in the accompanying consolidated financial statements and has established a valuation allowance of $ 101.6 As of December 31, ($ in thousands) 2017 2016 Deferred tax assets: Net operating loss carryforwards $ 71,616 $ 76,486 Amortization of license fees 13,648 7,277 Amortization of in-process R&D 557 742 Stock compensation 10,682 10,899 Accruals and reserves 5,166 4,025 Tax credits 7,376 6,305 Start up costs 75 98 Unrealized loss on investments - 1,095 Total deferred tax assets 109,120 106,927 Less: valuation allowance (101,645) (94,687) Net deferred tax assets $ 7,475 $ 12,240 Deferred tax liabilities: Unrealized gain/loss on investment $ (685) $ - Intangibles (3,321) (4,450) Basis in subsidiary (3,469) (7,790) Total deferred tax assets, net $ - $ - For the Year Ended December 31, 2017 2016 2015 Percentage of pre-tax income: U.S. federal statutory income tax rate 35 % 35 % 35 % State taxes, net of federal benefit 8 % 3 % 5 % Credits 1 % 2 % 1 % Non-deductible items (2) % (4) % - % Provision to return 1 % 2 % - % Stock based compensation shortfall (1) % (2) % (1) % Change in federal rate (43) % - % - % Change in state rate 2 % - % - % Intercomapny elimination adjustments (3) % - % - % Change in fair value of warrants 3 % - % - % Change in valuation allowance (7) % (33) % (44) % Change in subsidiary basis 4 % (3) % 3 % Other - % - % 1 % Effective income tax rate (2) % - % - % The Company files a consolidated income tax return with Subsidiaries for which the Company has an 80% or greater ownership interest. Subsidiaries for which the Company does not have an 80% or more ownership are not included in the Company’s consolidated income tax group and file their own separate income tax return. As a result, certain corporate entities included in these financial statements are not able to combine or offset their taxable income or losses with other entities' tax attributes. On December 22, 2017, “H.R.1”, formerly known as the “Tax Cuts and Jobs Act”, was signed into law. Among other items, H.R.1 reduces the federal corporate tax rate to 21 35 42.2 The SEC staff issued Staff Accounting Bulletin 118 (“SAB 118”) to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared or analyzed in reasonable detail to complete the accounting for certain income tax effects of the Tax Act and allows the registrant to record provisional amounts during the measurement period. The Company is in the process of analyzing the impact of the various provisions of the Tax Act. The Company expects to complete its analysis within the measurement period in accordance with SAB 118. ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of all positive and negative evidence, it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. Realization of the deferred tax assets is substantially dependent on the Company’s ability to generate sufficient taxable income within certain future periods. Management has considered the Company’s history of cumulative tax and book losses incurred since inception, and the other positive and negative evidence, and has concluded that it is more likely than not that the Company will not realize the benefits of the net deferred tax assets as of December 31, 2016 and December 31, 2017. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December 31, 2016 and December 31, 2017. The valuation allowance increased by a net $ 7.0 The Company has incurred net operating losses (“NOLs”) since inception. At December 31, 2017, the Company had federal NOLs of $259.0 million, which will begin to expire in the year 2020, state NOLs of $ 259.0 7.5 In 2016, the Company acquired approximately 56 8.8 As of December 31, 2017, the Company had no unrecognized tax benefits and does not anticipate any significant change to the unrecognized tax benefit balance. The Company would classify interest and penalties related to uncertain tax positions as income tax expense, if applicable. There was no interest expense or penalties related to unrecognized tax benefits recorded through December 31, 2017. The NOLs from tax years 2006 through 2017 remain open to examination (and adjustment) by the Internal Revenue Service and state taxing authorities. In addition, federal tax years ending December 31, 2014, 2015, 2016, and 2017 are open for assessment of federal taxes .

Net Capital Requirements of Bro

Net Capital Requirements of Broker-Dealer Subsidiaries	12 Months Ended
	Dec. 31, 2017
Brokers and Dealers [Abstract]
Net Capital Requirements of Broker-Dealer Subsidiaries	20. Net Capital Requirements of Broker-Dealer Subsidiaries National Securities is subject to the SEC’s Uniform Net Capital Rule (Rule 15c3-1), which, among other things, requires the maintenance of minimum net capital. In February 2015, pursuant to a directive form FINRA, National Securities reverted back to using the alternative method of computing net capital from the aggregate indebtedness method. At September 30, 2017, National Securities had net capital of $ 9.2 9.0 250,000 vFinance Investments is also subject to the SEC’s Uniform Net Capital Rule (Rule 15c3-1), which, among other things, requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 to 1. At September 30, 2017, vFinance Investments had net capital of $ 1.4 0.4 1.0 8 1 Advances, dividend payments and other equity withdrawals from its Broker-Dealer Subsidiaries are restricted by the regulations of the SEC, and other regulatory agencies. These regulatory restrictions may limit the amounts that a subsidiary may dividend or advance to the Company.

Off Balance Sheet Risk and Conc

Off Balance Sheet Risk and Concentrations of Credit Risk	12 Months Ended
	Dec. 31, 2017
Risks and Uncertainties [Abstract]
Off Balance Sheet Risk and Concentrations of Credit Risk	21. Off Balance Sheet Risk and Concentrations of Credit Risk National is engaged in trading and providing a broad range of securities brokerage and investment services to a diverse group of retail and institutional clientele, as well as corporate finance and investment banking services to corporations and businesses. Counterparties to National’s business activities include broker-dealers and clearing organizations, banks and other financial institutions. National uses clearing brokers to process transactions and maintain customer accounts for National on a fee basis. National permits the clearing firms to extend credit to its clientele secured by cash and securities in the client’s account. National’s exposure to credit risk associated with the non-performance by its customers and counterparties in fulfilling their contractual obligations can be directly impacted by volatile or illiquid trading markets, which may impair the ability of customers and counterparties to satisfy their obligations to National. National has agreed to indemnify the clearing brokers for losses they incur while extending credit to National’s clients. It is National’s policy to review, as necessary, the credit standing of its customers and counterparties. Amounts due from customers that are considered uncollectible by the clearing broker are charged back to National by the clearing broker when such amounts become determinable. Upon notification of a charge back, such amounts, in total or in part, are then either (i) collected from the customers, (ii) charged to the broker initiating the transaction and/or (iii) charged to operations, based on the particular facts and circumstances. National maintains cash in bank deposits, which, at times, may exceed federally insured limits. National has not experienced and does not expect to experience losses on such accounts. A short sale involves the sale of a security that is not owned in the expectation of purchasing the same security (or a security exchangeable) at a later date at a lower price. A short sale involves the risk of a theoretically unlimited increase in the market price of the security that would result in a theoretically unlimited loss.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Segment Information	22. Segment Information The Company operates in three reportable segments, Dermatology Product Sales, Pharmaceutical and Biotechnology Product Development and National. The accounting policies of the Company’s segments are the same as those described in Note 2. Pharmaceutical Dermatology Biotechnology Year Ended December 31, 2017 Products Product National Consolidated Net Revenue $ 15,520 $ 1,725 $ 170,339 $ 187,584 Direct cost of goods (3,658) - - (3,658) Sales and marketing costs (10,410) - - (10,410) Research and development - (52,486) - (52,486) General and administrative (1,140) (39,347) - (40,487) National expenses - - (181,751) (181,751) Segment profit (loss) from operations $ 312 $ (90,108) $ (11,412) $ (101,208) Segment assets $ 9,644 $ 187,941 $ 48,365 $ 245,950 Pharmaceutical Dermatology Biotechnology Year Ended December 31, 2016 Products Product National Consolidated Net Revenue $ 3,587 $ 2,570 $ 10,323 $ 16,480 Direct cost of goods (790) - - (790) Sales and marketing costs (5,774) - - (5,774) Research and development - (35,134) - (35,134) General and administrative (1,474) (26,755) - (28,229) National expenses - - (12,263) (12,263) Segment loss from operations $ (4,451) $ (59,319) $ (1,940) $ (65,710) Segment assets $ 4,469 $ 115,145 $ 51,117 $ 170,731 Pharmaceutical Dermatology Biotechnology Year Ended December 31, 2015 Products Product National Consolidated Net Revenue $ 273 $ 590 $ - $ 863 Direct cost of goods - - - - Sales and marketing costs (2,850) - - (2,850) Research and development - (29,810) - (29,810) General and administrative (1,682) (17,052) - (18,734) Segment loss from operations $ (4,259) $ (46,272) $ - $ (50,531) Segment assets $ 1,965 $ 116,542 $ - $ 118,610 Corporate pre-tax loss consists of certain expenses that have not been allocated to reportable segments. Significant Customers For the year ended December 31, 2017, three of the Company’s customers each accounted for more than 10.0% of its total gross product revenue in the amount of $ 10.8 7.7 5.4 For the year ended December 31, 2016, three of the Company’s customers each accounted for more than 10% of its total gross revenue in the amount of $ 1.9 1.1 0.7 For the year ended December 31, 2015, 100 At December 31, 2017, three of the Company’s customers each accounted for more than 10.0% of its total accounts receivable balance in the amount of $ 1.9 1.5 0.9 At December 31, 2016, two of the Company’s customers each accounted for more than 10.0% of its total accounts receivable balance in the amount of $ 1.1 0.5 Net Revenue from Pharmaceutical and Biotechnology Product Development represents collaboration revenue from TGTX in connection with Checkpoint, which is classified as related party revenue.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	2018 Venture Debt Financing On February 28, 2018 the Company entered into Note Purchase Agreements (the “Purchase Agreements”) with NSC Biotech Opportunities Fund, LLC I (“NSC Biotech Opportunities Fund”) and NSC Biotech Opportunities Fund QP, LLC (“NSC Biotech QP Fund”), both of which are accredited investors, and sold subordinated promissory notes (the “Notes”) of the Company (the “2018 Venture Debt Financing”) in the aggregate principal amount of $ 6.5 8 Each Note matures on the 24 month anniversary of issuance, provided that the Company may extend the maturity date for two six-month periods. 30.0 March 31, 2018 The Company entered into a Placement Agreement with National Securities Corporation (“NSC”), a subsidiary of National and a related party, (see Note 18). Pursuant to the terms of the Agreement NSC as placement agent for both funds receives an 8 0.3 The 2018 Venture Debt Financing allows for transfer of indebtedness to existing and future Fortress Companies. At the time such debt is transferred to the Fortress Company, the respective fund is issued a warrant to purchase a number of shares of common stock of the Fortress Company equal to twenty five percent (25%) of the Fortress Company’s share of proceeds divided by the lowest price at which equity securities are sold in the first third party financing of the Fortress Company. On February 28, 2018, the Company raised gross proceeds of $ 6.5 0.5 Checkpoint Public Offering of Common Stock On March 8, 2018, Checkpoint announced the pricing of an underwritten public offering, whereby it sold 4,600,000 690,000 4.35 23.0 20.9 2.0 Checkpoint with the Securities and Exchange Commission. The offering closed on March 12, 2018. Opus Credit Facility Agreement Maturity Date Extension On March 12, 2018, the Company and OPHIF amended and restated the Opus Credit Facility (the “A&R Opus Credit Facility”). The A&R Opus Credit Facility extends the maturity date of the notes issued under the Opus Credit Facility from September 14, 2018 by one year to September 14, 2019. The A&R Opus Credit Facility also permits the Company to make portions of interest and principal repayments in the form of shares of the Company’s common stock and/or in common stock of the Company’s publicly-traded subsidiaries, subject to certain conditions. Fortress retains the ability to prepay the Notes at any time without penalty. The notes payable under the A&R Opus Credit Facility continue to bear interest at 12 Discontinuation of Helocyte PepVax Development. During the first quarter of 2018, Helocyte elected to discontinue the further development of its HLA-restricted, single-antigen PepVax program.

Selected Quarterly Financial Da

Selected Quarterly Financial Data	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information	24. Selected Quarterly Financial Data (Unaudited) ($ in thousands, except per share data) First Quarter Second Quarter Third Quarter Fourth Quarter 2017 Total Revenue $ 44,682 $ 50,697 $ 46,886 $ 45,319 Operating expenses $ (62,259) $ (73,890) $ (79,489) $ (73,154) Other income/(expense) $ 3,015 $ 244 $ (3,704) $ 3,330 Income tax expense $ - $ - $ - $ 1,513 Non-controlling interests $ 2,580 $ 5,584 $ 9,191 $ 15,605 Net loss attributable to common stockholders $ (11,982) $ (17,365) $ (27,116) $ (10,413) Basic and diluted net loss per common share $ (0.30) $ (0.43) $ (0.67) $ (0.25) 2016 Total Revenue $ 660 $ 2,230 $ 975 $ 14,405 Operating expenses $ (15,571) $ (17,042) $ (17,180) $ (32,217) Other income/(expense) $ (1,552) $ (1,253) $ (710) $ (2,065) Non-controlling interests $ 4,438 $ 3,911 $ 3,975 $ 3,871 Net loss attributable to common stockholders $ (12,205) $ (12,478) $ (12,981) $ (17,431) Basic and diluted net loss per common share $ (0.31) $ (0.31) $ (0.32) $ (0.43)

Summary of Significant Accoun32

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Basis of Presentation and Principles of Consolidation	The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The Company’s consolidated financial statements include the accounts of the Company and the accounts of the Company’s subsidiaries, listed above. All intercompany balances and transactions have been eliminated. The accompanying consolidated financial statements include the accounts of the Company’s subsidiaries. For consolidated entities where the Company owns less than 100% of the subsidiary, the Company records net loss attributable to non-controlling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. The Company also consolidates subsidiaries in which it owns less than 50% of the subsidiary but maintains voting control. The National assets acquired, and liabilities assumed and revenues and expenses are reported on a one quarter lag. Therefore, the National assets acquired and liabilities assumed included in these consolidated financial statements as of December 31, 2017 are actually the assets acquired and liabilities assumed as of September 30, 2017 and the revenues and expenses included in these consolidated financial statements for the year ended December 31, 2017 are actually the revenues and expenses for the period from October 1, 2016 through September 30, 2017. National provides the company and certain Fortress Companies with investment banking services in connection with debt or equity raises. The company records the fees as expense, debt discount or equity. All such fees are eliminated in consolidation.
Use of Estimates	Use of Estimates The Company’s consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value of stock options and warrants, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.
Fair Value Measurement	The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories: Level 1 Level 2 Level 3 The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Certain of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable, accrued expenses and other current liabilities. The carrying value of the amount owed to Ovamed GmbH (“Ovamed”) upon the acquisition of certain manufacturing rights has been recorded at its net present value, which approximates its fair value, due to the short-term nature of the liability. The amount due to Ovamed is included in current liabilities at December 31, 2016 in the Consolidated Balance Sheets (see Note 12) and was paid in 2017. Debt carried at cost approximates fair value.
Segment Reporting	Segment Reporting Consistent with the increase in Journey’s operations as of April 1, 2016 and the investment in National as of September 9, 2016, the Company now operates in three operating and reportable segments, Dermatology Product Sales, Pharmaceutical and Biotechnology Product Development and National. The Company evaluates the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at December 31, 2017 and at December 31, 2016 consisted of cashand certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities.
Short-term Investments	Short-term Investments The company classifies its certificates of deposit as cash and cash equivalents or held to maturity in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification (“ASC”) 320, Investments - Debt and Equity Securities At December 31, 2017, the Company had approximately $50.0 million in certificates of deposit. The Company classified $ 14.0 36.0
Property and Equipment	Property and Equipment Office equipment is recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset. Leasehold improvements are amortized over the shorter of the estimated useful lives or the term of the respective leases.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows.
Restricted Cash	The Company records cash held in trust or pledged to secure certain debt obligations as restricted cash. As of December 31, 2017, and 2016, the Company has $ 17.4 15.9 14.9 2.5 1.0
Inventories	Inventories Inventories comprise finished goods, which are valued at the lower of cost or market, on a first-in, first-out basis. The Company evaluates the carrying value of inventories on a regular basis, taking into account anticipated future sales compared with quantities on hand, and the remaining shelf life of goods on hand.
Accounts Receivable	Accounts receivable consists of amounts due to the Company for product sales from JMC. The Company’s accounts receivable reflects discounts for estimated early payment and for product estimated returns. Accounts receivable are stated at amounts due from customers, net of an allowance for doubtful accounts. Accounts that are outstanding longer than the contractual payment terms are considered past due. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time trade accounts receivable are past due and the customer’s current ability to pay its obligation to the Company. The Company writes off accounts receivable when they become uncollectible. Accounts receivable are net of allowance for product estimated returns of $ 1.3 0.1 1.2 0.1
Investments at Fair Value	The Company elects the fair value option for its long-term investments at fair value (see Note 7). The decision to elect the fair value option, which is irrevocable once elected, is determined on an instrument by instrument basis and applied to an entire instrument. The net gains or losses, if any, on an investment for which the fair value option has been elected are recognized as a change in fair value of investments on the Consolidated Statements of Operations. The Company has various processes and controls in place to ensure that fair value is reasonably estimated. While the Company believes its valuation, methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.
Fair Value Option	As permitted under the FASB, ASC 825, Financial Instruments,
Accounting for Warrants at Fair Value	The Company classifies as liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The fair value of warrants that include price protection reset provision features are deemed to be “down-round protection” and, therefore, do not meet the scope exception for treatment as a derivative under ASC 815, Derivatives and Hedging The Company assessed the classification of warrants issued, in connection with the 2016 convertible note financings for Helocyte and Avenue, and Caelum’s convertible note financing in 2017 (the “Helocyte, Avenue and Caelum Warrants”), and determined that the Helocyte, Avenue and Caelum Warrants met the criteria for liability classification. Accordingly, the Company classified the Helocyte, Avenue and Caelum Warrants as a liability at their fair value and adjusts the instruments to fair value at each balance sheet date until the warrants are exercised or expired. Any change in the fair value of the Helocyte, Avenue and Caelum Warrants is recognized as “change in the fair value of warrant liabilities” in the Consolidated Statements of Operations. Also in accordance with ASC 815, the Company classified the fair value of the warrants granted in connection with the note in favor of National Security Corporations’s NSC Biotech Venture Fund I, LLC (“the NSC Note”) that was transferred to Avenue effective February 2015 (the “Contingently Issuable Warrants”) as a derivative liability. The Company valued these Contingently Issuable Warrants using an option pricing model and used estimates for an expected dividend yield, a risk-free interest rate, and expected volatility together with management’s estimate of the probability of issuance of the Contingently Issuable Warrants. At each reporting period, as long as the Contingently Issuable Warrants are potentially issuable and there is a potential for an insufficient number of authorized shares available to settle the Contingently Issuable Warrants, these Contingently Issuable Warrants will be revalued, and any difference from the previous valuation date will be recognized as a change in fair value of derivative liabilities in the Consolidated Statements of Operations.
Credit Facility With Detachable Warrant	The Company accounts for the Opus Credit Facility with detachable warrants in accordance with ASC 470, Debt The Company recorded the related issue costs and value ascribed to the warrants as a debt discount of the Opus Credit Facility. The discount is amortized utilizing the effective interest method over the term of the Opus Credit Facility. The unamortized discount, if any, upon repayment of the Opus Credit Facility will be expensed to interest expense. In accordance with ASC Subtopic 470-20, the Company determined the weighted average effective interest rate of the debt was approximately 28 Derivatives and Hedging
Issuance of Debt and Equity	The Company issues complex financial instruments which include both equity and debt features. The Company analyzes each instrument under ASC 480, Distinguishing Liabilities from Equity, Derivatives and Hedging Debt
Recognizing Assets Acquired and Liabilities Assumed in a Business Combination	Acquired assets and assumed liabilities are recognized in a business combination on the basis of their fair values at the date of acquisition. The Company assesses fair value, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, using a variety of methods including income approaches such as present value techniques or cost approaches such as the estimation of current selling prices and replacement values. Fair value of the assets acquired, and liabilities assumed, including intangible assets, are measured based on the assumptions and estimations with regards to the variable factors such as the amount and timing of future cash flows for the asset or liability being measured, appropriate risk-adjusted discount rates, nonperformance risk, or other factors that market participants would consider. Upon acquisition, the Company determines the estimated economic lives of the acquired intangible assets for amortization purposes, which are based on the underlying expected cash flows of such assets.
Goodwill, Intangible Assets and Long Lived Assets	Goodwill, Intangible Assets and Long-Lived Assets Goodwill represents the excess acquisition cost over the fair value of net tangible and intangible assets acquired. Goodwill is not amortized and is subject to annual impairment testing on October 1st or between annual tests if an event or change in circumstance occurs that would more likely than not reduce the fair value of a reporting unit below its carrying value. In testing for goodwill impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances lead to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events and circumstances, the Company concludes that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is not required. If the Company concludes otherwise, it is required to perform the two-step impairment test. The goodwill impairment test is performed at the reporting unit level by comparing the estimated fair value of a reporting unit with its respective carrying value. If the estimated fair value exceeds the carrying value, goodwill at the reporting unit level is not impaired. If the estimated fair value is less than carrying value, further analysis is necessary to determine the amount of impairment, if any, by comparing the implied fair value of the reporting unit’s goodwill to the carrying value of the reporting unit’s goodwill. The fair value of reporting units is based on widely accepted valuation techniques that the Company believes market participants would use, although the valuation process requires significant judgment and often involves the use of significant estimates and assumptions. The Company utilizes a market cap approach in estimating the fair value of reporting units. The estimates and assumptions used in determining fair value could have a significant effect on whether or not an impairment charge is recorded and the magnitude of such a charge. Adverse market or economic events could result in impairment charges in future periods. Intangible assets deemed to have finite lives are amortized on a straight line basis over their estimated useful lives, where the useful life is the period over which the asset is expected to contribute directly, or indirectly, to its future cash flows. Intangible assets are reviewed for impairment on an interim basis when certain events or circumstances exist. For amortizable intangible assets, impairment exists when the carrying amount of the intangible asset exceeds its fair value. At least annually, the remaining useful life is evaluated. An intangible asset with an indefinite useful life is not amortized but assessed for impairment annually, or more frequently, when events or changes in circumstances occur indicating that it is more likely than not that the indefinite-lived asset is impaired. Impairment exists when the carrying amount exceeds its fair value. In testing for impairment, the Company has the option to first perform a qualitative assessment to determine whether it is more likely than not that an impairment exists. If it is determined that it is not more likely than not that an impairment exists, a quantitative impairment test is not necessary. If the Company concludes otherwise, it is required to perform a quantitative impairment test. To the extent an impairment loss is recognized, the loss establishes the new cost basis of the asset that is amortized over the remaining useful life of that asset, if any. Subsequent reversal of impairment losses is not permitted. Long-lived assets, primarily fixed assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company will perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company would recognize an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value.
Research and Development	Research and Development Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company’s behalf will be expensed as services are rendered or when the milestone is achieved. Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third parties for license and milestone costs related to in-licensed products and technology, payments made to third party contract research organizations for preclinical and clinical studies, investigative sites for clinical trials, consultants, the cost of acquiring and manufacturing clinical trial materials, and costs associated with regulatory filings, laboratory costs and other supplies. In accordance with ASC 730-10-25-1, Research and Development
Contingencies	Contingencies The Company records accruals for contingencies and legal proceedings expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated. If a loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed.
Stock-Based Compensation	Stock-Based Compensation The Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards and forfeiture rates. For stock-based compensation awards to non-employees, the Company remeasures the fair value of the non-employee awards at each reporting period prior to vesting and finally at the vesting date of the award. Changes in the estimated fair value of these non-employee awards are recognized as compensation expense in the period of change. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model or 409A valuations, as applicable. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment.
Income Taxes	Income Taxes The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if management believes it is more likely than not that the deferred tax assets will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50 On December 22, 2017, “H.R.1”, formerly known as the “Tax Cuts and Jobs Act”, was signed into law. Among other items, H.R.1 reduces the federal corporate tax rate to 21 35
Non-Controlling Interests	Non-Controlling Interests Non-controlling interests in consolidated entities represent the component of equity in consolidated entities held by third parties. Any change in ownership of a subsidiary while the controlling financial interest is retained is accounted for as an equity transaction between the controlling and non-controlling interests.
Comprehensive Loss	Comprehensive Loss The Company’s comprehensive loss is equal to its net loss for all periods presented.
Reclassifications	Reclassifications Certain prior period amounts may have been reclassified to conform to the current year presentation.
Revenue Recognition	Revenue Recognition The Company recognizes revenue for the performance of services or the shipment of products when each of the following four criteria is met: (i) persuasive evidence of an arrangement exists; (ii) products are delivered or as services are rendered; (iii) the sales price is fixed or determinable; and (iv) collectability is reasonably assured. Collaborative Arrangements Checkpoint is paid by TGTX, a related party, a share of the cost of the license and future milestone payments that are payable to Dana-Farber Cancer Institute pursuant to the license agreement (see Note 8). Checkpoint is also paid by TGTX for the Sponsored Research Agreement between Checkpoint and NeuPharma (see Note 8). The gross amounts of these payments are reported as revenue in the accompanying Statements of Operations. Checkpoint acts as a principal, bears credit risk and may perform part of the services required in the transactions. Consistent with ASC 605-45-15 Revenue Recognition - Principal Agent Considerations The Company follows ASC 605-25, Revenue Recognition - Multiple-Element Arrangements Collaborative Arrangements ASC 605-25 provides guidance relating to the separability of deliverables included in an arrangement into different units of accounting and the allocation of arrangement consideration to the units of accounting. The evaluation of multiple-element arrangements requires management to make judgments about (i) the identification of deliverables, (ii) whether such deliverables are separable from the other aspects of the contractual relationship, (iii) the estimated selling price of each deliverable, and (iv) the expected period of performance for each deliverable. To determine the units of accounting under a multiple-element arrangement, management evaluates certain separation criteria, including whether the deliverables have stand-alone value, based on the relevant facts and circumstances for each arrangement. Management then estimates the selling price for each unit of accounting and allocates the arrangement consideration to each unit utilizing the relative selling price method. The allocated consideration for each unit of accounting is recognized over the related obligation period in accordance with the applicable revenue recognition criteria. If there are deliverables in an arrangement that are not separable from other aspects of the contractual relationship, they are treated as a combined unit of accounting, with the allocated revenue for the combined unit recognized in a manner consistent with the revenue recognition applicable to the final deliverable in the combined unit. Payments received prior to satisfying the relevant revenue recognition criteria are recorded as deferred revenue in the Consolidated Balance Sheets and recognized as revenue in the Consolidated Statements of Operations when the related revenue recognition criteria are met. Revenue Recognition – Milestone Method The Company follows ASC 605-28, Revenue Recognition-Milestone Method JMC Product Revenue JMC sells its products directly to wholesalers and specialty pharmacies. JMC recognizes product sales revenue when delivery has occurred, collectability is reasonably assured, and the price to the buyer is fixed or determinable, (in accordance with the specific contractual terms). Delivery occurs when title has transferred to the customer, and the customer has assumed the risks and rewards of ownership. Revenue from product sales is recognized net of provisions for estimated cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to certain of JMC’s wholesale customers. JMC establishes these provisions concurrently with the recognition of product sales revenue. JMC offers cash discounts for prompt payment and allowances are recorded at the time of sale. JMC allows customers to return product within a specified period of time before and after its expiration date. Provisions for returns are estimated based on historical levels for like products from external data sources, taking into account additional available information such as historical return and exchange levels, and inventory levels in the wholesale distribution channel through its partners. Although the company has limited history with these product sales, the Company believes based on its current level of sales that it can make reasonable estimates of returns based upon external data sources. JMC reviews its methodology and adequacy of the provision for returns on a quarterly basis, adjusting for changes in assumptions, historical internal and external results and business practices, as necessary. JMC’s co-promotion revenue for Dermasorb HC is based upon prescription volume over an established baseline.
Deferred Clearing and Marketing Credits	Deferred clearing credit represents a clearing fee rebate from National Financial Services (“NFS”), one of National’s clearing brokers, which is being recognized pro rata as a reduction of clearing charges over the term of the clearing agreement which expires in 2022. At September 30, 2017 and 2016, the deferred clearing credit amounted to approximately $ 0.5 0.7 Deferred marketing credit represents a marketing rebate from NFS, which is being recognized pro rata as a reduction of marketing expenses over the term of the clearing agreement which expires in 2022. At September 30, 2017 and 2016, the deferred marketing credit amounted to approximately $ 0.3
Reimbursement of Expenses	National incurs certain costs on behalf of its financial advisors including those for insurance, professional registration, technology and information services and legal services, amongst others, which are charged back to the advisors. It is National’s policy to record the reimbursement as a reduction of the respective operating expense. Total reimbursements in fiscal years 2017 and 2016 amounted to approximately $ 9.9 and $ 11.9 In many instances, it is not possible to determine whether any loss is probable or even possible or to estimate the amount of any loss or the size of any range of loss. National believes that, in the aggregate, the pending legal actions or regulatory proceedings and any other exams, investigations or similar reviews (both formal and informal) should not have a material adverse effect on the consolidated results of operations, cash flows or financial condition. In addition, National believes that any amount that could be reasonably estimated of potential loss or range of potential loss in excess of what has been provided in the consolidated financial statements is not material.
Recently Issued Accounting Standards	Recently Adopted Accounting Pronouncements In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230) Restricted Cash For the Years Ended December 31, 2017 2016 2015 Cash and cash equivalents $ 113,915 $ 88,294 $ 98,182 Restricted cash 17,387 15,860 14,586 Total cash, cash equivalents and restricted cash $ 131,302 $ 104,154 $ 112,768 In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients The Company adopted the new revenue standard on January 1, 2018 and recognized an increase of $0.1 million to accumulated deficit as the cumulative effect of adoption of this accounting change. The impact of adoption is primarily related to 1) National’s investment banking expenses that were deferred as of September 30, 2017 (National’s financials are included in the Company’s financials at a three-month lag) under the previously existing accounting guidance, which would have been expensed in prior periods under the new revenue standard. Accordingly, the new revenue standard will be applied prospectively in the Company’s financial statements from January 1, 2018 forward and reported financial information for historical comparable periods will not be revised and will continue to be reported under the accounting standards in effect during those historical periods. Further, the adoption of ASU 2014-09 did not have a material impact on net Fortress revenue. The new revenue guidance does not apply to revenue associated with financial instruments, including National’s warrants and securities that are accounted for under other U.S. GAAP, and as a result, did not have an impact on the elements of our Consolidated Statements of Operations most closely associated with financial instruments. The new revenue standard primarily impacts the following of our revenue recognition and presentation accounting policies: ⋅ Investment Banking Revenues. Advisory fees from mergers and acquisitions engagements are recognized at the point in time when the related transaction is completed, as the performance obligation is to successfully broker a specific transaction. ⋅ Investment Banking Advisory Expenses. Historically, expenses associated with investment banking advisory assignments were deferred until reimbursed by the client, the related fee revenue is recognized or the engagement is otherwise concluded. Under the new revenue standard, expenses are deferred only to the extent they are explicitly reimbursable by the client and the related revenue is recognized when all performance obligations are met. All other investment banking advisory related expenses are expensed as incurred. ⋅ Investment Banking Underwriting and Advisory Expenses. Expenses have historically been recorded net of client reimbursements and/or netted against revenues. Under the new revenue standard, all investment banking expenses will be recognized within their respective expense category on the consolidated income statement and any expense reimbursements will be recognized as investment banking revenues (i.e., expenses are no longer recorded net of client reimbursements and are not netted against revenues). The new revenue standard requires enhanced disclosures, which we will include in the footnotes to our consolidated financial statements beginning with the three months ended March 31, 2018. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments, In January 2016, FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Liabilities Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) Leases (Topic 840) In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception.
National [Member]
Use of Estimates	Use of Estimates The preparation of these financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Principals of Consolidation	Principals of Consolidation The consolidated financial statements include the accounts of National and its wholly owned and majority owned subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation. Further National’s results for 2015 are not included in the Company’s Consolidated Financial Statements. In addition, National may consolidate entities which meet the definition of a variable interest entity for which National is the primary beneficiary. The primary beneficiary is the party who has the power to direct the activities of a variable interest entity that most significantly impact the entity’s economic performance and who has an obligation to absorb losses of the entity or a right to receive benefits from the entity that could potentially be significant to the entity. As of December 31, 2017, and 2016, National did not consolidate any variable interest entities. Fees attributable to such arrangements were $ 16.5 17.0
Revenue Recognition	Revenue Recognition Commission revenue represents commissions generated by National’s financial advisors for their clients’ purchases and sales of mutual funds, variable annuities, general securities and other financial products, most of which is paid to the advisors as commissions for initiating the transactions. Commission revenue is generated from front-end sales commissions that occur at the point of sale, as well as trailing commissions. National recognizes front-end sales commission revenue and related clearing and other expenses on transactions introduced to its clearing brokers on a trade date basis. National also recognizes front-end sales commissions and related expenses on transactions initiated directly between the financial advisors and product sponsors upon receipt of notification from sponsors of the commission earned. Commission revenue also includes 12b-1 fees, and variable product trailing fees, collectively considered as trailing fees, which are recurring in nature. These trailing fees are earned by National based on a percentage of the current market value of clients’ investment holdings in trail eligible assets. Because trail commission revenues are generally paid in arrears, management estimates commission revenues earned during each period. These estimates are based on a number of factors including investment holdings and the applicable commission rate and the amount of trail commission revenue received in prior periods. Estimates are subsequently adjusted to actual based on notification from the sponsors of trail commissions earned. Net dealer inventory gains, which are recorded on a trade-date basis, include realized and unrealized net gains and losses resulting from the National’s principal trading activities. Investment banking revenues consist of underwriting revenues, advisory revenues and private placement fees. Underwriting revenues arise from securities offerings in which National acts as an underwriter and include management fees, selling concessions and underwriting fees, net of related syndicate expenses. Underwriting revenues are recorded at the time the underwriting is completed and the income is reasonably determined. Management estimates National’s share of the transaction-related expenses incurred by the syndicate, and recognizes revenues net of such expense. On final settlement, typically within 90 days from the trade date of the transaction, these amounts are adjusted to reflect the actual transaction-related expenses and the resulting underwriting fee. Investment advisory fees are derived from account management and investment advisory services. These fees are determined based on a percentage of the customers assets under management, may be billed monthly or quarterly and are recognized when earned. Interest is recorded on an accrual basis and dividends are recorded on the ex-dividend date. Transfer fees and fees for clearing services, which are recorded on a trade date basis, are principally charged to the broker on customer security transactions. Tax preparation and accounting fees are recognized upon completion of the services.
Securities	Securities Securities owned and securities sold, but not yet purchased, are recorded at fair value. Authoritative accounting guidance defines fair value, establishes a framework for measuring fair value, and establishes a fair value hierarchy which prioritizes the inputs to valuation techniques. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A fair value measurement assumes that the transaction to sell the asset or transfer the liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market. Valuation techniques that are consistent with the market, income or cost approach are used to measure fair value. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value are classified and disclosed in one of the following three categories: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 Inputs other than quoted market prices that are observable, either directly or indirectly, and reasonably available. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of National. Level 3 Unobservable inputs which reflect the assumptions that National develops based on available information about what market participants would use in valuing the asset or liability.

Summary of Significant Accoun33

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Schedule of Cash and Cash Equivalents	For the Years Ended December 31, 2017 2016 2015 Cash and cash equivalents $ 113,915 $ 88,294 $ 98,182 Restricted cash 17,387 15,860 14,586 Total cash, cash equivalents and restricted cash $ 131,302 $ 104,154 $ 112,768

National Holdings Corporation (

National Holdings Corporation (Tables)	12 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Schedule fair value of assets acquired and liabilities assumed at the date of the acquisition	The following table summarizes the fair value of assets acquired and liabilities assumed at the date of the acquisition ($ in thousands): Assets Cash and cash equivalents $ 27,498 Accounts receivable 4,889 Cash deposits with clearing organizations 1,030 Receivable from brokers, dealers and clearing agencies 1,607 Securities owned, at fair value 2,178 Prepaid expenses and other current assets 1,985 Property and equipment 1,132 Restricted cash 353 Intangible assets - trademark 3,000 Intangible assets - customer list 13,500 Goodwill 18,645 Total assets 75,817 Liabilities Accrued compensation payable $ 14,029 Accounts payable and accrued expenses 6,079 Deferred clearing and marketing credits 1,007 Warrants issuable 13,406 Other current liabilities 707 Total liabilities assumed 35,228 Non-controlling interests (17,717) Net assets acquired $ 22,872 Cash and cash equivalents from National $ 27,498 Cash to NHLD Shareholders (Tender Offer) (22,872) Net cash acquired in acquisition of National $ 4,626
Schedule of Acquired Finite-Lived Intangible Assets by Major Class	Amortization is calculated using the straight-line and accelerated methods over the following estimated useful lives: Useful Trademark 10 Customer lists 6
Schedule of Finite-Lived Intangible Assets	The gross carrying amounts related to acquired intangible assets as of December 31, 2017 and 2016 are as follows ($ in thousands): Intangible assets at September 9, 2016 $ 16,500 Amortization expense (509) Intangible assets at December 31, 2016 $ 15,991 Amortization expense (1,651) Intangible assets at December 31, 2017 $ 14,340
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Trademark Customer Total Year Ended December 31, 2018 $ 300 $ 2,250 $ 2,550 Year Ended December 31, 2019 300 2,250 2,550 Year Ended December 31, 2020 301 2,250 2,551 Year Ended December 31, 2021 300 2,250 2,550 Year Ended December 31, 2022 300 2,250 2,550 Thereafter 1,107 482 1,589 Total $ 2,608 $ 11,732 $ 14,340

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Components of Property and Equipment	Fortress’ property and equipment, exclusive of National’s property and equipment consisted of the following: Useful Life As of December 31, ($ in thousands) (Years) 2017 2016 Computer equipment 3 $ 543 $ 440 Furniture and fixtures 5 1,009 821 Machinery and Equipment 5 143 – Leasehold improvements 5 - 15 5,351 5,396 Construction in progress (1) NA 1,241 – Total property and equipment 8,287 6,657 Less: Accumulated depreciation (1,171) (445) Property and equipment, net $ 7,116 $ 6,212 (1) For build-out of Mustang’s cell processing 3.5 2.5
National Holdings Corporation [Member]
Property, Plant and Equipment [Line Items]
Components of Property and Equipment	National’s property and equipment as of September 30, 2017 consisted of the following: Estimated Useful September 30, ($ in thousands) Lives (in years) 2017 2016 Equipment 5 $ 1,306 $ 600 Furniture and fixtures 5 284 65 Leasehold improvements Lesser of useful life 1,006 259 Capital Leases (Primarily composed of computer equipment) 5 276 276 Total property and equipment 2,872 1,200 Less: Accumulated depreciation (475) (36) Property and equipment, net $ 2,397 $ 1,164

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2017
Fair Value for Derivative Contingently Issuable Warrant Liabilities	($ in thousands) Avenue’s Beginning balance at January 1, 2016 $ 114 Additions - Change in fair value 188 Ending balance at December 31, 2016 302 Conversion into common shares (750) Change in fair value 448 Ending balance at December 31, 2017 $ -
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables classify into the fair value hierarchy of Fortress’ financial instruments, exclusive of National’s financial instruments, measured at fair value on a recurring basis on the Consolidated Balance Sheets as of December 31, 2017 and 2016: Fair Value Measurement as of December 31, 2017 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Long-term investments, at fair value $ - $ - $ 1,390 $ 1,390 Total $ - $ - $ 1,390 $ 1,390 Liabilities Warrant liabilities $ - $ - $ 87 $ 87 Caelum Convertible Note, at fair value - - 10,059 10,059 Helocyte Convertible Note, at fair value - - 4,700 4,700 Total $ - $ - $ 14,846 $ 14,846 Fair Value Measurement as of December 31, 2016 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Long-term investments, at fair value $ - $ - $ 1,414 $ 1,414 Total $ - $ - $ 1,414 $ 1,414 Liabilities Contingently Issuable Warrants $ - $ - $ 302 $ 302 Warrant liabilities - - 179 179 Helocyte Convertible Note, at fair value - - 4,487 4,487 Avenue Convertible Note, at fair value - - 200 200 Total $ - $ - $ 5,168 $ 5,168
Schedule of changes in fair value of financial instruments	Convertible Notes, at fair value ($ in thousands) Investment in Investment in Helocyte Avenue Caelum Issued Warrant Total Balance at December 31, 2016 $ 1,164 $ 250 $ 4,487 $ 200 $ - $ 14,661 $ 179 $ 20,941 Additions during the period - - - - 9,914 - - 9,914 Conversion into common shares - - - (299) - (750) (15) (1,064) Loss on write off investment - (250) - - - - - (250) Change in fair value of investments 226 - - - - - - 226 Change in fair value of convertible notes - - 213 99 145 - - 457 Change in fair value of derivative liabilities - - - - - 448 (8,839) (8,391) Balance at December 30, 2017 $ 1,390 $ - $ 4,700 $ - $ 10,059 $ 14,359 $ (8,675) $ 21,833 Convertible Notes, at Fair Value ($ in thousands) Investment in Investment in Contingently Helocyte Avenue Warrant Total Balance at December 31, 2015 $ 2,235 $ 250 $ 114 $ - $ - $ - $ 2,599 Additions during the period - - 14,040 4,409 200 440 19,089 Issuance of warrants - - (793) - - - (793) Change in fair value of investments (1,071) - - - - - (1,071) Change in fair value of convertible notes - - - 78 - 78 Change in fair value of derivative liabilities - - 1,300 - (261) 1,039 Balance at December 31, 2016 $ 1,164 $ 250 $ 14,661 $ 4,487 $ 200 $ 179 $ 20,941
Warrants Issuable [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	Such valuation (using level 3 inputs) was determined by use of the Black-Scholes option pricing model using the following assumptions: September 30 2017 2016 Dividend yield - % - % Expected volatility 91.0 % 118.85 % Risk-free interest rate 1.890 % 1.14 % Life (in years) 4.20 5
Checkpoint [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	The fair value of Checkpoint’s Contingently Issuable Warrants was determined at various issuance dates from March 19, 2015 to August 31, 2015 (“Issuance Dates”) for $ 0.2 0.6 Issuance October 30, Risk-free interest rate 2.26 % 2.16 % Expected dividend yield - - Expected term in years 10.00 10.00 Expected volatility 83 % 100.86 % Probability of issuance of the warrant 25 % 100 %
Fair Value for Derivative Contingently Issuable Warrant Liabilities	The following table sets forth the changes in the estimated fair value for Checkpoint’s Level 3 classified derivative Contingently Issuable Warrant liabilities: ($ in thousands) Checkpoint’s Beginning balance at January 1, 2015 $ - Additions 175 Change in fair value 438 Issuance of Warrants (October 30, 2015) (613) Ending balance at December 31, 2015 $ -
Avenue [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	The fair value of Avenue’s Contingently Issuable Warrants was determined by applying management’s estimate of the probability of issuance of the Contingently Issuable Warrants together with an option pricing model, with the following key assumptions: December 31, 2017 2016 Risk-free interest rate - % 2.45 % Expected dividend yield - - Expected term in years - 10.00 Expected volatility - % 87 % Probability of issuance of the warrant - 50 %
Avenue [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the convertible debt that is categorized within Level 3 of the fair value hierarchy for the year ended December 31, 2016 is as follows: December 31, 2016 Risk-free interest rate 0.62% - 1.20 % Expected dividend yield - % Expected term in years 0.50 - 2.00 Expected volatility 63.1 %
Fair Value for Derivative Contingently Issuable Warrant Liabilities	($ in thousands) Convertible Beginning balance at January 1, 2016 $ - Additions 200 Ending balance at December 31, 2016 200 Conversion into common shares (299) Change in fair value of convertible notes 99 Ending balance at December 31, 2017 $ -
Avenue [Member] | Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	A summary of the weighted average (in aggregate) significant unobservable inputs (level 3 inputs) used in measuring the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy for the year ended December 31, 2016 is as follows: December 31, Risk-free interest rate 2.45 % Expected dividend yield - % Expected term in years 10.00 Expected volatility 87 %
Mustang [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	The fair value of Mustang’s Contingently Issuable Warrants was determined by applying management’s estimate of the probability of issuance of the Contingently Issuable Warrants together with an option-pricing model, with the following key assumptions: Issuance Risk-free interest rate 1.37 % Expected dividend yield - Expected term in years 10.00 Expected volatility 76.70 % Probability of issuance of the warrant 100 %
Fair Value for Derivative Contingently Issuable Warrant Liabilities	($ in thousands) Mustang’s Beginning balance at January 1, 2016 $ - Additions 634 Change in fair value 159 Issuance of Warrants (October 25, 2016) (793) Ending balance at December 31, 2016 $ -
Mustang [Member] | Warrant [Member]
Fair Value for Derivative Contingently Issuable Warrant Liabilities	($ in thousands) Fair Value of Beginning balance at January 1, 2016 $ - Additions 12 Change in fair value of derivative liabilities - Ending balance at December 31, 2016 $ 12 Conversion into common shares (15) Change in fair value 3 Ending balance at December 31, 2017 $ -
Helocyte [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the convertible debt that is categorized within Level 3 of the fair value hierarchy for the year ended December 31, 2017 and 2016 is as follows: December 31 2017 2016 Risk-free interest rate 1.53% - 1.72 % 0.74% - 1.17 % Expected dividend yield - % - % Expected term in years 0.50 – 0.911 0.75 - 1.91 Expected volatility 52.4 % 61.7 %
Fair Value for Derivative Contingently Issuable Warrant Liabilities	Convertible Note ($ in thousands) At Fair Value Beginning balance at January 1, 2016 $ - Additions 4,409 Change in fair value of convertible notes 78 Ending balance at December 31, 2016 4,487 Change in fair value of convertible notes 213 Ending balance at December 31, 2017 $ 4,700
Helocyte [Member] | Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	A summary of the weighted average (in aggregate) significant unobservable inputs (level 3 inputs) used in measuring the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy for the year ended December 31, 2017 and 2016 are as follows: December 31 2017 2016 Risk-free interest rate 2.04% - 2.08 % 1.82% - 1.91 % Expected dividend yield - % - % Expected term in years 3.50 – 3.92 4.50 - 4.92 Expected volatility 70.0 % 70.0 % Strike price $ 0.46 $ 0.44
Fair Value for Derivative Contingently Issuable Warrant Liabilities	($ in thousands) Fair Value of Beginning balance at January 1, 2016 $ - Additions 428 Change in fair value of derivative liabilities (261) Ending balance at December 31, 2016 $ 167 Change in fair value of derivative liabilities (80) Ending balance at December 31, 2017 $ 87
Caelum [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring Caelum’s convertible debt that is categorized within Level 3 of the fair value hierarchy as of December 31, 2017 is as follows: December 31, Risk-free interest rate 1.506%- 1.851 % Expected dividend yield - % Expected term in years 0.46 - 1.70 Expected volatility 70.0 %
Fair Value for Derivative Contingently Issuable Warrant Liabilities	($ in thousands) Convertible Beginning balance at January 1, 2017 $ - Additions 9,914 Change in fair value of convertible notes 145 Ending balance at December 31, 2017 $ 10,059
Caelum [Member] | Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring Caelum’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of December 31, 2017 is as follows: December 31, Risk-free interest rate 2.154% - 2.168 % Expected dividend yield - % Expected term in years 4.58 - 4.71 Expected volatility 70.0 % Strike price $ 1.01
Fair Value for Derivative Contingently Issuable Warrant Liabilities	($ in thousands) Fair Value of Derivative Beginning balance at January 1, 2017 $ - Additions 226 Change in fair value of derivative liabilities (3) Ending balance at December 31, 2017 $ 223
National Holdings Corporation [Member]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	Fair Value Measurement as of September 30, 2017 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Securities owned, at fair value Corporate stock $ 116 $ - $ - $ 116 Municipal bonds - 1,239 - 1,239 Restricted stock - 82 - 82 Warrants - - 5,665 5,665 Total $ 116 $ 1,321 $ 5,665 $ 7,102 Liabilities Securities sold, but not yet purchased at fair value Contingent consideration $ - $ - $ 311 $ 311 Municipal bonds - 151 - 151 Warrants issued - - 5,597 5,597 Total $ - $ 151 $ 5,908 $ 6,059 Fair Value Measurement as of September 30, 2016 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Corporate stock 101 - 101 Municipal bonds - 2,111 - 2,111 Restricted stock - 145 - 145 Total $ 101 $ 2,256 $ - $ 2,357 Liabilities Corporate stock 298 - - 298 Warrants issuable 14,359 14,359 Total $ 298 $ - $ 14,359 $ 14,657

Licenses Acquired (Tables)

Licenses Acquired (Tables)	12 Months Ended
	Dec. 31, 2017
Research and Development [Abstract]
Research and Development Arrangement, Contract to Perform for Others	For the years ended December 31, 2017, 2016 and 2015, the Company’s research and development-licenses acquired are comprised of the following: For the Years Ended December 31, ($ in thousands) 2017 2016 2015 Fortress $ 300 $ 325 $ - Fortress Companies: Avenue - - 3,000 Caelum 219 - - Cellvation - 312 - Checkpoint 400 3,160 3,159 Coronado SO - - 1,607 Cyprium 100 - - Escala - - 1,295 Helocyte - 53 200 Mustang 2,875 1,682 2,147 Tamid 270 - - Total $ 4,164 $ 5,532 $ 11,408

Debt and Interest (Tables)

Debt and Interest (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Schedule Of Interest Expenses	Total debt consists of the following as of December 31, 2017 and December 31, 2016 December 31, ($ in thousands) 2017 2016 Interest rate Maturity IDB Note $ 14,929 $ 14,929 2.25 % Aug - 2020 NSC Note - 3,608 8.00 % Sep - 2018 2017 Subordinated Note Financing 3,254 - 8.00 % March - 2020 2017 Subordinated Note Financing 13,893 - 8.00 % May - 2020 2017 Subordinated Note Financing 1,820 - 8.00 % June - 2020 2017 Subordinated Note Financing 3,018 - 8.00 % August - 2020 2017 Subordinated Note Financing 6,371 - 8.00 % September - 2020 Opus Credit Facility 9,500 7,000 12.00 % Sep - 2018 Helocyte Convertible Note, at fair value 1,000 1,031 5.00% - 8.00 % December 2017 Helocyte Convertible Note, at fair value 2,194 2,051 5.00% - 8.00 % March - 2018 Helocyte Convertible Note, at fair value 1,062 991 5.00% - 8.00 % April - 2018 Helocyte Convertible Note, at fair value 444 414 5.00% - 8.00 % May - 2018 Avenue Convertible Note, at fair value - 200 5.00% - 8.00 % June - 2018 Caelum Convertible Note, at fair value 1,017 - 8.00 % January - 2019 Caelum Convertible Note, at fair value 6,900 - 8.00 % February - 2019 Caelum Convertible Note, at fair value 2,142 - 8.00 % June - 2019 Total notes payable 67,544 30,224 Less: Discount on notes payable 1,035 2,009 Total notes payable $ 66,509 $ 28,215
Schedule Of Interest Expenses For Debt Arrangements	The following table shows the details of interest expense for all debt arrangements during the periods presented. Interest expense includes contractual interest and amortization of the debt discount and amortization of fees represents fees associated with loan transaction costs, amortized over the life of the loan: For the Years Ended December 31, ($ in thousands) 2017 2016 2015 IDB Note Interest $ 340 $ 328 $ 314 Amortization of fees - 1 5 Total IDB Note 340 329 319 NSC Debt Interest 147 599 690 Amortization of fees 201 1,270 309 Total NSC Debt 348 1,869 999 2017 Subordinated Note Interest 2,234 - - Amortization of fees 76 - - Total 2017 Subordinated Note 2,310 - - Opus Credit Facility Interest 1,087 192 - Amortization of fees 1,037 195 - Total Opus Note 2,124 387 - Ovamed Interest - - 166 Total Ovamed - - 166 LOC Fees Interest 36 11 - Total LOC 36 11 - Helocyte Convertible Note Interest 261 61 - Financing fee 1 962 - Total Helocyte Convertible Note 262 1,023 - Avenue Convertible Note Interest 5 - - Financing fee 3 70 - Total Avenue Convertible Note 8 70 - Caelum Convertible Note Interest 265 - - Financing fee 100 - - Total Caelum Convertible Note 365 - - Falk CSR Interest 64 - - Total Falk CSR 64 - - D&O Insurance Interest 3 1 - Total D&O Insurance 3 1 - Total Interest Expense and Financing Fee $ 5,860 $ 3,690 $ 1,484

Accrued Liabilities and other39

Accrued Liabilities and other Long-Term Liabilities (Tables)	12 Months Ended
	Dec. 31, 2017
Components of Accrued Expenses and Other Long-Term Liabilities	Accrued expenses and other long-term liabilities, excluding National, consisted of the following ($ in thousands): December 31, 2017 2016 Accrued expenses: Professional fees $ 1,625 $ 1,253 Salaries, bonuses and related benefits 5,279 2,846 Accrued expenses – related party 95 - Accrued severance - 53 Ovamed manufacturing rights - short term component - 900 Research and development 4,046 394 Dr. Falk Pharma milestone (See Note 16) 3,059 2,634 Accrued royalties payable 1,411 263 Accrued coupon expense 1,087 463 Lease impairment - 128 Other 1,030 1,148 Total accrued expenses $ 17,632 $ 10,082 Other long-term liabilities: Deferred rent and long-term lease abandonment charge 4,739 5,014 Total other long-term liabilities $ 4,739 $ 5,014
National Holdings Corporation [Member]
Components of Accrued Expenses and Other Long-Term Liabilities	National’s accounts payable and other accrued expenses as of September 30, 2017, consisted of the following ($ in thousands): September 30, 2017 2016 Legal $ 877 $ 1,346 Audit 176 198 Telecommunications 205 209 Data Services 464 425 Regulatory 540 444 Settlements 2,403 832 Deferred rent 497 65 Other 3,242 3,223 Total $ 8,404 $ 6,742

Non-Controlling Interests (Tabl

Non-Controlling Interests (Tables)	12 Months Ended
	Dec. 31, 2017
Noncontrolling Interest [Abstract]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net	Non-controlling interests in consolidated entities are as follows ($ in thousands): As of December 31, 2017 NCI equity share Net gain/(loss) attributable to Non-controlling Non-controlling Aevitas $ (126) $ (168) $ (294) 35.4 % Avenue 2 17,454 (4,646) 12,808 66.1 % Caelum (815) (1,262) (2,077) 34.7 % Cellvation (259) (96) (355) 21.5 % Checkpoint 1 21,635 (12,314) 9,321 62.0 % Coronado SO (236) (54) (290) 13.0 % Cyprium (143) (15) (158) 11.1 % Helocyte (1,907) (1,193) (3,100) 20.0 % JMC (469) 7 (462) 6.3 % Mustang 2 48,740 (11,911) 36,829 61.6 % National Holdings 17,021 (1,216) 15,805 43.4 % Tamid (6) (92) (98) 24.0 % Total $ 100,889 $ (32,960) $ 67,929 As of December 31, 2016 NCI equity share Net loss attributable to Non-controlling Non-controlling Avenue (494) (349) (843) 10.2 % Cellvation 4 (158) (154) 22.0 % Checkpoint 1 32,160 (11,733) 20,427 62.9 % Coronado SO (217) (19) (236) 13.0 % Helocyte (612) (1,155) (1,767) 20.5 % JMC (192) (355) (547) 7.0 % Mustang 12,376 (1,805) 10,571 26.7 % National Holdings 17,643 (621) 17,022 43.4 % Total $ 60,668 $ (16,195) $ 44,473 As of December 31, 2015 NCI equity share Net loss attributable to Non-controlling Non-controlling Avenue $ 6 $ (567) $ (561) 11.5 % Checkpoint 1 32,760 (3,855) 28,905 62.3 % Coronado SO 23 (240) (217) 13.0 % JMC 79 (420) (341) 8.8 % Mustang 14 (373) (359) 10.0 % Total $ 32,882 $ (5,455) $ 27,427 (1) Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights. (2) Avenue and Mustang are consolidated with Fortress’ operations because Fortess maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights.

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Computations of Diluted Weighted Average Shares Outstanding	The following shares of potentially dilutive securities, weighted during the years ended December 31, 2017, 2016, and 2015 have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive: For the Years Ended December 31, 2017 2016 2015 Warrants to purchase Common Stock 745,285 456,150 685,061 Opus warrants to purchase Common Stock 628,383 1,780,000 - Options to purchase Common Stock 1,093,283 1,604,214 1,960,443 Series A Preferred Stock 2,740 - - Unvested Restricted Stock 9,840,614 8,749,052 6,816,321 Unvested Restricted Stock Units 1,390,799 1,087,563 427,627 Total 13,701,104 13,676,979 9,889,452

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share Based Compensation Stock Options, and Other Types of Grants of Stock Option	The table below provides a summary of those plans as of December 31, 2017: Fortress Company Stock Plan Shares Authorized Shares Avenue Avenue Therapeutics, Inc. 2015 Stock Plan 2,000,000 1,115,000 Caelum Caelum Biosciences Inc. 2017 Incentive Plan 2,000,000 125,002 Cellvation Cellvation Inc. 2016 Incentive Plan 2,000,000 300,000 Checkpoint Checkpoint Therapeutics, Inc. Amended and Restated 2015 Stock Plan 5,000,000 2,961,697 Cyprium Cyprium Therapeutics, Inc. 2017 Stock Plan 2,000,000 2,000,000 Helocyte DiaVax Biosciences, Inc. 2015 Incentive Plan 2,000,000 341,667 Journey Journey Medical Corporation 2015 Stock Plan 3,000,000 614,792 Mustang Mustang Bio, Inc. 2016 Incentive Plan 2,000,000 444,325 Tamid FBIO Acquisition Corp. V 2017 Incentive Plan 2,000,000 1,600,000
Schedule of Share-based Compensation, Activity	For the Years Ended December 31, ($ in thousands) 2017 2016 2015 Employee awards $ 6,606 $ 7,386 $ 8,130 Executive awards of Fortress Companies’ stock - - 2,228 Non-employee awards 83 33 33 Fortress Companies: Avenue 604 28 51 Caelum 595 - - Cellvation 31 7 - Checkpoint 3,118 3,867 3,252 Helocyte 128 250 - JMC 224 515 597 Mustang 2,013 - - Tamid 1 - - National 602 42 - Total stock-based compensation expense $ 14,005 $ 12,128 $ 14,291
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable	The following table summarizes Fortress stock option activities excluding activities related to Fortress Companies: Number of Weighted Total Weighted Options vested and expected to vest at December 31, 2015 1,779,365 $ 4.37 $ 666,396 6.32 Forfeited (648,864) 0.51 - - Options vested and expected to vest at December 31, 2016 1,130,501 3.73 602,451 4.93 Exercised (20,000) 1.37 52,400 - Exercisable as of December 31, 2016 1,110,501 $ 3.78 $ 1,351,080 3.95 Options vested and expected to vest at December 31, 2017 1,085,501 $ 3.75 $ 1,351,080 3.93
Nonvested Restricted Stock Shares Activity	The following table summarizes Fortress restricted stock awards and restricted stock units activities, excluding activities related to Fortress Companies: Number of shares Weighted Unvested balance at December 31, 2015 8,757,935 $ 2.47 Restricted stock granted 1,240,868 2.77 Restricted stock cancelled (33,333) 2.69 Restricted stock vested (173,333) 2.73 Restricted stock units granted 641,000 2.93 Restricted stock units cancelled (111,750) 3.58 Restricted stock units vested (227,292) 3.56 Unvested balance at December 31, 2016 10,094,095 $ 2.49 Restricted stock granted 1,325,396 2.70 Restricted stock vested (213,333) 2.75 Restricted stock units granted 1,128,750 4.17 Restricted stock units forfeited (15,000) 2.98 Restricted stock units vested (445,874) 3.50 Unvested balance at December 31, 2017 11,874,034 $ 2.63
Schedule of Warrant Activities	The following table summarizes Fortress warrant activities, excluding activities related to Fortress Companies: Number of Weighted Total Weighted Outstanding as of December 31, 2015 569,835 $ 6.31 $ 120,700 1.84 Granted 1,880,000 3.00 - 5.65 Expired (161,382) 6.30 - - Exercised (*) (25,000) 1.37 33,250 - Outstanding as of December 31, 2016 2,263,453 $ 3.62 $ 79,800 4.74 Granted 816,180 3.84 260,380 4.87 Forfeited (305,444) 7.07 - - Outstanding as of December 31, 2017 2,774,189 $ 3.30 $ 2,204,530 4.47 Exercisable as of December 31, 2017 869,189 $ 3.96 $ 318,580 4.05 (*) – cashless
Schedule of Fair Value of Separate Accounts by Major Category of Investment	500,000 2015 Warrant Risk Free Volatility Life Exercise Fair Value Mustang 1,000,000 2.36 % 106.11 % 10 $ 0.147 $ 135,000 Checkpoint 1,000,000 2.36 % 106.11 % 10 $ 0.129 $ 118,000 Avenue 1,000,000 2.36 % 106.11 % 10 $ 0.146 $ 134,000 CNDO SO 1,000,000 2.36 % 106.11 % 10 $ 1.190 $ 1,091,000 Helocyte 1,000,000 2.36 % 106.11 % 10 $ 0.097 $ 89,000 JMC 1,000,000 2.36 % 106.11 % 10 $ 0.650 $ 596,000 Escala 1,000,000 2.36 % 106.11 % 10 $ 0.071 $ 65,000 2016 Cellvation 1,000,000 2.86 % 70 % 9 $ 0.024 $ 18,000 Beginning in 2017, the LTIP equity interest grants were made in the form of stock. During the year ended December 31, 2017, Mr. Weiss and Dr. Rosenwald received, for their services to the Company, stock awards of 500,000 5 Risk Free Discount for Exercise 2017 Stock Shares Rate Volatility Marketability price Fair Value Aevitas 1,000,000 1.92 79.8 % 42.6 % $ 0.020 $ 20,000 Caelum 1,000,000 1.93 70.0 % 49.5 % $ 0.028 $ 28,000 Cyprium 1,000,000 1.92 84.3 % 44.2 % $ 0.004 $ 4,000 Acquisition Corp. III 1,000,000 1.92 83.9 % 44.0 % $ 0.007 $ 7,000 Acquisition Corp. IV 1,000,000 1.92 83.9 % 44.0 % $ 0.007 $ 7,000 Tamid 1,000,000 1.92 83.9 % 44.0 % $ 0.007 $ 7,000 Acquisition Corp. VI 1,000,000 1.92 83.9 % 44.0 % $ 0.007 $ 7,000 Acquisition Corp. VII 1,000,000 1.92 83.9 % 44.0 % $ 0.007 $ 7,000 Acquisition Corp. VIII 1,000,000 1.92 83.9 % 44.0 % $ 0.007 $ 7,000

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Schedule of Future Minimum Rental Payments for Operating Leases	Total future minimum lease payments under these leases are: ($ in thousands) 2018 $ 2,761 2019 2,976 2020 3,203 2021 3,084 2022 3,084 Beyond 26,600 Total minimum lease payments $ 41,708
National Holdings [Member]
Schedule of Future Minimum Rental Payments for Operating Leases	As of September 30, 2017, National leases office space in various states expiring at various dates through August 2025, and is committed under operating leases for future minimum lease payments as follows ($ in thousands): Fiscal Year Ending Rental Less, Sublease Net 2018 $ 3,040 $ 360 $ 2,680 2019 2,481 30 2,451 2020 2,346 — 2,346 2021 2,043 — 2,043 2022 1,331 — 1,331 Thereafter 4,524 — 4,524 Total $ 15,765 $ 390 $ 15,375

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Effective Date and Equity Fee Payable	The following table summarizes, by subsidiary, the effective date of the Founders Agreements and PIK dividend or equity fee payable to the Company in accordance with the terms of the Founders Agreements, Exchange Agreements and the subsidiaries’ certificates of incorporation. Fortress Company Effective Date (1) PIK Dividend as Class of Stock Helocyte March 20, 2015 2.5 % Common Stock Avenue February 17, 2015 2.5 % Common Stock Mustang March 13, 2015 2.5 % Common Stock Checkpoint March 17, 2015 0.0 % (2) Common Stock Cellvation October 31, 2016 2.5 % Common Stock Caelum January 1, 2017 2.5 % Common Stock Cyprium March 13, 2017 2.5 % Common Stock Aevitas July 28, 2017 2.5 % Common Stock Tamid November 30, 2017 (3) 2.5 % Common Stock (1) - Represents the effective date of each subsidiary’s Founders Agreement. Each PIK dividend and equity fee is payable on the annual anniversary of the effective date of the original Founders Agreement. (2) - Instead of a PIK dividend, Checkpoint pays the Company an annual equity fee in shares of Checkpoint’s common stock equal to 2.5
Dividends Declared	The following table summarizes, by subsidiary, the PIK dividend or equity fee recorded by the Company in accordance with the terms of the Founders Agreements, Exchange Agreements and the subsidiaries’ certificates of incorporation for the year ended December 31, 2017 ($ in thousands): Fortress Company PIK Dividend Year Ended 1 Year Ended Aevitas 2 July 28 $ - $ - Avenue February 17 1,103 49 Caelum January 1 302 - Cellvation October 31 8 - Checkpoint March 17 2,296 3,919 Cyprium January 1 1 - Helocyte March 20 321 - Mustang March 13 9,479 4,396 Tamid3 November 30 - - Fortress (13,510) (8,364) Consolidated (Income)/Expense $ - $ - Note 1: Includes 2018 PIK dividend accrued for the year ended December 31, 2017, as Type 1 subsequent event Note 2: Aevitas PIK dividend wll be recorded during the third quarter of 2018 Note 3: Tamid PIK dividend will be recorded during the fourth quarter of 2018
Schedule of Effective Date and Annual Management Services Agreement Fee income expense	The following table summarizes, by Fortress Company, the effective date of the MSA and the annual consulting fee payable by the subsidiary to the Company in quarterly installments ($ in thousands): Fortress Company Effective Date R&D G&A Annual MSA Fee Helocyte March 20, 2015 $ 250 $ 250 $ 500 Avenue February 17, 2015 250 250 500 Mustang March 13, 2015 250 250 500 Checkpoint March 17, 2015 250 250 500 Cellvation October 31, 2016 250 250 500 Caelum January 1, 2017 250 250 500 Cyprium March 13, 2017 250 250 500 Aevitas July 28, 2017 250 250 500 Tamid November 30, 2017 (1) 250 250 500 Fortress (2,250) (2,250) (4,500) Consolidated (Income)/Expense $ - $ - $ - (1) – Represents the Trigger Date.
Schedule of Information about Fees Earned	The following table summarizes, by entity, fees earned by National for the periods ending September 30, 2017 and 2016, respectively ($ in thousands): September 30, September 30, Fortress Company Description 2017 2016 Fortress Subordinated Financing $ 2,836 $ - Avenue IPO Fees 2,331 - Mustang Private Placement Offering 9,527 1,265 Caelum Convertible Debt Raise 991 - Total Fees per Fortress 15,685 1,265 Less: Mustang fee recorded by National in 2016 1,265 - Total National Fees $ 14,420 $ 1,265

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit)	The components of the income tax provision (benefit) are as follows: For the years ended December 31, ($ in thousands) 2017 2016 Current Federal $ 1,074 $ - State 439 - Deferred Federal - - State - - Total $ 1,513 $ -
Schedule of Deferred Tax Assets and Liabilities	As of December 31, ($ in thousands) 2017 2016 Deferred tax assets: Net operating loss carryforwards $ 71,616 $ 76,486 Amortization of license fees 13,648 7,277 Amortization of in-process R&D 557 742 Stock compensation 10,682 10,899 Accruals and reserves 5,166 4,025 Tax credits 7,376 6,305 Start up costs 75 98 Unrealized loss on investments - 1,095 Total deferred tax assets 109,120 106,927 Less: valuation allowance (101,645) (94,687) Net deferred tax assets $ 7,475 $ 12,240 Deferred tax liabilities: Unrealized gain/loss on investment $ (685) $ - Intangibles (3,321) (4,450) Basis in subsidiary (3,469) (7,790) Total deferred tax assets, net $ - $ -
Schedule of Effective Income Tax Rate Reconciliation	For the Year Ended December 31, 2017 2016 2015 Percentage of pre-tax income: U.S. federal statutory income tax rate 35 % 35 % 35 % State taxes, net of federal benefit 8 % 3 % 5 % Credits 1 % 2 % 1 % Non-deductible items (2) % (4) % - % Provision to return 1 % 2 % - % Stock based compensation shortfall (1) % (2) % (1) % Change in federal rate (43) % - % - % Change in state rate 2 % - % - % Intercomapny elimination adjustments (3) % - % - % Change in fair value of warrants 3 % - % - % Change in valuation allowance (7) % (33) % (44) % Change in subsidiary basis 4 % (3) % 3 % Other - % - % 1 % Effective income tax rate (2) % - % - %

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	Pharmaceutical Dermatology Biotechnology Year Ended December 31, 2017 Products Product National Consolidated Net Revenue $ 15,520 $ 1,725 $ 170,339 $ 187,584 Direct cost of goods (3,658) - - (3,658) Sales and marketing costs (10,410) - - (10,410) Research and development - (52,486) - (52,486) General and administrative (1,140) (39,347) - (40,487) National expenses - - (181,751) (181,751) Segment profit (loss) from operations $ 312 $ (90,108) $ (11,412) $ (101,208) Segment assets $ 9,644 $ 187,941 $ 48,365 $ 245,950 Pharmaceutical Dermatology Biotechnology Year Ended December 31, 2016 Products Product National Consolidated Net Revenue $ 3,587 $ 2,570 $ 10,323 $ 16,480 Direct cost of goods (790) - - (790) Sales and marketing costs (5,774) - - (5,774) Research and development - (35,134) - (35,134) General and administrative (1,474) (26,755) - (28,229) National expenses - - (12,263) (12,263) Segment loss from operations $ (4,451) $ (59,319) $ (1,940) $ (65,710) Segment assets $ 4,469 $ 115,145 $ 51,117 $ 170,731 Pharmaceutical Dermatology Biotechnology Year Ended December 31, 2015 Products Product National Consolidated Net Revenue $ 273 $ 590 $ - $ 863 Direct cost of goods - - - - Sales and marketing costs (2,850) - - (2,850) Research and development - (29,810) - (29,810) General and administrative (1,682) (17,052) - (18,734) Segment loss from operations $ (4,259) $ (46,272) $ - $ (50,531) Segment assets $ 1,965 $ 116,542 $ - $ 118,610

Selected Quarterly Financial 47

Selected Quarterly Financial Data (Tables)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	The following table contains quarterly financial information for fiscal years 2017 and 2016. The Company believes that the following information reflects all normal recurring adjustments necessary for a fair statement of the information for the periods presented. ($ in thousands, except per share data) First Quarter Second Quarter Third Quarter Fourth Quarter 2017 Total Revenue $ 44,682 $ 50,697 $ 46,886 $ 45,319 Operating expenses $ (62,259) $ (73,890) $ (79,489) $ (73,154) Other income/(expense) $ 3,015 $ 244 $ (3,704) $ 3,330 Income tax expense $ - $ - $ - $ 1,513 Non-controlling interests $ 2,580 $ 5,584 $ 9,191 $ 15,605 Net loss attributable to common stockholders $ (11,982) $ (17,365) $ (27,116) $ (10,413) Basic and diluted net loss per common share $ (0.30) $ (0.43) $ (0.67) $ (0.25) 2016 Total Revenue $ 660 $ 2,230 $ 975 $ 14,405 Operating expenses $ (15,571) $ (17,042) $ (17,180) $ (32,217) Other income/(expense) $ (1,552) $ (1,253) $ (710) $ (2,065) Non-controlling interests $ 4,438 $ 3,911 $ 3,975 $ 3,871 Net loss attributable to common stockholders $ (12,205) $ (12,478) $ (12,981) $ (17,431) Basic and diluted net loss per common share $ (0.31) $ (0.31) $ (0.32) $ (0.43)

Organization and Description 48

Organization and Description of Business - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Sep. 09, 2016	Dec. 31, 2017	Dec. 01, 2017	Jun. 01, 2017	Dec. 31, 2016	Apr. 27, 2016
Organization And Nature Of Business [Line Items]
Common Stock Par Or Stated Value Per Share		$ 0.001	$ 3.26	$ 1.90	$ 0.001
National Holdings Corporation [Member]
Organization And Nature Of Business [Line Items]
Merger Agreement Minimum Percentage Of Shares In Tender Offer To Completed Merger	56.60%	56.60%
Merger Agreement Termination Fee	$ 22.9
Common Stock Par Or Stated Value Per Share	$ 0.02					$ 0.02
Business Acquisition, Share Price	$ 3.25					$ 3.25

Summary of Significant Accoun49

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash and cash equivalents	$ 113,915	$ 88,294	$ 98,182
Restricted cash	17,387	15,860	14,586
Total cash, cash equivalents and restricted cash	$ 131,302	$ 104,154	$ 112,768

Summary of Significant Accoun50

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Feb. 28, 2018	Jan. 02, 2018	Sep. 30, 2017	Sep. 30, 2016
Accounting Policies [Line Items]
Percentage of tax benefit likely of being realized		50.00%
Restricted Cash and Cash Equivalents		$ 17,400	$ 15,900
Allowance for Doubtful Accounts Receivable		$ 1,300	100
Debt Instrument, Interest Rate, Stated Percentage		28.00%
Deferred Revenue and Credits, Current		$ 786	995
Pledged Assets Separately Reported, Loans Pledged as Collateral, at Fair Value		2,500	1,000
Variable Interest Entity, Measure of Activity, Expense		16,500	17,000
Reimbursement expenses		$ 9,900	$ 11,900
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		35.00%	35.00%	35.00%
Revenue Recognition, Sales Returns, Reserve for Sales Returns		$ 1,200	$ 100
Scenario, Plan [Member]
Accounting Policies [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%
Subsequent Event [Member]
Accounting Policies [Line Items]
Debt Instrument, Interest Rate, Stated Percentage					8.00%
Cumulative Effect of New Accounting Principle in Period of Adoption						$ 800
Held-to-maturity Securities [Member]
Accounting Policies [Line Items]
Time Deposits, at Carrying Value		36,000
Cash and Cash Equivalents [Member]
Accounting Policies [Line Items]
Time Deposits, at Carrying Value		14,000
Deferred Clearing [Member]
Accounting Policies [Line Items]
Deferred Revenue and Credits, Current							$ 500	$ 700
Marketing Credits [Member]
Accounting Policies [Line Items]
Deferred Revenue and Credits, Current							$ 300	$ 300
Hercules Note Payble [Member]
Accounting Policies [Line Items]
Restricted Cash and Cash Equivalents		$ 14,900	$ 14,900

National Holdings Corporation -

National Holdings Corporation - Fair value of assets acquired and liabilities assumed at the date of the acquisition (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Assets
Cash and cash equivalents	$ 27,498
Accounts receivable	4,889
Cash deposits with clearing organizations	1,030
Receivable from brokers, dealers and clearing agencies	1,607
Securities owned, at fair value	2,178
Prepaid expenses and other current assets	1,985
Property and equipment	1,132
Restricted cash	353
Goodwill	18,645	$ 18,645
Total assets	75,817
Liabilities
Accrued compensation payable	14,029
Accounts payable and accrued expenses	6,079
Deferred clearing and marketing credits	1,007
Warrants issuable	13,406
Other current liabilities	707
Total liabilities assumed	35,228
Non-controlling interests	(17,717)
Net assets acquired	22,872
Cash and cash equivalents from National	27,498
Cash to NHLD Shareholders (Tender Offer)	(22,872)
Net cash acquired in acquisition of National	4,626
Trademarks [Member]
Assets
Intangible assets	3,000
Customer Lists [Member]
Assets
Intangible assets	$ 13,500

National Holdings Corporation52

National Holdings Corporation - Amortization is calculated using the straight-line method over the estimated useful lives (Detail)	12 Months Ended
	Dec. 31, 2017
Trademarks [Member]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	10 years
Customer Lists [Member]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	6 years

National Holdings Corporation53

National Holdings Corporation - gross carrying amounts related to acquired intangible assets (Detail) - USD ($) $ in Thousands	4 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Intangible assets	$ 16,500	$ 15,991
Amortization expense	(509)	(1,651)	$ 0	$ 0
Intangible assets	$ 15,991	$ 14,340	$ 15,991

National Holdings Corporation54

National Holdings Corporation - future amortization of these intangible assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Sep. 09, 2016
Year Ended December 31, 2018	$ 2,550
Year Ended December 31, 2019	2,550
Year Ended December 31, 2020	2,551
Year Ended December 31, 2021	2,550
Year Ended December 31, 2022	2,550
Thereafter	1,589
Total	14,340	$ 15,991	$ 16,500
Customer Lists [Member]
Year Ended December 31, 2018	2,250
Year Ended December 31, 2019	2,250
Year Ended December 31, 2020	2,250
Year Ended December 31, 2021	2,250
Year Ended December 31, 2022	2,250
Thereafter	482
Trademarks [Member]
Year Ended December 31, 2018	300
Year Ended December 31, 2019	300
Year Ended December 31, 2020	301
Year Ended December 31, 2021	300
Year Ended December 31, 2022	300
Thereafter	$ 1,107

National Holdings Corporation55

National Holdings Corporation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	1 Months Ended		12 Months Ended
	Sep. 30, 2016	Apr. 27, 2016	Dec. 31, 2017	Dec. 01, 2017	Jun. 01, 2017	Mar. 17, 2017	Dec. 31, 2016	Sep. 09, 2016
Business Combination, Consideration Transferred			$ 22,872
Common Stock Par Or Stated Value Per Share			$ 0.001	$ 3.26	$ 1.90		$ 0.001
Goodwill			$ 18,645				$ 18,645
National Holdings Corporation [Member]
Business Acquisition, Percentage of Voting Interests Acquired	56.60%	56.00%				56.60%		56.60%
Business Acquisition, Share Price		$ 3.25						$ 3.25
Number Of Shares Tendered		7
Business Combination, Consideration Transferred	$ 22,900	$ 22,900
Common Stock Par Or Stated Value Per Share		$ 0.02						$ 0.02

Broker-Dealers and Clearing O56

Broker-Dealers and Clearing Organizations and Other Receivables - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2016
Brokers And Dealers [Line Items]
Receivables from Brokers-Dealers and Clearing Organizations	$ 7,395		$ 3,357
Allowance for Doubtful Accounts Receivable	$ 1,300		$ 100
Accounts Receivable, Net		$ 5,200		$ 5,400
Broker -Dealers And clearing Organisation [Member]
Brokers And Dealers [Line Items]
Receivables from Brokers-Dealers and Clearing Organizations		7,400		3,400
Allowance for Doubtful Accounts Receivable		$ 500		$ 700

Forgivable Loans Receivable - A

Forgivable Loans Receivable - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2016
Debt Instrument, Interest Rate, Stated Percentage	28.00%
Notes, Loans and Financing Receivable, Net, Current	$ 1,616	$ 1,600	$ 1,712	$ 1,700
Forgivable Loan Receivable [Member]
Debt Instrument, Interest Rate, Stated Percentage	9.00%

Property and Equipment - Compon

Property and Equipment - Components of Property and Equipment (Detail) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2016
Property, Plant and Equipment [Line Items]
Total property and equipment			$ 2,872		$ 1,200
Less: Accumulated depreciation			(475)		(36)
Property and equipment, net		$ 9,513	2,397	$ 7,376	1,164
Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		8,287		6,657
Less: Accumulated depreciation		(1,171)		(445)
Property and equipment, net		7,116		6,212
Computer Equipment [Member] | Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		$ 543		440
Useful Life (Years)		3 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment			284		65
Useful Life (Years)		5 years
Furniture and Fixtures [Member] | Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		$ 1,009		821
Useful Life (Years)		5 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment			$ 1,006		$ 259
Leasehold Improvements [Member] | Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		$ 5,351		5,396
Leasehold Improvements [Member] | Fortress Biotech Inc [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Life (Years)		15 years
Leasehold Improvements [Member] | Fortress Biotech Inc [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful Life (Years)		5 years
Construction in progress [Member] | Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	[1]	$ 1,241		0
Machinery and Equipment [Member] | Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		$ 143		$ 0
Useful Life (Years)		5 years
[1]	For build-out of Mustang’s cell processing facility in Worcester, MA. The total cost of the construction for the Worcester facility is expected to be $3.5 million. The cost of the equipment for the facility is expected to be $2.5 million

Property and Equipment - Schedu

Property and Equipment - Schedule Of National’s property and equipment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2016
Property, Plant and Equipment [Line Items]
Property Plant And Equipment Gross		$ 2,872		$ 1,200
Less: Accumulated depreciation		(475)		(36)
Property Plant And Equipment Net	$ 9,513	2,397	$ 7,376	1,164
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property Plant And Equipment Gross		1,306		600
Property Plant And Equipment Useful Life	5 years
Furniture And Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property Plant And Equipment Gross		284		65
Property Plant And Equipment Useful Life	5 years
Leaseholds And Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property Plant And Equipment Gross		1,006		259
Property, Plant and Equipment, Estimated Useful Lives	Lesser of useful life or term of lease
Assets Held under Capital Leases [Member]
Property, Plant and Equipment [Line Items]
Property Plant And Equipment Gross		$ 276		$ 276
Property Plant And Equipment Useful Life	5 years

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($)		1 Months Ended	12 Months Ended
		Sep. 30, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Depreciation			$ 700,000	$ 400,000	$ 26,000
Expected Cost of Construction	[1]		3,500,000
Expected Cost of Equipment			2,500,000
National Holdings Corporation [Member]
Property, Plant and Equipment [Line Items]
Depreciation		$ 36,000	$ 400,000
[1]	For build-out of Mustang’s cell processing facility in Worcester, MA. The total cost of the construction for the Worcester facility is expected to be $3.5 million. The cost of the equipment for the facility is expected to be $2.5 million

Fair Value Measurements - Avenu

Fair Value Measurements - Avenue's Contingently Issuable Warrants with option pricing model (Detail)	1 Months Ended	5 Months Ended	12 Months Ended
	Oct. 30, 2015	Aug. 31, 2015	Dec. 31, 2017	Dec. 31, 2016
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected dividend yield			0.00%
Expected volatility			70.00%
Avenue [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate			0.00%	2.45%
Expected dividend yield			0.00%	0.00%
Expected term in years			0 years	10 years
Expected volatility			0.00%	87.00%
Probability of issuance of the warrant			0.00%	50.00%
Mustang [Member] | Contingently Issuable Warrants [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate			1.37%
Expected dividend yield			0.00%
Expected term in years			10 years
Expected volatility			76.70%
Probability of issuance of the warrant			100.00%
Checkpoint [Member] | Contingently Issuable Warrants [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	2.16%	2.26%
Expected dividend yield	0.00%	0.00%
Expected term in years	10 years	10 years
Expected volatility	100.86%	83.00%
Probability of issuance of the warrant	100.00%	25.00%

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Fair Value of Financial Instruments (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	$ 20,941	$ 2,599
Additions during the period	9,914	19,089
Conversion into common shares	(1,064)
Issuance of warrants		(793)
Loss on write off investment	250	0	$ 0
Change in fair value of investments	226	(1,071)
Change in fair value of convertible notes	457	78
Change in fair value of derivative liabilities	(8,391)	1,039
Balance	21,833	20,941	2,599
Contingently Issuable Warrant [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	14,661	114
Additions during the period		14,040
Issuance of warrants		(793)
Change in fair value of investments		0
Change in fair value of convertible notes		0
Change in fair value of derivative liabilities		1,300
Balance		14,661	114
Helocyte [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	4,487	0
Additions during the period	0	4,409
Conversion into common shares	0
Issuance of warrants		0
Loss on write off investment	0
Change in fair value of investments	0	0
Change in fair value of convertible notes	213	78
Change in fair value of derivative liabilities	0	0
Balance	4,700	4,487	0
Avenue [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	200	0
Additions during the period	0	200
Conversion into common shares	(299)
Issuance of warrants		0
Loss on write off investment	0
Change in fair value of investments	0	0
Change in fair value of convertible notes	99
Change in fair value of derivative liabilities	0
Balance	0	200	0
Caelum Convertible Notes [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	0
Additions during the period	9,914
Conversion into common shares	0
Loss on write off investment	0
Change in fair value of investments	0
Change in fair value of convertible notes	145
Change in fair value of derivative liabilities	0
Balance	10,059	0
Issued Warrants [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	14,661
Additions during the period	0
Conversion into common shares	(750)
Loss on write off investment	0
Change in fair value of investments	0
Change in fair value of convertible notes	0
Change in fair value of derivative liabilities	448
Balance	14,359	14,661
Warrant liabilities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	179	0
Additions during the period	0	440
Conversion into common shares	(15)
Issuance of warrants		0
Loss on write off investment	0
Change in fair value of investments	0	0
Change in fair value of convertible notes	0	0
Change in fair value of derivative liabilities	(8,839)	(261)
Balance	(8,675)	179	0
Investment In Laser Device [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	250	250
Additions during the period	0	0
Conversion into common shares	0
Issuance of warrants		0
Loss on write off investment	(250)
Change in fair value of investments	0	0
Change in fair value of convertible notes	0	0
Change in fair value of derivative liabilities	0	0
Balance	0	250	250
Investment In Origo [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	1,164	2,235
Additions during the period	0	0
Conversion into common shares	0
Issuance of warrants		0
Loss on write off investment	0
Change in fair value of investments	226	(1,071)
Change in fair value of convertible notes	0	0
Change in fair value of derivative liabilities	0	0
Balance	$ 1,390	$ 1,164	$ 2,235

Fair Value Measurements - Warra

Fair Value Measurements - Warrant Liabilities And Convertible Notes At Fair Value (Detail) - $ / shares	1 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2017	Dec. 31, 2016
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected dividend yield			0.00%
Expected volatility			70.00%
Strike price			$ 1.01
Warrants Issuable [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	1.89%	1.14%
Expected dividend yield	0.00%	0.00%
Expected term in years	4 years 2 months 12 days	5 years
Expected volatility	91.00%	118.85%
Avenue [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected dividend yield				0.00%
Expected volatility				63.10%
Avenue [Member] | Minimum [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate				0.62%
Expected term in years				6 months
Avenue [Member] | Maximum [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate				1.20%
Expected term in years				2 years
Avenue [Member] | Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate				2.45%
Expected dividend yield				0.00%
Expected term in years				10 years
Expected volatility				87.00%
Helocyte [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected dividend yield			0.00%	0.00%
Expected volatility			52.40%	61.70%
Helocyte [Member] | Minimum [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate			1.53%	0.74%
Expected term in years			6 months	9 months
Helocyte [Member] | Maximum [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate			1.72%	1.17%
Expected term in years			10 months 28 days	1 year 10 months 28 days
Helocyte [Member] | Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected dividend yield			0.00%	0.00%
Expected volatility			70.00%	70.00%
Strike price			$ 0.46	$ 0.44
Helocyte [Member] | Warrant [Member] | Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate			2.04%	1.82%
Expected term in years			3 years 6 months	4 years 6 months
Helocyte [Member] | Warrant [Member] | Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate			2.08%	1.91%
Expected term in years			3 years 11 months 1 day	4 years 11 months 1 day
Caelum Warrant Liabilities [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected dividend yield			0.00%
Expected volatility			70.00%
Strike price			$ 1.43
Caelum Warrant Liabilities [Member] | Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate			2.154%
Expected term in years			4 years 6 months 29 days
Caelum Warrant Liabilities [Member] | Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate			2.168%
Expected term in years			4 years 8 months 16 days
Caelum Convertible Notes [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected dividend yield			0.00%
Expected volatility			70.00%
Caelum Convertible Notes [Member] | Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate			1.506%
Expected term in years			5 months 16 days
Caelum Convertible Notes [Member] | Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate			1.851%
Expected term in years			1 year 8 months 12 days

Fair Value Measurements - Deriv

Fair Value Measurements - Derivative Contingently Issuable Warrant liabilities (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Additions	$ 9,914	$ 19,089
Conversion into common shares	(1,064)
Caelum Warrant Liabilities [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Beginning balance	0
Additions	226
Change in fair value	(3)
Ending balance	223	0
Avenue [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Beginning balance	200	0
Additions		200
Conversion into common shares	(299)
Change in fair value	99
Ending balance	0	200	$ 0
Avenue [Member] | Contingently Issuable Warrants [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Beginning balance	302	114
Additions		0
Conversion into common shares	(750)
Change in fair value	488	188
Ending balance	0	302	114
Mustang [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Beginning balance	12	0
Additions		12
Conversion into common shares	(15)
Change in fair value	3	0
Ending balance	0	12	0
Mustang [Member] | Contingently Issuable Warrants [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Beginning balance	0	0
Additions		634
Conversion into common shares		(793)
Change in fair value		159
Ending balance		0	0
Checkpoint [Member] | Contingently Issuable Warrants [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Beginning balance		0	0
Additions			175
Conversion into common shares			(613)
Change in fair value			438
Ending balance			0
Helocyte [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Beginning balance	167	0
Additions		428
Change in fair value	(80)	(261)
Ending balance	87	167	0
Helocyte [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Beginning balance	4,487	0
Additions		4,409
Change in fair value	213	78
Ending balance	4,700	4,487	$ 0
Caelum Convertible Notes [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Beginning balance	0
Additions	9,914
Change in fair value	145
Ending balance	$ 10,059	$ 0

Fair Value Measurements - Natio

Fair Value Measurements - National Financial Instruments Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2016
Assets
Long-term investments, at fair value	$ 1,390		$ 1,414
Total	1,390		1,414
Liabilities
Liabilities	14,846		5,168
National Holdings Corporation [Member]
Assets
Total		$ 7,102		$ 2,357
Liabilities
Liabilities		6,059		14,657
Contingently Issuable Warrant [Member]
Liabilities
Liabilities			302
Warrant [Member]
Liabilities
Liabilities	87		179
Warrant [Member] | National Holdings Corporation [Member]
Assets
Total		5,665
Helocyte Convertible Note One [Member]
Liabilities
Liabilities	4,700		4,487
Avenue Convertible Note [Member]
Liabilities
Liabilities			200
Corporate stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		116		101
Liabilities
Liabilities				298
Municipal bonds Assets [Member] | National Holdings Corporation [Member]
Assets
Total		1,239		2,111
Liabilities
Liabilities		151
Restricted stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		82		145
Warrants Issuable [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		5,597		14,359
Caelum Convertible Notes [Member]
Liabilities
Liabilities	10,059
Contingent consideration [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		311
Fair Value, Inputs, Level 1 [Member]
Assets
Long-term investments, at fair value	0		0
Total	0		0
Liabilities
Liabilities	0		0
Fair Value, Inputs, Level 1 [Member] | National Holdings Corporation [Member]
Assets
Total		1,355		101
Liabilities
Liabilities		0		298
Fair Value, Inputs, Level 1 [Member] | Contingently Issuable Warrant [Member]
Liabilities
Liabilities			0
Fair Value, Inputs, Level 1 [Member] | Warrant [Member]
Liabilities
Liabilities	0		0
Fair Value, Inputs, Level 1 [Member] | Warrant [Member] | National Holdings Corporation [Member]
Assets
Total		0
Fair Value, Inputs, Level 1 [Member] | Helocyte Convertible Note One [Member]
Liabilities
Liabilities	0		0
Fair Value, Inputs, Level 1 [Member] | Avenue Convertible Note [Member]
Liabilities
Liabilities			0
Fair Value, Inputs, Level 1 [Member] | Corporate stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		116		101
Fair Value, Inputs, Level 1 [Member] | Municipal bonds Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0		0
Liabilities
Liabilities		0
Fair Value, Inputs, Level 1 [Member] | Restricted stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0		0
Fair Value, Inputs, Level 1 [Member] | Corporate stock Liabilities [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities				298
Fair Value, Inputs, Level 1 [Member] | Warrants Issuable [Member] | National Holdings Corporation [Member]
Assets
Total		0
Fair Value, Inputs, Level 1 [Member] | Caelum Convertible Notes [Member]
Liabilities
Liabilities	0
Fair Value, Inputs, Level 1 [Member] | Contingent consideration [Member] | National Holdings Corporation [Member]
Assets
Total		0
Fair Value, Inputs, Level 2 [Member]
Assets
Long-term investments, at fair value	0		0
Total	0		0
Liabilities
Liabilities	0		0
Fair Value, Inputs, Level 2 [Member] | National Holdings Corporation [Member]
Assets
Total		1,321		2,256
Liabilities
Liabilities		151		0
Fair Value, Inputs, Level 2 [Member] | Contingently Issuable Warrant [Member]
Liabilities
Liabilities			0
Fair Value, Inputs, Level 2 [Member] | Warrant [Member]
Liabilities
Liabilities	0		0
Fair Value, Inputs, Level 2 [Member] | Warrant [Member] | National Holdings Corporation [Member]
Assets
Total		0
Fair Value, Inputs, Level 2 [Member] | Helocyte Convertible Note One [Member]
Liabilities
Liabilities	0		0
Fair Value, Inputs, Level 2 [Member] | Avenue Convertible Note [Member]
Liabilities
Liabilities			0
Fair Value, Inputs, Level 2 [Member] | Corporate stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0
Fair Value, Inputs, Level 2 [Member] | Municipal bonds Assets [Member] | National Holdings Corporation [Member]
Assets
Total		1,239		2,111
Liabilities
Liabilities		151
Fair Value, Inputs, Level 2 [Member] | Restricted stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		82		145
Fair Value, Inputs, Level 2 [Member] | Corporate stock Liabilities [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities				0
Fair Value, Inputs, Level 2 [Member] | Warrants Issuable [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		0
Fair Value, Inputs, Level 2 [Member] | Caelum Convertible Notes [Member]
Liabilities
Liabilities	0
Fair Value, Inputs, Level 2 [Member] | Contingent consideration [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		0
Fair Value, Inputs, Level 3 [Member]
Assets
Long-term investments, at fair value	1,390		1,414
Total	1,390		1,414
Liabilities
Liabilities	14,846		5,168
Fair Value, Inputs, Level 3 [Member] | National Holdings Corporation [Member]
Assets
Total		5,665		0
Liabilities
Liabilities		5,908		14,359
Fair Value, Inputs, Level 3 [Member] | Contingently Issuable Warrant [Member]
Liabilities
Liabilities			302
Fair Value, Inputs, Level 3 [Member] | Warrant [Member]
Liabilities
Liabilities	87		179
Fair Value, Inputs, Level 3 [Member] | Warrant [Member] | National Holdings Corporation [Member]
Assets
Total		5,665
Fair Value, Inputs, Level 3 [Member] | Helocyte Convertible Note One [Member]
Liabilities
Liabilities	4,700		4,487
Fair Value, Inputs, Level 3 [Member] | Avenue Convertible Note [Member]
Liabilities
Liabilities			$ 200
Fair Value, Inputs, Level 3 [Member] | Corporate stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0		0
Fair Value, Inputs, Level 3 [Member] | Municipal bonds Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0		0
Liabilities
Liabilities		0
Fair Value, Inputs, Level 3 [Member] | Restricted stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0		0
Fair Value, Inputs, Level 3 [Member] | Corporate stock Liabilities [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities				0
Fair Value, Inputs, Level 3 [Member] | Warrants Issuable [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		5,597		$ 14,359
Fair Value, Inputs, Level 3 [Member] | Caelum Convertible Notes [Member]
Liabilities
Liabilities	$ 10,059
Fair Value, Inputs, Level 3 [Member] | Contingent consideration [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		$ 311

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)	1 Months Ended						5 Months Ended	12 Months Ended
	Jun. 26, 2017	Oct. 31, 2016	Sep. 30, 2016	Oct. 30, 2015	Mar. 17, 2014	Mar. 17, 2014	Aug. 31, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 01, 2017	Jun. 01, 2017	Dec. 30, 2016	Sep. 18, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Method Investments					$ 250,000	$ 250,000		$ 300,000	$ 300,000
Equity Method Investment, Ownership Percentage					35.00%	35.00%
Fair Value Assumptions, Exercise Price								$ 1.01
Fair Value Assumptions, Expected Volatility Rate								70.00%
Share Price											$ 3.83	$ 2.24
Investments in and Advances to Affiliates, at Fair Value, Period Increase (Decrease), Total								$ 200,000	1,100,000
Investment Owned, at Fair Value								1,985,000	2,357,000
Fair Value Adjustment of Warrants								$ (8,391,000)	$ 1,039,000	$ 438,000
Warrants Issued				139,592
Value of Warrants Issued				$ 600,000			$ 200,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.02							$ 2,500						$ 7
Equity Securities Called by Warrant													$ 10,000
Debt Conversion, Converted Instrument, Shares Issued	49,749
Exercise Price Of Warrant Discount Percentage	33.00%
Common Stock Par Or Stated Value Per Share								$ 0.001	$ 0.001		$ 3.26	$ 1.90
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								7
Stock Issued During Period, Value, New Issues									$ 53,000,000
Investment Write Down					$ 300,000
Origo Acquisition Corporation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment Owned, at Fair Value								$ 1,400,000	$ 1,200,000
Investments In Subsidiary Number Of Shares Transferred To Subsidiary								1,050,000
Investments In Subsidiary Number Of Shares Outstanding								265,000
Fair Value Assumptions Probability Of Business Combination								46.53%	51.53%
Working Capital Note Convertible To Equity								$ 300,000
National Holdings Corporation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage of Outstanding Stock To Be Issued Upon Exercise of Warrants			44.00%
Percentage of outstanding shares, Tendered			80.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 3.25
Warrants Not Settleable in Cash, Fair Value Disclosure			$ 5,400,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	125,000
Debt Instrument, Face Amount	$ 3,000,000
Mustang Bio, Inc. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Number of Warrants Issued		138,462
Contingently Issuance Warrants		$ 800,000
Westpark [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.02
Exercise Price Of Warrant Discount Percentage	33.00%
Common Stock Par Or Stated Value Per Share	$ 6
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,488
Avenue Therapeutics, Inc. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common Stock Par Or Stated Value Per Share	$ 6
Stock Issued During Period, Value, New Issues	$ 38,000,000
Binomial Lattice Model [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Exercise Price								$ 11.50
Risk free rate								1.28%	0.85%
Binomial Lattice Model [Member] | Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Share Price								$ 1.06	$ 0.82
Ghaidarov Model [Member] | Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Share Price								1.07	0.58
Private Units [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Share Price								$ 10.65	$ 8.16
Argus Neurooptics Llc [Member] | Class A Preferred Stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Shares Received Under Purchase Agreement						$ 13,409,962
Percentage Of Shares Received Under Purchase Agreement						83.00%
Preferred Units, Issued					16,091,954	16,091,954

Licenses Acquired - Summary Of

Licenses Acquired - Summary Of Research and Development Arrangement Contract (Detail) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Apr. 28, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		$ 4,164	$ 5,532	$ 11,408
Fortress [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		300	325	0
Avenue [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		0	0	3,000
Caelum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		219	0	0
Cellvation [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		0	312	0
Checkpoint [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		400	3,160	3,159
Coronado SO [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		0	0	1,607
Cyprium [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		100	0	0
Escala [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		0	0	1,295
Helocyte [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	$ 200	0	53	200
Mustang [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		2,875	1,682	2,147
Tamid [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		$ 270	$ 0	$ 0

Licenses Acquired - Additional

Licenses Acquired - Additional Information (Detail) - USD ($)

Jul. 03, 2017

Jul. 03, 2017

May 11, 2015

Jan. 31, 2018

Nov. 30, 2017

Nov. 30, 2017

Oct. 31, 2017

Jun. 26, 2017

May 31, 2017

Apr. 25, 2017

Mar. 31, 2017

Mar. 17, 2017

Feb. 17, 2017

Jan. 31, 2017

Oct. 31, 2016

Sep. 30, 2016

May 31, 2016

Feb. 23, 2016

Dec. 31, 2015

Oct. 31, 2015

Sep. 30, 2015

Sep. 18, 2015

Jul. 16, 2015

Jun. 17, 2015

Apr. 28, 2015

Mar. 31, 2015

Feb. 28, 2015

Sep. 30, 2017

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Dec. 01, 2017

Jun. 01, 2017

Jul. 31, 2016

Mar. 17, 2014

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payments to Acquire Intangible Assets

$ 0

$ 350,000

$ 1,250,000

Research And Development In Process

4,164,000

5,532,000

11,408,000

Payments for Fees

$ 2,700,000

$ 100,000

$ 1,265,000

Stock Issued During Period, Shares, Issued for Services

10,000

Research And Development Expense

52,486,000

35,134,000

29,810,000

Payments To Acquire In Process Research And Development

3,365,000

3,785,000

10,448,000

Share Price

$ 3.83

$ 2.24

Proceeds from Issuance of Common Stock

$ 34,200,000

Share-based Compensation

$ 14,005,000

12,128,000

14,291,000

Fair Value Assumptions, Expected Volatility Rate

70.00%

Stock Issued During Period, Value, New Issues

53,000,000

Stock Issued During Period, Shares, New Issues

43,292

10,000

Equity Method Investment, Ownership Percentage

35.00%

Development Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

$ 22,000,000

$ 10,700,000

Sale Millstone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

7,000,000

26,200,000

NeuPharma [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research And Development In Process

$ 1,000,000

$ 600,000

1,000,000

0

NeuPharma [Member] | Development Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

40,000,000

NeuPharma [Member] | Sale Millstone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

40,000,000

NeuPharma [Member] | Regulatory Approvals To Commercialize Products [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

$ 22,500,000

City Of Hope [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Marketability Percentage Of Invested Capital

44.80%

Payments for Fees

$ 100,000

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

30.00%

Share Price

$ 0.147

Stock Issued During Period, Value, Other

$ 100,000

100,000

Revenue Recognition Milestone Method Payments Due

100,000

City Of Hope [Member] | Development Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

$ 1,500,000

City Of Hope [Member] | Sale Millstone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

13,000,000

National Institutes of Health [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment of Upfront Milestone Fees

700,000

New Zealand Pharmaceuticals Ltd [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Reimbursement Revenue

600,000

UCLA License [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

$ 14,300,000

Tamid [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Share Price

$ 0.015

Fair Value Assumptions, Expected Volatility Rate

75.00%

Fair Value Inputs, Discount for Lack of Marketability

40.50%

Equity Method Investment, Ownership Percentage

10.00%

Proceeds from License Fees Received

$ 15,000

Dana-Farber [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Shares Issued, Price Per Share

$ 0.065

Stock Issued During Period, Shares, Issued for Services

500,000

136,830

Stock Issued During Period, Value, Issued for Services

$ 32,500

$ 600,000

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners

5.00%

Proceeds from Issuance of Common Stock

$ 10,000,000

Dana-Farber [Member] | First Commercial Sale Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

21,500,000

Dana-Farber [Member] | Additional Sales Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

$ 60,000,000

Mustang Bio, Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research And Development Expense

600,000

Payment of Upfront Fees

$ 9,300,000,000

Revenue Recognition Milestone Method Payments Due

100,000

Royalty Guarantees, Commitments, Amount

$ 1,000,000

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners

10.00%

Minimum Annual Royalty Payable

$ 1,000,000

Mustang Bio, Inc [Member] | Development Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

14,500,000

Mustang Bio, Inc [Member] | Financial Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

2,000,000

Escala Therapeutics, Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment of Upfront Fees

$ 1,300,000

1,300,000

Gene Medicine, Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

19,300,000

Royalty Guarantees, Commitments, Amount

$ 100,000

$ 300,000

Effcon Laboratories, Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment of Upfront Fees

$ 200,000

Revenue Recognition Milestone Method Payments Due

5,300,000

Royalty Guarantees, Commitments, Amount

$ 1,600,000

Teva Pharmaceutical Industries Ltd [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payments for Fees

$ 500,000

Teva Pharmaceutical Industries Ltd [Member] | Regulatory Approvals To Commercialize Products [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

206,500,000

Teva Pharmaceutical Industries Ltd [Member] | Clinical Development and Regulatory Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

$ 220,000,000

Jubilant Biosys Ltd [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research And Development In Process

2,000,000

Revenue Recognition Milestone Method Payments Due

$ 87,200,000

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners

50.00%

Payment Of Upfront Licensing Fee

$ 2,000,000

Royalty Revenue

$ 1,000,000

1,500,000

0

Jubilant Biosys Ltd [Member] | Sale Millstone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Milestone Method Revenue Additional Payments Eligible To Receive

89,000,000

Jubilant Biosys Ltd [Member] | Regulatory Approvals To Commercialize Products [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

59,500,000

Jubilant Biosys Ltd [Member] | Completion Of Three Clinical Development Milestones For Two Licensed Products [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

25,500,000

Jubilant Biosys Ltd [Member] | Five Regulatory Approvals And First Commercial Sales [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

61,700,000

Jubilant Biosys Ltd [Member] | Three Sales Milestones Based On Aggregate Net Sales [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

89,000,000

Jubilant Biosys Ltd [Member] | Clinical Development and Regulatory Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

$ 89,000,000

Jubilant Biosys Ltd [Member] | TG Therapeutics, Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment of Upfront Fees

1,000,000

Columbia University [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Stock Issued During Period, Shares, Purchase of Assets

1,050,000

Shares Issued, Price Per Share

$ 0.028

Stock Issued During Period, Value, Purchase of Assets

$ 29,000

Payment of Upfront Fees

200,000

Revenue Recognition Milestone Method Payments Due

$ 5,500,000

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners

10.00%

Fair Value Assumptions, Expected Volatility Rate

70.00%

Fair Value Assumptions, Expected Term

5 years

Fair Value Assumptions, Risk Free Interest Rate

1.93%

Fair Value Inputs, Discount for Lack of Marketability

49.50%

National Institute of Child Health and Human Development [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment of Upfront Fees

100,000

Collaborative Agreements with TGTX [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payments for Fees

500,000

Collaborative Agreements with TGTX [Member] | NeuPharma [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payments for Fees

84,000

42,000

600,000

Agreement With City Of Hope [Member] | Mustang Bio, Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment Of Upfront Licensing Fee

2,000,000

Triplex [Member] | City Of Hope [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Minimum Annual Royalty Payable

750,000

Pentameter [Member] | City Of Hope [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Minimum Annual Royalty Payable

750,000

Pentameter [Member] | City Of Hope [Member] | Development Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

5,500,000

Pentameter [Member] | City Of Hope [Member] | Sale Millstone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

26,000,000

Coronado SO Co, Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research And Development In Process

0

$ 0

$ 1,607,000

Shares Issued, Price Per Share

$ 4.6197

Payments for Fees

$ 900,000

Stock Issued During Period, Shares, Other

150,000

Research And Development Expense

$ 500,000

$ 300,000

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners

13.00%

13.00%

13.00%

13.00%

Payment For Research And Development Licenses

$ 50,000

Stock Issued During Period, Value, New Issues

$ 200,000

Proceed from sale of milestone payment

$ 1,800,000

Checkpoint Therapeutics, Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research And Development In Process

400,000

$ 3,160,000

$ 3,159,000

Stock Issued During Period, Value, Purchase of Assets

$ 22,000,000

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners

[1]

62.30%

62.00%

62.90%

62.30%

Checkpoint Therapeutics, Inc [Member] | First Commercial Sale Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

$ 21,500,000

Checkpoint Therapeutics, Inc [Member] | Additional Sales Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

60,000,000

Checkpoint Therapeutics, Inc [Member] | Clinical Development Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

7,000,000

Checkpoint Therapeutics, Inc [Member] | Commercial Sales In Specified Territories [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

14,500,000

Checkpoint Therapeutics, Inc [Member] | NeuPharma [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research And Development In Process

$ 1,000,000

Checkpoint Therapeutics, Inc [Member] | Dana-Farber [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Stock Issued During Period, Value, Purchase of Assets

4,200,000

5,500,000

$ 11,400,000

Helocyte [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research And Development In Process

200,000

$ 0

$ 53,000

200,000

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners

20.00%

20.50%

Helocyte [Member] | Triplex [Member] | Development Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

9,000,000

Helocyte [Member] | Triplex [Member] | Sale Millstone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

26,000,000

Licensing Agreements [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payments to Acquire Intangible Assets

$ 45,000

$ 150,000

Licensing Agreements [Member] | City Of Hope [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Marketability Percentage Of Invested Capital

44.50%

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

30.00%

Share Price

$ 0.097

Stock Issued During Period, Value, Other

$ 48,500

Licensing Agreements [Member] | City Of Hope [Member] | Common Class A [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued

500,000

Licensing Agreements [Member] | Dana-Farber [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payments for Fees

$ 1,000,000

Licensing Agreements [Member] | Mustang Bio, Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Stock Issued During Period, Shares, Issued for Services

293,588

Stock Issued During Period, Value, Issued for Services

$ 1,700,000

Share Price

$ 5.73

Proceeds from Third Party Investors

$ 10,000,000

Licensing Agreements [Member] | Cellvation Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Marketability Percentage Of Invested Capital

40.20%

Stock Issued During Period, Shares, Issued for Services

500,000

Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent

30.00%

Share Price

$ 0.024

Stock Issued During Period, Value, Other

$ 12,000

Payment of Upfront Fees

$ 300,000

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners

5.00%

Licensing Agreements [Member] | Cellvation Inc [Member] | Development Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

$ 6,200,000

Licensing Agreements [Member] | Cellvation Inc [Member] | Sale Millstone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

6,000,000

Licensing Agreements [Member] | Cellvation Inc [Member] | Minimum [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Additional Minimum Annual Royalty Payable

50,000

Licensing Agreements [Member] | Cellvation Inc [Member] | Maximum [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Additional Minimum Annual Royalty Payable

200,000

Licensing Agreements [Member] | Cellvation Inc [Member] | Research and Development - Licenses Acquired [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Share-based Compensation

$ 12,000

Licensing Agreements [Member] | IV Tramadol [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payments to Acquire Intangible Assets

$ 1,000,000

Payments for Fees

$ 2,000,000

Licensing Agreements [Member] | Coronado SO Co, Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Marketability Percentage Of Invested Capital

44.80%

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

30.00%

Share Price

$ 1.19

Licensing Agreements [Member] | Helocyte [Member] | Common Class A [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued

8,333

Avenue Therapeutics, Inc. [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Shares Issued, Price Per Share

$ 6

Debt Instrument, Fee Amount

$ 3,000,000

Secondary License [Member] | Cellvation Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment of Upfront Fees

50,000

Revenue Recognition Milestone Method Payments Due

300,000

Second TBI License [Member] | Cellvation Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Minimum Annual Royalty Payable

$ 100,000

AR CD123 License [Member] | City Of Hope [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

$ 14,500,000

AR IL-13 License [Member] | City Of Hope [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research And Development In Process

500,000

Revenue Recognition Milestone Method Payments Due

14,500,000

HER2 Technology License [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment of Upfront Fees

600,000

Revenue Recognition Milestone Method Payments Due

14,900,000

Annual Maintenance Fee Payable

$ 50,000

CS1 Technology License [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment of Upfront Fees

$ 600,000

Revenue Recognition Milestone Method Payments Due

$ 14,900,000

Annual Maintenance Fee Payable

50,000

PSCA Technology License [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment of Upfront Fees

300,000

Revenue Recognition Milestone Method Payments Due

14,900,000

Annual Maintenance Fee Payable

$ 50,000

University of California [Member] | UCLA License [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment of Upfront Fees

$ 200,000

Fred Hutchinson Cancer Research Center License [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment of Upfront Fees

300,000

Revenue Recognition Milestone Method Payments Due

$ 39,100,000

Annual Maintenance Fee Payable

$ 50,000

Harvard College License [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

2,700,000

Revenue Recognition, Sales and Marketing Milestone Method Payments Due

$ 14,000,000

Harvard College License [Member] | Subsequent Event [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment of Upfront Fees

$ 200,000

MPS1 license [Member] | Subsequent Event [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment of Upfront Fees

85,000

Revenue Recognition, Sales and Marketing Milestone Method Payments Due

7,500,000

Revenue Recognition, Development Milestone Method Payments Due

$ 5,500,000

Revenue Recognition, Milestone Method, Extension Description

Extension for such milestones is $10,000 per milestone for the first year and $20,000 per milestone thereafter.

Nanadysferlin License [Member] | Subsequent Event [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment of Upfront Fees

$ 85,000

Revenue Recognition, Sales and Marketing Milestone Method Payments Due

33,000,000

Revenue Recognition, Development Milestone Method Payments Due

$ 5,400,000

Revenue Recognition, Milestone Method, Extension Description

Extension for such milestones is $10,000 per milestone for the first year and $20,000 per milestone thereafter.

HLA-G License [Member] | Subsequent Event [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment of Upfront Fees

$ 85,000

Revenue Recognition, Sales and Marketing Milestone Method Payments Due

42,000,000

Revenue Recognition, Development Milestone Method Payments Due

$ 5,400,000

Revenue Recognition, Milestone Method, Extension Description

Extension for such milestones is $10,000 per milestone for the first year and $20,000 per milestone thereafter.

[1]

Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.

Milestones and Sponsored Rese69

Milestones and Sponsored Research Agreements - Additional Information (Detail) - USD ($)	Jul. 03, 2017	Nov. 28, 2017	Jun. 30, 2017	Feb. 17, 2017	Mar. 31, 2016	Feb. 29, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Oct. 31, 2016	Mar. 31, 2015
Research And Development Expense							$ 52,486,000	$ 35,134,000	$ 29,810,000
Payments To Acquire In Process Research And Development							3,365,000	3,785,000	10,448,000
Reimbursement Of Cost Recognized As Revenue							600,000	1,000,000
SPR Sponsored Research Agreement [Member]
Research And Development Expense							100,000
Revenue Recognition Milestone Method Payments Due Over Three Years		$ 800,000
Checkpoint Therapeutics, Inc [Member]
Stock Issued During Period, Value, Purchase of Assets							22,000,000
AR CD123 License [Member]
Revenue Recognition Milestone Method Payments Due Over Three Years				$ 200,000
Pep Vax [Member]
Payments For Research And Development Expenses							1,100,000	2,500,000	0
Triplex [Member]
Payments For Research And Development Expenses							2,600,000	1,800,000	0
Helocyte Inc [Member]
Payments For Research And Development Expenses							3,700,000	4,300,000	0
Helocyte Inc [Member] | Pentamer Sponsored Research Agreement [Member]
Payment of Upfront Fees			$ 1,500,000				200,000	0
Mustang Bio, Inc [Member]
Research And Development Expense Payable Milestone Payment				200,000			2,000,000	2,000,000	$ 1,500,000		$ 2,000,000
Research And Development Expense							600,000
Payment of Upfront Fees				9,300,000,000
Revenue Recognition Milestone Method Payments Due				100,000
Mustang Bio, Inc [Member] | AR IL-13 License [Member]
Research And Development Expense							1,400,000
Mustang Bio, Inc [Member] | CD20 Technology License [Member]
Payment of Upfront Fees	$ 5,300,000
UCLB [Member]
Payment of Upfront Fees							$ 100,000
Milestone Payments					$ 400,000
UCLB [Member] | Minimum [Member]
Royalty Percentage							3.00%
UCLB [Member] | Maximum [Member]
Royalty Percentage							5.00%
Cellvation [Member]
Research And Development Expense Payable Milestone Payment										$ 800,000
Research And Development Expense							$ 100,000	$ 200,000
City Of Hope [Member]
Research And Development Expense Payable Milestone Payment					2,000,000	$ 3,400,000
Payments To Acquire In Process Research And Development					$ 1,000,000	$ 1,000,000
City Of Hope [Member] | AR CD123 License [Member]
Research And Development Expense							$ 1,100,000
Payment of Upfront Fees				20,000,000,000
Revenue Recognition Milestone Method Payments Due				$ 100,000

Intangibles - Additional Inform

Intangibles - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended	4 Months Ended	12 Months Ended
	Jan. 31, 2016	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Indefinite-lived Intangible Assets [Line Items]
Payments to Acquire Intangible Assets				$ 0	$ 350,000	$ 1,250,000
Cost of Goods Sold, Amortization				534,000	183,000	0
Amortization of Intangible Assets			$ 509,000	1,651,000	0	$ 0
General and Administrative Expense [Member]
Indefinite-lived Intangible Assets [Line Items]
Amortization of Intangible Assets				1,700,000	500,000
Journey Medical Corporation [Member]
Indefinite-lived Intangible Assets [Line Items]
Payments to Acquire Intangible Assets	$ 50,000	$ 1,300,000			300,000
Cost of Goods Sold, Amortization				$ 500,000	$ 200,000

Debt and Interest - Long-term d

Debt and Interest - Long-term debt (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Jul. 31, 2016	Mar. 31, 2015
Debt [Line Items]
Total notes payable, long-term	$ 67,544	$ 30,224
Less: Discount of notes payable	1,035	2,009
Total notes payable	$ 66,509	28,215
Interest Rate	28.00%
Maturity Date	May - 2018
IDB Note [Member]
Debt [Line Items]
Total notes payable, long-term	$ 14,929	14,929
Interest Rate	2.25%
Maturity Date	Aug - 2020
NSC Note [Member]
Debt [Line Items]
Total notes payable, long-term	$ 0	$ 3,608
Less: Discount of notes payable			$ 600
Total notes payable				$ 10,000
Interest Rate	8.00%	8.00%
Maturity Date	Sep - 2018
2017 Subordinated Note Financing One [Member]
Debt [Line Items]
Total notes payable, long-term	$ 3,254	$ 0
Interest Rate	8.00%
Maturity Date	March - 2020
2017 Subordinated Note Financing One [Member] | Minimum [Member]
Debt [Line Items]
Interest Rate	5.00%
2017 Subordinated Note Financing One [Member] | Maximum [Member]
Debt [Line Items]
Interest Rate	8.00%
2017 Subordinated Note Financing Two [Member]
Debt [Line Items]
Total notes payable, long-term	$ 13,893	0
Interest Rate	8.00%
Maturity Date	May - 2020
2017 Subordinated Note Financing Two [Member] | Minimum [Member]
Debt [Line Items]
Interest Rate	5.00%
2017 Subordinated Note Financing Two [Member] | Maximum [Member]
Debt [Line Items]
Interest Rate	8.00%
2017 Subordinated Note Financing Three [Member]
Debt [Line Items]
Total notes payable, long-term	$ 1,820	0
Interest Rate	8.00%
Maturity Date	June - 2020
2017 Subordinated Note Financing Three [Member] | Minimum [Member]
Debt [Line Items]
Interest Rate	5.00%
2017 Subordinated Note Financing Three [Member] | Maximum [Member]
Debt [Line Items]
Interest Rate	8.00%
2017 Subordinated Note Financing Four [Member]
Debt [Line Items]
Total notes payable, long-term	$ 3,018	0
Interest Rate	8.00%
Maturity Date	August - 2020
2017 Subordinated Note Financing Four [Member] | Minimum [Member]
Debt [Line Items]
Interest Rate	5.00%
2017 Subordinated Note Financing Four [Member] | Maximum [Member]
Debt [Line Items]
Interest Rate	8.00%
2017 Subordinated Note Financing Five [Member]
Debt [Line Items]
Total notes payable, long-term	$ 6,371	0
Interest Rate	8.00%
Maturity Date	September - 2020
2017 Subordinated Note Financing Five [Member] | Minimum [Member]
Debt [Line Items]
Interest Rate	5.00%
2017 Subordinated Note Financing Five [Member] | Maximum [Member]
Debt [Line Items]
Interest Rate	8.00%
Opus Credit Facility [Member]
Debt [Line Items]
Total notes payable, long-term	$ 9,500	7,000
Interest Rate	12.00%
Maturity Date	Sep - 2018
Helocyte Convertible Note One [Member]
Debt [Line Items]
Total notes payable, long-term	$ 1,000	$ 1,031
Maturity Date	December 2,017
Helocyte Convertible Note One [Member] | Minimum [Member]
Debt [Line Items]
Interest Rate		5.00%
Helocyte Convertible Note Two [Member]
Debt [Line Items]
Total notes payable, long-term	$ 2,194	$ 2,051
Maturity Date	March - 2018
Helocyte Convertible Note Three [Member]
Debt [Line Items]
Total notes payable, long-term	$ 1,062	991
Maturity Date	April - 2018
Helocyte Convertible Note Four [Member]
Debt [Line Items]
Total notes payable, long-term	$ 444	414
Avenue Convertible Note [Member]
Debt [Line Items]
Total notes payable, long-term	$ 0	200
Maturity Date	June - 2018
Caelum Convertible Note One [Member]
Debt [Line Items]
Total notes payable, long-term	$ 1,017	0
Interest Rate	8.00%
Maturity Date	January - 2019
Caelum Convertible Note Two [Member]
Debt [Line Items]
Total notes payable, long-term	$ 6,900	0
Interest Rate	8.00%
Maturity Date	February - 2019
Caelum Convertible Note Three [Member]
Debt [Line Items]
Total notes payable, long-term	$ 2,142	$ 0
Interest Rate	8.00%
Maturity Date	June - 2019

Debt and Interest - Schedule of

Debt and Interest - Schedule of Interest Expenses for Debt Arrangements (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Debt [Line Items]
Total Interest Expense and Financing Fee	$ 5,860	$ 3,690	$ 1,484
LOC Fees [Member]
Debt [Line Items]
Interest	36	11	0
Interest and Debt Expense	36	11	0
IDB Note [Member]
Debt [Line Items]
Interest	340	328	314
Amortization of fees	0	1	5
Interest and Debt Expense	340	329	319
NSC Debt [Member]
Debt [Line Items]
Interest	147	599	690
Amortization of fees	201	1,270	309
Interest and Debt Expense	348	1,869	999
2017 Subordinated Note [Member]
Debt [Line Items]
Interest	2,234	0	0
Amortization of fees	76	0	0
Interest and Debt Expense	2,310	0	0
Ovamed [Member]
Debt [Line Items]
Interest	0	0	166
Interest and Debt Expense	0	0	166
Helocyte Convertible Note [Member]
Debt [Line Items]
Interest	261	61	0
Financing fee	1	962	0
Interest and Debt Expense	262	1,023	0
Opus Credit Facility [Member]
Debt [Line Items]
Interest	1,087	192	0
Amortization of fees	1,037	195	0
Interest and Debt Expense	2,124	387	0
Avenue Convertible Note [Member]
Debt [Line Items]
Interest	5	0	0
Financing fee	3	70	0
Interest and Debt Expense	8	70	0
Caelum Convertible Note [Member]
Debt [Line Items]
Interest	265	0	0
Financing fee	100	0	0
Interest and Debt Expense	365	0	0
Falk CSR [Member]
Debt [Line Items]
Interest	64	0	0
Interest and Debt Expense	64	0	0
D&O Insurance [Member]
Debt [Line Items]
Interest	3	1	0
Interest and Debt Expense	$ 3	$ 1	$ 0

Debt and Interest- Additional I

Debt and Interest- Additional Information (Detail) - USD ($)

Jan. 02, 2018

Jul. 05, 2017

Sep. 14, 2016

Feb. 13, 2014

Feb. 28, 2018

Nov. 30, 2017

Nov. 30, 2017

Sep. 30, 2017

Aug. 31, 2017

Jul. 31, 2017

Jun. 30, 2017

May 31, 2017

May 02, 2017

Mar. 31, 2017

Oct. 25, 2016

Sep. 30, 2016

Jun. 30, 2016

Feb. 29, 2016

Oct. 30, 2015

Sep. 30, 2017

Sep. 30, 2016

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Mar. 16, 2018

Jun. 26, 2017

Jul. 31, 2016

Oct. 31, 2015

Sep. 18, 2015

Mar. 31, 2015

Debt [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

7

Warrant exercise price

$ 2,500

$ 4.02

$ 7

Debt Instrument, Interest Rate, Stated Percentage

28.00%

Debt discount recorded

$ 1,035,000

$ 2,009,000

Cash proceeds from 2008 Senior Convertible Notes

0

920,000

$ 0

Notes Payable

$ 66,509,000

28,215,000

Debt Instrument, Maturity Date, Description

May - 2018

Debt Instrument, Unamortized Discount (Premium), Net, Total

400,000

Percentage of Cash Flow Pursuant to ASC 470

10.00%

Fair Value Adjustment of Warrants

$ (8,391,000)

1,039,000

438,000

Legal Fees

$ 1,500,000

$ 200,000

Payments for Other Fees

$ 100,000

$ 2,700,000

$ 1,265,000

Convertible Notes Payable, Current

4,700,000

1,031,000

Proceeds from Fees Received

$ 14,420,000

$ 1,265,000

Proceeds from Convertible Debt

9,914,000

4,609,000

0

Payments of Financing Costs

$ 0

0

855,000

Subsequent Event [Member]

Debt [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Debt Instrument, Face Amount

$ 6,500,000

Debt Instrument, Maturity Date, Description

Each Note matures on the 24 month anniversary of issuance, provided that the Company may extend the maturity date for two six-month periods.

Maturity Date

Mar. 31, 2018

Letter of Credit [Member]

Debt [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

2.00%

Letters of Credit Outstanding, Amount

$ 2,000,000

Minimum [Member]

Debt [Line Items]

Warrant exercise price

$ 3.61

Maximum [Member]

Debt [Line Items]

Warrant exercise price

$ 4.75

Israel Discount Bank Of New York [Member]

Debt [Line Items]

Current portion of note payable

$ 14,900,000

14,900,000

Debt Instrument, Fee Amount

$ 15,000,000

Notes Payable

$ 14,900,000

IDB Promissory Note Payable [Member]

Debt [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

2.25%

Debt Instrument, Unused Borrowing Capacity, Amount

100,000

Debt Instrument, Periodic Payment

14,000,000

Debt Instrument, Fee Amount

$ 15,000,000

Opus Credit Facility [Member]

Debt [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

12.00%

Class Of Warrant Or Right Value Of Securities Called By Warrants Or Rights

$ 1,500,000

Class Of Warrant Or Right Exercise Price Percentage Of Warrants Or Rights

3.00%

Legal Fees

$ 25,000,000

Warrants and Rights Outstanding

$ 9,500,000

$ 7,000,000

Maturity Date

Sep. 14, 2018

Opus Credit Facility [Member] | Subsequent Event [Member]

Debt [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

12.00%

NSC Notes Payable [Member]

Debt [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

8.00%

8.00%

Debt discount recorded

$ 600,000

Debt Instrument, Face Amount

900,000

Long-term Debt, Gross

$ 3,600,000

Notes Payable

$ 10,000,000

Debt Instrument, Term

10 years

Debt Instrument, Maturity Date, Description

Sep - 2018

Debt Instrument, Interest Rate, Effective Percentage

14.00%

17.83%

Contingently Issuable Warrants Percentage

25.00%

25.00%

Helocyte Convertible Note One [Member]

Debt [Line Items]

Debt Instrument, Term

18 months

Debt Instrument, Maturity Date, Description

December 2,017

Proceeds from Issuance or Sale of Equity

$ 10,000,000

Class Of Warrant Or Right Value Of Securities Called By Warrants Or Rights

$ 400,000

Class Of Warrant Or Right Exercise Price Percentage Of Warrants Or Rights

110.00%

Legal Fees

$ 100,000

Helocyte Convertible Note One [Member] | Subsequent Event [Member]

Debt [Line Items]

Repayments of Long-term Debt

$ 1,000,000

Helocyte Convertible Note One [Member] | Conversion One [Member]

Debt [Line Items]

Debt Instrument, Convertible, Terms of Conversion Feature

(a) the lowest price per share at which equity securities of Helocyte are sold in such sale less a 33% discount and (b) a per share price based on a pre-offering valuation of $50.0 million divided by the number of common shares outstanding on a fully-diluted basis.

Helocyte Convertible Note One [Member] | Conversion Two [Member]

Debt [Line Items]

Debt Instrument, Convertible, Terms of Conversion Feature

(a) a discount to the price per share being paid in the Sale of Helocyte equal to 33% or (b) a conversion price per share based on a pre-sale valuation of $50.0 million divided by the fully-diluted common stock of Helocyte immediately prior to the Sale of Helocyte (excluding the notes).

Helocyte Convertible Note One [Member] | Minimum [Member]

Debt [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Avenue Convertible Note [Member]

Debt [Line Items]

Subsequent private placement

$ 200,000

Debt Instrument, Term

18 months

Debt Instrument, Maturity Date, Description

June - 2018

Debt Related Commitment Fees and Debt Issuance Costs

$ 3,000

$ 70,000

0

Debt Instrument, Convertible, Terms of Conversion Feature

(a) the lowest price per share at which equity securities of Helocyte are sold in such sale less a 33% discount and (b) a per share price based on a pre-offering valuation of $50.0 million divided by the number of common shares outstanding on a fully-diluted basis.

Proceeds from Issuance or Sale of Equity

10,000,000

Class Of Warrant Or Right Value Of Securities Called By Warrants Or Rights

10,000

Legal Fees

$ 44,000

Debt Instrument, Interest Rate, Stated Percentage,Current Year

5.00%

Net Proceeds From Issuance Of Private Placement After Paying Fees

$ 100,000

Payments for Other Fees

58,000

Paymens For Placement Fee

10,000

Professional Fees

4,000

Convertible Notes Payable, Current

$ 0

$ 200,000

Placement Fee Percentage

10.00%

10.00%

Avenue Convertible Note [Member] | Conversion One [Member]

Debt [Line Items]

Debt Instrument, Convertible, Terms of Conversion Feature

(a) the lowest price per share at which equity securities of Avenue are sold in such sale less a 33% discount and (b) a per share price based on a pre-offering valuation of $30.0 million divided by the number of common shares outstanding on a fully-diluted basis.

Avenue Convertible Note [Member] | Conversion Two [Member]

Debt [Line Items]

Debt Instrument, Convertible, Terms of Conversion Feature

(a) a discount to the price per share being paid in the Sale of Avenue equal to 33% or (b) a conversion price per share based on a pre-sale valuation of $30.0 million divided by the fully-diluted common stock of Avenue immediately prior to the Sale of Avenue (excluding the Avenue Notes).

Helocyte Convertible Note [Member] | Maximum [Member]

Debt [Line Items]

Debt Instrument, Face Amount

$ 5,000,000

Caelum Convertible Note [Member]

Debt [Line Items]

Debt Instrument, Face Amount

$ 10,000,000

Debt Related Commitment Fees and Debt Issuance Costs

$ 100,000

0

0

Class Of Warrant Or Right Exercise Price Percentage Of Warrants Or Rights

110.00%

Class of Warrant or Right Exercise Price Description

the exercise price will be $75 million dollars divided by the total number of fully-diluted shares of Common Stock outstanding immediately prior to exercise of the warrant, giving effect to the assumed conversion of all options, warrants, and convertible securities of the Company .

Debt Conversion, Description

The notes convert upon a qualified financing in which Caelum raises gross proceeds of at least $10 million as follows: the lesser of (a) a discount to the price per common share being paid in the Sale of the Company equal to 20% or (b) a conversion price per share based on a pre-sale valuation of $75,000,000 divided by the number of common shares outstanding at that time assuming the hypothetical conversion or exercise of any convertible securities, options, warrants and other rights to acquire common shares of the Company.

Percentage Of Placement Agent Fee

10.00%

Debt Instrument Issuance Percentage of Commission

10.00%

Proceeds from Convertible Debt

$ 9,900,000

Payments of Financing Costs

$ 900,000

Class of Warrant or Right Percentage Securities Called by Warrants or Rights

10.00%

NSC 2017 Note [Member]

Debt [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Debt Instrument, Face Amount

$ 3,250,000

Debt Instrument, Maturity Date, Description

Each Note is due on the third anniversary of its issuance, provided that the Company may extend the maturity date for two one-year periods in its sole discretion.

Paid-in-kind Interest Percentage

7.00%

Line of Credit Facility, Current Borrowing Capacity

$ 50,000,000

Percentage Of Placement Agent Fee

10.00%

Warrant on Sale Price of Note Percentage

10.00%

NSC 2017 Note [Member] | First Closing [Member]

Debt [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

87,946

Warrant exercise price

$ 3.70

Cash proceeds from 2008 Senior Convertible Notes

$ 3,200,000

Proceeds from Fees Received

300,000

NSC 2017 Note [Member] | Secoud Closing [Member]

Debt [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

234,438

Warrant exercise price

$ 3.65

Cash proceeds from 2008 Senior Convertible Notes

$ 8,600,000

Proceeds from Fees Received

$ 900,000

NSC 2017 Note [Member] | Third Closing [Member]

Debt [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

147,806

Warrant exercise price

$ 3.61

Cash proceeds from 2008 Senior Convertible Notes

$ 5,300,000

Proceeds from Fees Received

$ 500,000

NSC 2017 Note [Member] | Fourth Closing [Member]

Debt [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

38,315

Warrant exercise price

$ 4.75

Cash proceeds from 2008 Senior Convertible Notes

$ 1,800,000

Proceeds from Fees Received

$ 200,000

NSC 2017 Note [Member] | Fifth Closing [Member]

Debt [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

63,526

Warrant exercise price

$ 4.75

Cash proceeds from 2008 Senior Convertible Notes

$ 3,000,000

Proceeds from Fees Received

$ 300,000

NSC 2017 Note [Member] | Sixth Closing [Member]

Debt [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

144,149

144,149

Warrant exercise price

$ 4.42

$ 4.42

Cash proceeds from 2008 Senior Convertible Notes

$ 6,400,000

Proceeds from Fees Received

$ 600,000

NSC 2017 Note [Member] | Maximum [Member]

Debt [Line Items]

Debt Instrument, Face Amount

$ 40,000,000

NSC [Member]

Debt [Line Items]

Repayments of Debt

$ 3,600,000

Checkpoint [Member]

Debt [Line Items]

Debt Instrument, Unamortized Discount (Premium), Net, Total

$ 300,000

Long-term Debt, Fair Value

200,000

Fees Related To Loan Issuance Costs

$ 2,800,000

Checkpoint [Member] | NSC Notes Payable [Member]

Debt [Line Items]

Debt Related Commitment Fees and Debt Issuance Costs

2,800,000

Avenue [Member] | NSC Notes Payable [Member]

Debt [Line Items]

Debt Related Commitment Fees and Debt Issuance Costs

3,000,000

Warrant to NSC [Member]

Debt [Line Items]

Approximate fair value of the warrant

$ 600,000

Debt discount recorded

$ 200,000

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted

139,592

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price

$ 0.0001

$ 0.0001

Fair Value Adjustment of Warrants

$ 800,000

$ 400,000

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Issued

138,462

Contingently Issuable Warrants issued in connection with NSC Note Avenue [Member]

Debt [Line Items]

Debt Instrument, Unamortized Discount (Premium), Net, Total

$ 100,000

$ 100,000

Mustang [Member] | NSC Notes Payable [Member]

Debt [Line Items]

Debt Related Commitment Fees and Debt Issuance Costs

$ 3,600,000

Accrued Liabilities and other74

Accrued Liabilities and other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accrued expenses:
Professional fees	$ 1,625	$ 1,253
Salaries, bonuses and related benefits	5,279	2,846
Accrued expenses - related party	95	0
Accrued severance	0	53
Ovamed manufacturing rights - short term component	0	900
Research and development	4,046	394
Dr. Falk Pharma milestone (See Note 16)	3,059	2,634
Accrued royalties payable	1,411	263
Accrued coupon expense	1,087	463
Lease impairment	0	128
Other	1,030	1,148
Total accrued expenses	17,632	10,082
Other long-term liabilities:
Deferred rent and long-term lease abandonment charge	4,739	5,014
Total other long-term liabilities	$ 4,739	$ 5,014

Accrued Liabilities and other75

Accrued Liabilities and other Long-Term Liabilities- Accounts Payable and Other Accrued Expenses (Detail) $ in Thousands, € in Millions	Dec. 31, 2017USD ($)	Sep. 30, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2016EUR (€)	Sep. 30, 2016USD ($)
Legal	$ 1,625		$ 1,253
Other	1,030		1,148
Total	$ 36,127		$ 24,295	€ 2.5
National Holdings Corporation [Member]
Legal		$ 877			$ 1,346
Audit		176			198
Telecommunications		205			209
Data Services		464			425
Regulatory		540			444
Settlements		2,403			832
Deferred rent		497			65
Other		3,242			3,223
Total		$ 8,404			$ 6,742

Non-Controlling Interests - Sum

Non-Controlling Interests - Summary Of Non-controlling Interests in Consolidated Entities (Detail) - USD ($) $ in Thousands		3 Months Ended									12 Months Ended
		Dec. 31, 2017		Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017		Dec. 31, 2016	Dec. 31, 2015
Noncontrolling Interest [Line Items]
NCI equity share											$ 100,889		$ 60,668	$ 32,882
Net loss attributed to non-controlling interests		$ 15,605		$ 9,191	$ 5,584	$ 2,580	$ 3,871	$ 3,975	$ 3,911	$ 4,438	(32,960)		(16,195)	(5,455)
Non-controlling interests in consolidated entities		67,929					44,473				67,929		44,473	27,427
Aevitas [Member]
Noncontrolling Interest [Line Items]
NCI equity share											(126)
Net loss attributed to non-controlling interests											(168)
Non-controlling interests in consolidated entities		$ (294)									$ (294)
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		35.40%									35.40%
Avenue [Member]
Noncontrolling Interest [Line Items]
NCI equity share											$ 17,454	[1]	(494)	6
Net loss attributed to non-controlling interests											(4,646)	[1]	(349)	(567)
Non-controlling interests in consolidated entities		$ 12,808	[1]				$ (843)				$ 12,808	[1]	$ (843)	$ (561)
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		66.10%	[1]				10.20%				66.10%	[1]	10.20%	11.50%
Caelum [Member]
Noncontrolling Interest [Line Items]
NCI equity share											$ (815)
Net loss attributed to non-controlling interests											(1,262)
Non-controlling interests in consolidated entities		$ (2,077)									$ (2,077)
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		34.70%									34.70%
Cellvation [Member]
Noncontrolling Interest [Line Items]
NCI equity share											$ (259)		$ 4
Net loss attributed to non-controlling interests											(96)		(158)
Non-controlling interests in consolidated entities		$ (355)					$ (154)				$ (355)		$ (154)
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		21.50%					22.00%				21.50%		22.00%
Checkpoint Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
NCI equity share	[2]										$ 21,635		$ 32,160	$ 32,760
Net loss attributed to non-controlling interests	[2]										(12,314)		(11,733)	(3,855)
Non-controlling interests in consolidated entities	[2]	$ 9,321					$ 20,427				$ 9,321		$ 20,427	$ 28,905
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	[2]	62.00%					62.90%				62.00%		62.90%	62.30%
Coronado SO Co, Inc [Member]
Noncontrolling Interest [Line Items]
NCI equity share											$ (236)		$ (217)	$ 23
Net loss attributed to non-controlling interests											(54)		(19)	(240)
Non-controlling interests in consolidated entities		$ (290)					$ (236)				$ (290)		$ (236)	$ (217)
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		13.00%					13.00%				13.00%		13.00%	13.00%
Cyprium [Member]
Noncontrolling Interest [Line Items]
NCI equity share											$ (143)
Net loss attributed to non-controlling interests											(15)
Non-controlling interests in consolidated entities		$ (158)									$ (158)
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		11.10%									11.10%
Helocyte [Member]
Noncontrolling Interest [Line Items]
NCI equity share											$ (1,907)		$ (612)
Net loss attributed to non-controlling interests											(1,193)		(1,155)
Non-controlling interests in consolidated entities		$ (3,100)					$ (1,767)				$ (3,100)		$ (1,767)
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		20.00%					20.50%				20.00%		20.50%
JMC [Member]
Noncontrolling Interest [Line Items]
NCI equity share											$ (469)		$ (192)	$ 79
Net loss attributed to non-controlling interests											7		(355)	(420)
Non-controlling interests in consolidated entities		$ (462)					$ (547)				$ (462)		$ (547)	$ (341)
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		6.30%					7.00%				6.30%		7.00%	8.80%
Mustang Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
NCI equity share											$ 48,740	[1]	$ 12,376	$ 14
Net loss attributed to non-controlling interests											(11,911)	[1]	(1,805)	(373)
Non-controlling interests in consolidated entities		$ 36,829	[1]				$ 10,571				$ 36,829	[1]	$ 10,571	$ (359)
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		61.60%	[1]				26.70%				61.60%	[1]	26.70%	10.00%
National Holdings [Member]
Noncontrolling Interest [Line Items]
NCI equity share											$ 17,021		$ 17,643
Net loss attributed to non-controlling interests											(1,216)		(621)
Non-controlling interests in consolidated entities		$ 15,805					$ 17,022				$ 15,805		$ 17,022
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		43.40%					43.40%				43.40%		43.40%
Tamid [Member]
Noncontrolling Interest [Line Items]
NCI equity share											$ (6)
Net loss attributed to non-controlling interests											(92)
Non-controlling interests in consolidated entities		$ (98)									$ (98)
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		24.00%									24.00%
[1]	Avenue and Mustang are consolidated with Fortress’ operations because Fortess maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights.
[2]	Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.

Net Loss per Common Share - Com

Net Loss per Common Share - Computations of Diluted Weighted Average Shares Outstanding (Detail) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	13,701,104	13,676,979	9,889,452
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	745,285	456,150	685,061
Opus warrants to purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	628,383	1,780,000	0
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	1,093,283	1,604,214	1,960,443
Unvested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	9,840,614	8,749,052	6,816,321
Unvested Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	1,390,799	1,087,563	427,627
Series A Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	2,740	0	0

Net Loss per Common Share - Add

Net Loss per Common Share - Additional Information (Detail) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount	13,701,104	13,676,979	9,889,452
Restricted Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount	9,840,614	8,749,052	6,816,321

Stockholders' Equity - share ba

Stockholders' Equity - share based compensation activity (Detail)	Dec. 31, 2017shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares Authorized	12,506,679
Avenue Therapeutics, Inc. 2015 Stock Plan [Member] | Avenue [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares Authorized	2,000,000
Shares available	1,115,000
Caelum Biosciences Inc. 2017 Incentive Plan [Member] | Caelum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares Authorized	2,000,000
Shares available	125,002
Cellvation Inc. 2016 Incentive Plan [Member] | Cellvation [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares Authorized	2,000,000
Shares available	300,000
Checkpoint Therapeutics, Inc. Amended and Restated 2015 Stock Plan [Member] | Checkpoint [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares Authorized	5,000,000
Shares available	2,961,697
Cyprium Therapeutics, Inc. 2017 Stock Plan [Member] | Cyprium [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares Authorized	2,000,000
Shares available	2,000,000
DiaVax Biosciences, Inc. 2015 Incentive Plan [Member] | Helocyte [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares Authorized	2,000,000
Shares available	341,667
Journey Medical Corporation 2015 Stock Plan [Member] | Journey [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares Authorized	3,000,000
Shares available	614,792
Mustang Bio, Inc. 2016 Incentive Plan [Member] | Mustang [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares Authorized	2,000,000
Shares available	444,325
FBIO Acquisition Corp. V 2017 Incentive Plan [Member] | Tamid [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares Authorized	2,000,000
Shares available	1,600,000

Stockholders' Equity - Employee

Stockholders' Equity - Employee Stock Purchase Programs (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 14,005	$ 12,128	$ 14,291
National [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	602	42	0
Avenue [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	604	28	51
Caelum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	595	0	0
Cellvation [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	31	7	0
Checkpoint [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	3,118	3,867	3,252
Helocyte [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	128	250	0
JMC [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	224	515	597
Mustang [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2,013	0	0
Tamid [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	1	0	0
Employee Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	6,606	7,386	8,130
Executive Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	0	0	2,228
Non-Employee Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 83	$ 33	$ 33

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, Options exercised		(20,000)
Weighted Average Exercise Price, Options exercised		$ 1.37
Number of shares, Options vested and expected to vest	1,130,501	1,779,365
Number of shares, Forfeited		(648,864)
Number of shares, Options vested and expected to vest	1,085,501	1,130,501	1,779,365
Number of shares, Exercisable as of December 31, 2016		1,110,501
Weighted average exercise price, Forfeited		$ 0.51
Weighted average exercise price, Options vested and expected to vest	$ 3.75	3.73	$ 4.37
Weighted average exercise price, Exercisable as of December 31, 2016		$ 3.78
Total Weighted average intrinsic value, Options vested and expected to vest	$ 1,351,080	$ 602,451	$ 666,396
Total Weighted Average Intrinsic Value, Options exercised	52,400
Total weighted average intrinsic value, Exercisable	$ 1,351,080
Weighted average remaining contractual life (years), Options vested and expected to vest	3 years 11 months 5 days	4 years 11 months 5 days	6 years 3 months 25 days
Weighted average remaining contractual life (years), Exercisable as of December 31, 2016		3 years 11 months 12 days

Stockholders' Equity - Restrict

Stockholders' Equity - Restricted Stock Activity (Detail) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, Unvested balance	10,094,095	8,757,935
Number of shares, Restricted stock granted	1,325,396	1,240,868
Number of shares, Restricted stock cancelled		(33,333)
Number of shares, Restricted stock vested	(213,333)	(173,333)
Number of shares, Restricted stock units granted	1,128,750	641,000
Number of shares, Forfeited	(15,000)	(111,750)
Restricted stock units vested	(445,874)	(227,292)
Number of shares, Unvested balance	11,874,034	10,094,095
Weighted average grant price, Unvested balance	$ 2.49	$ 2.47
Weighted average grant price, Restricted stock granted	2.70	2.77
Weighted average grant price, Restricted stock cancelled		2.69
Weighted average grant price, Restricted stock vested	2.75	2.73
Weighted average grant price, Restricted stock units granted	4.17	2.93
Weighted average grant price, Restricted stock units cancelled	2.98	3.58
Weighted average grant price, Restricted stock units vested	3.50	3.56
Weighted average grant price, Unvested balance	$ 2.63	$ 2.49

Stockholders' Equity - Summariz

Stockholders' Equity - Summarizes Fortress warrant activities (Detail) - Warrant [Member] - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016		Dec. 31, 2015
Subsidiary or Equity Method Investee [Line Items]
Number of shares, Outstanding		2,263,453	569,835
Number of shares, Granted		816,180	1,880,000
Number of shares, Expired			(161,382)
Number of shares, Exercised	[1]		(25,000)
Number of shares, Forfeited		(305,444)
Number of shares, Outstanding		2,774,189	2,263,453		569,835
Number of shares, Exercisable		869,189
Weighted average exercise price, Outstanding		$ 3.62	$ 6.31
Weighted average exercise price, Granted		3.84	3
Weighted average exercise price, Expired			6.30
Weighted average exercise price, Exercised	[1]		1.37
Weighted average exercise price, Forfeited		7.07
Weighted average exercise price, Outstanding		3.30	$ 3.62		$ 6.31
Weighted average exercise price, Exercisable		$ 3.96
Total weighted average instrinsic value, Outstanding		$ 79,800	$ 120,700
Total weighted average intrinsic value, Granted		260,380	0
Total weighted average intrinsic value, Exercised	[1]		33,250
Total weighted average intrinsic value, Forfeited		0
Total weighted average instrinsic value, Outstanding		2,204,530	$ 79,800		$ 120,700
Total weighted average intrinsic value, Exercisable		$ 318,580
Weighted average remaining contractual life (years), Outstanding		4 years 5 months 19 days	4 years 8 months 26 days		1 year 10 months 2 days
Weighted average remaining contractual life, Granted (years)		4 years 10 months 13 days	5 years 7 months 24 days
Weighted average remaining contractual life, Exercisable (years)		4 years 18 days	0 years	[1]
[1]	cashless

Stockholders' Equity - Warrants

Stockholders' Equity - Warrants (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Volatilty	70.00%
Exercise price	$ 1.01
Mustang [Member]
Warrant Shares			1,000,000
Risk Free Rate			2.36%
Volatilty			106.11%
Life			10 years
Exercise price			$ 0.147
Fair Value			$ 135,000
Checkpoint [Member]
Warrant Shares			1,000,000
Risk Free Rate			2.36%
Volatilty			106.11%
Life			10 years
Exercise price			$ 0.129
Fair Value			$ 118,000
Avenue [Member]
Warrant Shares			1,000,000
Risk Free Rate			2.36%
Volatilty			106.11%
Life			10 years
Exercise price			$ 0.146
Fair Value			$ 134,000
CNDO SO [Member]
Warrant Shares			1,000,000
Risk Free Rate			2.36%
Volatilty			106.11%
Life			10 years
Exercise price			$ 1.19
Fair Value			$ 1,091,000
Helocyte [Member]
Warrant Shares			1,000,000
Risk Free Rate			2.36%
Volatilty			106.11%
Life			10 years
Exercise price			$ 0.097
Fair Value			$ 89,000
JMC [Member]
Warrant Shares			1,000,000
Risk Free Rate			2.36%
Volatilty			106.11%
Life			10 years
Exercise price			$ 0.65
Fair Value			$ 596,000
Escala [Member]
Warrant Shares			1,000,000
Risk Free Rate			2.36%
Volatilty			106.11%
Life			10 years
Exercise price			$ 0.071
Fair Value			$ 65,000
Cellvation [Member]
Warrant Shares		1,000,000
Risk Free Rate		2.86%
Volatilty		70.00%
Life		9 years
Exercise price		$ 0.024
Fair Value		$ 18,000
Aevitas [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	1,000,000
Risk Free Rate	1.92%
Discount for Lack of Marketability	42.60%
Volatilty	79.80%
Exercise price	$ 0.020
Fair Value	$ 20,000
Caelum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	1,000,000
Risk Free Rate	1.93%
Discount for Lack of Marketability	49.50%
Volatilty	70.00%
Exercise price	$ 0.028
Fair Value	$ 28,000
Cyprium [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	1,000,000
Risk Free Rate	1.92%
Discount for Lack of Marketability	44.20%
Volatilty	84.30%
Exercise price	$ 0.004
Fair Value	$ 4,000
Acquisition Corp. III [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	1,000,000
Risk Free Rate	1.92%
Discount for Lack of Marketability	44.00%
Volatilty	83.90%
Exercise price	$ 0.007
Fair Value	$ 7,000
Acquisition Corp. IV [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	1,000,000
Risk Free Rate	1.92%
Discount for Lack of Marketability	44.00%
Volatilty	83.90%
Exercise price	$ 0.007
Fair Value	$ 7,000
Tamid [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	1,000,000
Risk Free Rate	1.92%
Discount for Lack of Marketability	44.00%
Volatilty	83.90%
Exercise price	$ 0.007
Fair Value	$ 7,000
Acquisition Corp. VI [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	1,000,000
Risk Free Rate	1.92%
Discount for Lack of Marketability	44.00%
Volatilty	83.90%
Exercise price	$ 0.007
Fair Value	$ 7,000
Acquisition Corp. VII [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	1,000,000
Risk Free Rate	1.92%
Discount for Lack of Marketability	44.00%
Volatilty	83.90%
Exercise price	$ 0.007
Fair Value	$ 7,000
Acquisition Corp. VIII [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	1,000,000
Risk Free Rate	1.92%
Discount for Lack of Marketability	44.00%
Volatilty	83.90%
Exercise price	$ 0.007
Fair Value	$ 7,000

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	Jul. 15, 2015	Jun. 01, 2015	Dec. 01, 2017	Nov. 30, 2017	Nov. 30, 2017	Oct. 31, 2017	Jun. 26, 2017	Jun. 01, 2017	Jan. 31, 2017	Dec. 31, 2016	Jun. 01, 2016	May 31, 2016	Feb. 23, 2016	Jan. 31, 2016	Jan. 02, 2016	Dec. 02, 2015	Oct. 30, 2015	Sep. 18, 2015	Jun. 30, 2013	Dec. 31, 2016	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 15, 2017	Oct. 26, 2017	Jun. 02, 2015	Mar. 17, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Based compensation, authorized number of shares																								12,506,679
Employee Stock Purchase Plan to eligible employees, Reckoning fair value percentage during offering period			85.00%					85.00%																85.00%
Employee Stock Purchase Plan to eligible employees, compensation expense recognized																								$ 200,000	$ 0.1	$ 45,000
Common Stock issued in connection with the first ESPP offering			45,657					22,076
Share Based Compensation Restricted Stock Units																								$ 11,300,000	$ 9,900,000	6,900,000
Common Stock Par Or Stated Value Per Share			$ 3.26					$ 1.90		$ 0.001										$ 0.001				$ 0.001	$ 0.001
Share Price			$ 3.83					$ 2.24
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																								12,506,679
Proceeds from Stock Options Exercised																								$ 27,000	$ 0	216,000
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 4.02											$ 7						$ 2,500
Stock Issued During Period, Shares, Issued for Services													10,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																								7
Proceeds from issuance of Common stock							$ 34,200,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized																								7,700,000
Share-based Compensation																								$ 14,005,000	12,128,000	14,291,000
Net Proceeds From Issuance Of Warrants																								$ 51,500,000
Stock Issued For Exercise Of Warrants																								10,000
Warrant Purchase Price Per Unit																								$ 50,000
Common Stock, Capital Shares Reserved for Future Issuance																								125,000
Stock Issued During Period Shares warrants Exercised																		2,500
Stock Issued During Period, Shares, New Issues						43,292												10,000
Stock Issued During Period, Value of Warrants Excercised																		$ 50,000
Equity Method Investment, Ownership Percentage																														35.00%
Warrants Issued																	139,592
Stock Issued During Period, Value, New Issues																									53,000,000
Payments of Stock Issuance Costs																								$ 2,804,000	0	0
Adjustments To Additional Paid In Capital At Market Offering Costs																									$ (79,000)
Preferred Stock Shares Outstanding										0										0				1,000,000	0
Preferred Stock Shares Authorized										15,000,000										15,000,000				15,000,000	15,000,000
Preferred Stock, Value, Issued										$ 0										$ 0				$ 1,000	$ 0
Preferred Stock Shares Issued										0										0				1,000,000	0
Dividends, Preferred Stock																								$ 299,000
Proceeds from Issuance of Preferred Stock and Preference Stock																								$ 25,000,000	$ 0	$ 0
Payments for Other Fees				$ 2,700,000	$ 100,000																	$ 1,265,000
Proceeds from Fees Received																						14,420,000	$ 1,265,000
Percentage of Placement of Agent Fee																		10.00%						10.00%
Common Stock Shares Outstanding										48,932,023										48,932,023				50,991,285	48,932,023
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized																								$ 0
Employee Service Share Based Compensation Vested Awards Total Compensation Cost Not Yet Recognized																								0
Common Stock Value							800,000			$ 49,000										$ 49,000				$ 51,000	$ 49,000
Payments for Fees				$ 2,700,000	$ 100,000																	$ 1,265,000
Market Offering [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares Issued, Price Per Share												$ 2.89
Proceeds from issuance of Common stock												$ 400,000
Issuance of Common Stock for At the Market Offering in shares												150,556
Adjustments To Additional Paid In Capital At Market Offering Costs												$ 79,000
IPO [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fees and Commissions							$ 2,300,000
Plan 2013 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Based compensation, authorized number of shares																								10,000,000
Stock Based compensation, shares available for issuance																								3,493,321
Employee Stock Purchase Plan to eligible employees, compensation expense recognized																								$ 2,300,000,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																								10,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant																								3,493,321
Plan 2007 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Based compensation, authorized number of shares										1,500,000										1,500,000				6,000,000	1,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized										1,500,000										1,500,000				6,000,000	1,500,000
Longterm Incentive Program [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value																								$ 1,500,000	$ 1,400,000
Class of Warrant or Right, Outstanding	500,000
Weighted Market Value Percentage of Invested Capital	44.80%
Weighted Average Cost Percentage of Capital	30.00%
Stock Issued During Period, Shares, Issued for Services																								500,000
Capital Units, Authorized																								100,000,000
Share-based Compensation																								$ 600,000	300,000
Sharebased Compensation Arrangement By Sharebased Payment Award Percentage Of Shares Granted															1.00%
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners																								5.00%
Plan 2017 and 2013 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Based compensation, shares available for issuance																										16,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant																										16,000,000
Series A Preferred Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares Issued, Price Per Share				$ 25	$ 25
Stock Issued During Period, Value, New Issues				$ 25,000,000
Adjustments To Additional Paid In Capital At Market Offering Costs																									$ 0
Preferred Stock Shares Outstanding										0										0					0
Preferred Stock Shares Authorized																												5,000,000
Preferred Stock, Value, Issued																											$ 25,000,000
Preferred Stock Shares Issued										0										0					0		1,000,000
Preferred Stock, Dividend Rate, Percentage				9.375%																				9.375%
Dividends Payable, Amount Per Share																								$ 0.299479			$ 2.34375
Dividends, Preferred Stock																								$ 0
Preferred Stock, Liquidation Preference Per Share																								$ 25
Proceeds from Issuance of Preferred Stock and Preference Stock				$ 22,200,000
After Amendment [Member] | Convertible Preferred Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Price																								$ 0.001
Capital Units, Authorized																								100,000,000
Checkpoint [Member] | Private Placement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights													$ 7
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total													$ 126,640
Class of Warrant or Right, Number of Securities Called by Warrants or Rights													3,500
Warrant Purchase Price Per Unit													$ 45,000
Proceeds from Issuance of Private Placement													$ 600,000
Warrants Issued													44,324
Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																								1,900,000
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost																								$ 2,500,000	$ 400,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting year																								December 2,022
Former Board Of Director [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Restricted Stock Units	$ 133,000
Dr. Rosenwald [Member] | Longterm Incentive Program [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period									552,698					510,434
Mustang [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Based compensation, authorized number of shares																								8,610,774
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																								8,610,774
Stock Issued During Period, Value, New Issues																								$ 56,000,000
Warrants Issued number																								2,152,693
Proceeds from Fees Received																								$ 5,600,000
Percentage of Placement of Agent Fee																								10.00%
Warrants Issued on During Period																								861,077
Senior Vice President [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50.00%
Stock Issued During Period, Value, Issued for Services																								$ 300,000	$ 1,200,000	$ 1,900,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																			200,000
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost	$ 3,700,000
Non-employee [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation																										3,000,000
Avenue Therapeutics, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares Issued, Price Per Share							$ 6
Mustang Bio, Inc [Member] | Private Placement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights																					$ 8.50		$ 8.50
Stock Issued During Period, Value, New Issues																					$ 39,100,000
Mustang Bio, Inc [Member] | Market Offering [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Issued During Period Shares warrants Exercised																				2,500
Stock Issued During Period, Value of Warrants Excercised																				$ 65,000
Checkpoint Therapeutics, Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity Method Investment, Ownership Percentage																								37.70%
Stock Issued During Period, Value, New Issues																								$ 57,800,000
National Holdings Corporation [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights																					$ 3.25		$ 3.25
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							125,000
National Holdings Corporation [Member] | Private Placement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Issued During Period Shares warrants Exercised																				10
Payments of Stock Issuance Costs																				$ 3,900,000
Private Placement Stock Units Shares To Be Issued										10,000										10,000					10,000
Warrants Issued During Period																								601,486
National Securities Corp [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Payments for Other Fees				2,100,000
Payments for Fees				$ 2,100,000
Research and Development Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense																								$ 4,000,000	$ 4,700,000	5,800,000
General and Administrative Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense																								10,000,000	7,400,000	8,500,000
General and Administrative Expense [Member] | Longterm Incentive Program [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation																								$ 100,000	$ 18,000	2,200,000
Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Restricted Stock Units																										$ 400,000
Deferred Compensation Arrangement with Individual, Shares Issued																								230,000	230,000	290,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted in Period, Fair Value																								$ 3,600,000	$ 3,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period																								1,325,396	1,240,868
Restricted Stock Units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition																								4 years 7 months 6 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options																								$ 3,200,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted in Period, Fair Value																								$ 4,700,000	$ 1,800,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period																								1,128,750	641,000
Restricted Stock Units (RSUs) [Member] | Senior Vice President [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares																								150,000	150,000	300,000
New Award [Member] | Senior Vice President [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost	$ 3,300,000
Old Award [Member] | Senior Vice President [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost	$ 400,000
Employee Stock Option [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Stock Purchase Plan to eligible employees, Reckoning fair value percentage during offering period										85.00%						85.00%				85.00%					85.00%				85.00%
Employee Stock Purchase Plan to eligible employees, Number of shares purchased by employees	85
Common Stock issued in connection with the first ESPP offering		14,681								52,769	33,958					13,317								245,652
Common Stock Par Or Stated Value Per Share	$ 2.40															$ 2.41													$ 1.80
Share Price										$ 2.39	$ 2.82					$ 2.84				$ 2.39					$ 2.39				$ 2.12
Proceeds from Stock Options Exercised																								$ 27,000	$ 0	$ 200,000
Common Stock, Capital Shares Reserved for Future Issuance																								154,348
Unvested Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition																								1 year 6 months
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options																								$ 3,400,000

Commitments and Contingencies -

Commitments and Contingencies - Total future minimum lease payments (Detail) $ in Thousands	Dec. 31, 2017USD ($)
Operating Leased Assets [Line Items]
2,018	$ 2,761
2,019	2,976
2,020	3,203
2,021	3,084
2,022	3,084
Thereafter	26,600
Total minimum lease payments	41,708
National Holdings [Member]
Operating Leased Assets [Line Items]
2,018	3,040
2,019	2,481
2,020	2,346
2,021	2,043
2,022	1,331
Thereafter	4,524
Total minimum lease payments	15,765
Less, Sublease Income 2018	360
Less, Sublease Income 2019	30
Less, Sublease Income 2020	0
Less, Sublease Income 2021	0
Less, Sublease Income 2022	0
Less, Sublease Income Thereafter	0
Less, Sublease Income Total	390
Net, 2018	2,680
Net, 2019	2,451
Net, 2020	2,346
Net, 2021	2,043
Net, 2022	1,331
Net, Thereafter	4,524
Net, Total	$ 15,375

Commitments and Contingencies87

Commitments and Contingencies - Additional Information (Detail) € in Millions	Aug. 02, 2017EUR (€)	Oct. 03, 2014USD ($)	Nov. 30, 2017USD ($)	Oct. 27, 2017USD ($)a	Sep. 30, 2017USD ($)	Aug. 31, 2017EUR (€)	Jun. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2016USD ($)	Jul. 31, 2016USD ($)a	Oct. 31, 2015USD ($)ft²	Apr. 30, 2013USD ($)ft²	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2012USD ($)ft²	Dec. 31, 2017EUR (€)	Dec. 31, 2016EUR (€)	Mar. 20, 2012EUR (€)
Operating Leased Assets [Line Items]
Land Subject to Ground Leases										2,295	6,100					8,700
Operating Leases, Rent Expense		$ 2,700,000					$ 55,000			$ 53,000	$ 200,000					$ 100,000
Operating Leases, Rent Expense, Net, Total													$ 1,200,000	$ 1,800,000	$ 400,000
Lease Expiration Period											5 years
Prepaid Rent													1,000,000		200,000
Accounts Payable and Accrued Liabilities, Current													36,127,000	24,295,000				€ 2.5
Legal Fees					$ 1,500,000				$ 200,000
Payments of Stock Issuance Costs													2,804,000	0	0
Letter of Credit [Member]
Operating Leased Assets [Line Items]
Operating Leases, Rent Expense					4,300,000
Collateralized Agreements					1,400,000			$ 400,000	$ 400,000
Increase (Decrease) in Security Deposits				$ 1,000,000
General and Administrative Expense [Member]
Operating Leased Assets [Line Items]
Legal Fees			$ 2,200,000
New York, NY office space [Member]
Operating Leased Assets [Line Items]
Lease Expiration Period		15 years
Opus Point Partners Management, LLC [Member]
Operating Leased Assets [Line Items]
Operating Leases, Rent Expense		$ 300,000
Percentage of Rentable Area		10.00%
Prepaid Rent													1,000,000	1,300,000	200,000
TG Therapeutics, Inc [Member]
Operating Leased Assets [Line Items]
Operating Leases, Rent Expense		$ 1,100,000
Percentage of Rentable Area		45.00%
Journey Medical Corporation [Member]
Operating Leased Assets [Line Items]
Operating Leases, Rent Expense, Net, Total													0	100,000	0
TSO Laboratories, Inc [Member]
Operating Leased Assets [Line Items]
Operating Leases, Rent Expense								200,000
Operating Leases, Income Statement, Sublease Revenue								$ 8,200
Lease Expiration Date																Feb. 28, 2018
Operating Leases, Rent Expense, Sublease Rentals					$ 200,000
Mustang [Member]
Operating Leased Assets [Line Items]
Land Subject to Ground Leases | a				27,043
Operating Leases, Rent Expense, Net, Total													0.1	0	$ 0
Payments for Legal Settlements			$ 200,000
Operating Leases, Rent Expense, Sublease Rentals				$ 3,600,000
Land Improvements				3,500,000
Security Deposit				800,000
Increase (Decrease) in Security Deposits				1,300,000
Mustang [Member] | Cash [Member]
Operating Leased Assets [Line Items]
Security Deposit				300,000
Increase (Decrease) in Security Deposits				300,000
Mustang [Member] | Letter of Credit [Member]
Operating Leased Assets [Line Items]
Increase (Decrease) in Security Deposits				$ 500,000
Dr.Falk Pharma [Member]
Operating Leased Assets [Line Items]
Contractual Obligation | €																			€ 2.5
Loss Contingency, Damages Sought, Value | €						€ 2.5
Loss Contingency, Damages Awarded, Value | €	€ 2.5
Accounts Payable and Accrued Liabilities, Current													$ 3,000,000	$ 2,600,000			€ 2.5
Lease Agreements [Member]
Operating Leased Assets [Line Items]
Land Subject to Ground Leases | ft²												1,500
Operating Leases, Rent Expense												$ 100,000

Employee Benefit Plan - Additio

Employee Benefit Plan - Additional Information (Detail) - USD ($) $ in Millions	Jan. 01, 2008	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Defined Benefit Plan Disclosure [Line Items]
Employee contribution percentage	4.00%
Employer matching contribution		$ 0.2	$ 0.2	$ 0.1
National Holdings [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent		75.00%

Related Party Transactions - Sc

Related Party Transactions - Schedule of Effective Date and Equity Fee Payble (Detail)	12 Months Ended
	Dec. 31, 2017
Helocyte Inc [Member]
Related Party Transaction [Line Items]
Dividends Paid in kind percentage	2.50%
Dividends Payable, Date Declared	Mar. 20, 2015	[1]
Avenue Therapeutics, Inc. [Member]
Related Party Transaction [Line Items]
Dividends Paid in kind percentage	2.50%
Dividends Payable, Date Declared	Feb. 17, 2015	[1]
Mustang Bio, Inc [Member]
Related Party Transaction [Line Items]
Dividends Paid in kind percentage	2.50%
Dividends Payable, Date Declared	Mar. 13, 2015	[1]
Checkpoint Therapeutics, Inc [Member]
Related Party Transaction [Line Items]
Dividends Paid in kind percentage	0.00%	[2]
Dividends Payable, Date Declared	Mar. 17, 2015	[1]
Cellvation Inc [Member]
Related Party Transaction [Line Items]
Dividends Paid in kind percentage	2.50%
Dividends Payable, Date Declared	Oct. 31, 2016	[1]
Caelum Bio sciences Inc [Member]
Related Party Transaction [Line Items]
Dividends Paid in kind percentage	2.50%
Dividends Payable, Date Declared	Jan. 1, 2017	[1]
Cyprium Bio sciences Inc [Member]
Related Party Transaction [Line Items]
Dividends Paid in kind percentage	2.50%
Dividends Payable, Date Declared	Mar. 13, 2017	[1]
Aevitas Inc [Member]
Related Party Transaction [Line Items]
Dividends Paid in kind percentage	2.50%
Dividends Payable, Date Declared	Jul. 28, 2017	[1]
Tamid [Member]
Related Party Transaction [Line Items]
Dividends Paid in kind percentage	2.50%
Dividends Payable, Date Declared	Nov. 30, 2017	[1],[3]
[1]	Represents the effective date of each subsidiary’s Founders Agreement. Each PIK dividend and equity fee is payable on the annual anniversary of the effective date of the original Founders Agreement.
[2]	Instead of a PIK dividend, Checkpoint pays the Company an annual equity fee in shares of Checkpoint’s common stock equal to 2.5% of Checkpoint’s fully diluted outstanding capitalization.
[3]	Represents the Trigger Date

Related Party Transactions - 90

Related Party Transactions - Schedule of dividend or equity fee recorded by the Company (Detail) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2017		Dec. 31, 2016
Dividends Payable, Current		$ 0	[1]	$ 0
Aevitas [Member]
Dividends Payable Date Of Record Description	[2]	July 28
Dividends Payable, Current	[2]	$ 0	[1]	0
Avenue [Member]
Dividends Payable Date Of Record Description		February 17
Dividends Payable, Current		$ 1,103	[1]	49
Caelum [Member]
Dividends Payable Date Of Record Description		January 1
Dividends Payable, Current		$ 302	[1]	0
Cellvation [Member]
Dividends Payable Date Of Record Description		October 31
Dividends Payable, Current		$ 8	[1]	0
Checkpoint [Member]
Dividends Payable Date Of Record Description		March 17
Dividends Payable, Current		$ 2,296	[1]	3,919
Cyprium [Member]
Dividends Payable Date Of Record Description		January 1
Dividends Payable, Current		$ 1	[1]	0
Helocyte [Member]
Dividends Payable Date Of Record Description		March 20
Dividends Payable, Current		$ 321	[1]	0
Mustang [Member]
Dividends Payable Date Of Record Description		March 13
Dividends Payable, Current		$ 9,479	[1]	4,396
Tamid [Member]
Dividends Payable Date Of Record Description	[3]	November 30
Dividends Payable, Current	[3]	$ 0	[1]	0
Fortress [Member]
Dividends Payable, Current		$ (13,510)	[1]	$ (8,364)
[1]	Includes 2018 PIK dividend accrued for the year ended December 31, 2017, as Type 1 subsequent event.
[2]	Aevitas PIK dividend wll be recorded during the third quarter of 2018
[3]	Tamid PIK dividend will be recorded during the fourth quarter of 2018

Related Party Transactions - 91

Related Party Transactions - Schedule of The Effective Date and Annual Management Services agreement Fee (Income) Expense (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	$ 0
Helocyte Inc [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	$ 500
Annual Consulting Fee Payable Effective Date	Mar. 20, 2015
Avenue Therapeutics, Inc. [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	$ 500
Annual Consulting Fee Payable Effective Date	Feb. 17, 2015
Mustang Bio, Inc [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	$ 500
Annual Consulting Fee Payable Effective Date	Mar. 13, 2015
Checkpoint Therapeutics, Inc [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	$ 500
Annual Consulting Fee Payable Effective Date	Mar. 17, 2015
Cellvation Inc [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	$ 500
Annual Consulting Fee Payable Effective Date	Oct. 31, 2016
Caelum Bio sciences Inc [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	$ 500
Annual Consulting Fee Payable Effective Date	Jan. 1, 2017
Cyprium Bio sciences Inc [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	$ 500
Annual Consulting Fee Payable Effective Date	Mar. 13, 2017
Aevitas Inc [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	$ 500
Annual Consulting Fee Payable Effective Date	Jul. 28, 2017
Tamid Bio sciences Inc [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	$ 500	[1]
Annual Consulting Fee Payable Effective Date	Nov. 30, 2017
Fortress Biotech Inc [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	$ (4,500)
Research and Development Expense [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	0
Research and Development Expense [Member] | Helocyte Inc [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	250
Research and Development Expense [Member] | Avenue Therapeutics, Inc. [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	250
Research and Development Expense [Member] | Mustang Bio, Inc [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	250
Research and Development Expense [Member] | Checkpoint Therapeutics, Inc [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	250
Research and Development Expense [Member] | Cellvation Inc [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	250
Research and Development Expense [Member] | Caelum Bio sciences Inc [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	250
Research and Development Expense [Member] | Cyprium Bio sciences Inc [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	250
Research and Development Expense [Member] | Aevitas Inc [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	250
Research and Development Expense [Member] | Tamid Bio sciences Inc [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	250	[1]
Research and Development Expense [Member] | Fortress Biotech Inc [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	(2,250)
Selling, General and Administrative Expenses [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	0
Selling, General and Administrative Expenses [Member] | Helocyte Inc [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	250
Selling, General and Administrative Expenses [Member] | Avenue Therapeutics, Inc. [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	250
Selling, General and Administrative Expenses [Member] | Mustang Bio, Inc [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	250
Selling, General and Administrative Expenses [Member] | Checkpoint Therapeutics, Inc [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	250
Selling, General and Administrative Expenses [Member] | Cellvation Inc [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	250
Selling, General and Administrative Expenses [Member] | Caelum Bio sciences Inc [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	250
Selling, General and Administrative Expenses [Member] | Cyprium Bio sciences Inc [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	250
Selling, General and Administrative Expenses [Member] | Aevitas Inc [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	250
Selling, General and Administrative Expenses [Member] | Tamid Bio sciences Inc [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	250	[1]
Selling, General and Administrative Expenses [Member] | Fortress Biotech Inc [Member]
Related Party Transaction [Line Items]
Annual Management Services Agreement Fee Income expense	$ (2,250)
[1]	Represents the Trigger Date

Related Party Transactions Sche

Related Party Transactions Schedule of Information about Fees Earned (Detail) - USD ($) $ in Thousands	1 Months Ended		9 Months Ended
	Nov. 30, 2017	Nov. 30, 2017	Sep. 30, 2017	Sep. 30, 2016
Related Party Transaction [Line Items]
Gross Proceeds from Fee Received			$ 15,685
Less:	$ 2,700	$ 100	1,265
Proceeds from Fees Received			14,420	1,265
Fortress [Member]
Related Party Transaction [Line Items]
Gross Proceeds from Fee Received			2,836	0
Avenue [Member]
Related Party Transaction [Line Items]
Gross Proceeds from Fee Received			2,331	0
Mustang [Member]
Related Party Transaction [Line Items]
Gross Proceeds from Fee Received			9,527	1,265
Caelum [Member]
Related Party Transaction [Line Items]
Gross Proceeds from Fee Received			$ 991	$ 0

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	Oct. 03, 2014	Nov. 30, 2017	Nov. 30, 2017	Oct. 31, 2017	Jul. 31, 2017	Jun. 30, 2017	Jun. 26, 2017	Mar. 17, 2017	Sep. 30, 2016	Jul. 31, 2016	May 31, 2016	Apr. 27, 2016	Oct. 31, 2015	Sep. 18, 2015	May 31, 2015	Sep. 30, 2014	Sep. 30, 2017	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2012	Sep. 09, 2016	Mar. 17, 2014
Related Party Transaction [Line Items]
Interest own in percent by family members of principal stockholder or director																			0.00%
Costs and Expenses, Related Party																			$ 0	$ 84,000	$ 24,000
Payments for Fees		$ 2,700,000	$ 100,000															$ 1,265,000
Operating Leases, Rent Expense	$ 2,700,000					$ 55,000				$ 53,000			$ 200,000									$ 100,000
Lease Sharing Agreements Contributions To Property Under Lease																			163,000	4,800,000
Business Combination, Consideration Transferred																			$ 22,872,000
Equity Method Investment, Ownership Percentage																								35.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																			7
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 4.02							$ 7					$ 2,500
Proceeds from Convertible Debt																			$ 9,914,000	4,609,000	0
Payments of Financing Costs																			$ 0	0	855,000
Stock Issued During Period, Shares, New Issues				43,292										10,000
Stock Issued During Period, Value, New Issues																				53,000,000
Maximum [Member]
Related Party Transaction [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights																			$ 4.75
Minimum [Member]
Related Party Transaction [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights																			$ 3.61
National Holdings Corporation [Member]
Related Party Transaction [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired								56.60%	56.60%			56.00%											56.60%
Business Combination, Consideration Transferred									$ 22,900,000			$ 22,900,000
NSC Note [Member]
Related Party Transaction [Line Items]
Payments for Rent								$ 2,800,000
Percentage Of Placement Agent Fee								10.00%
Warrant on Sale Price of Note Percentage								10.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																			716,180
Opus Credit Facility [Member]
Related Party Transaction [Line Items]
Payments of Loan Costs																			$ 1,100,000	$ 200,000	$ 0
Caelum Convertible Notes [Member]
Related Party Transaction [Line Items]
Payments for Fees																			$ 1,000,000
Debt Instrument, Face Amount					$ 10,000,000
Proceeds from Convertible Debt					$ 9,900,000
Debt Instrument Issuance Percentage of Commission					10.00%
Payments of Financing Costs					$ 1,000,000
Class of Warrant or Right Percentage Securities Called by Warrants or Rights					10.00%
Class Of Warrant Or Right Exercise Price Percentage Of Warrants Or Rights					110.00%
Class of Warrant or Right Exercise Price Description																			the exercise price will be $75 million dollars divided by the total number of fully-diluted shares of Common Stock outstanding immediately prior to exercise of the warrant, giving effect to the assumed conversion of all options, warrants, and convertible securities of the Company
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Interest own in percent by principal stockholder or director																			13.00%	12.30%	12.20%
Chord Advisors, LLC [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party															$ 10,000
Board of Directors Chairman [Member] | National Holdings Corporation [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage									4.60%
TG Therapeutics, Inc [Member]
Related Party Transaction [Line Items]
Payments for Rent																			$ 1,000,000	$ 400,000
Percentage of Rentable Area											45.00%					40.00%
Operating Leases, Rent Expense																$ 1,100,000
Due from Related Parties, Current																			135,000	95,000
Checkpoint [Member] | Chord Advisors, LLC [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party																			$ 65,000	75,000	$ 10,000
Founders Agreement [Member]
Related Party Transaction [Line Items]
Agreement Description Term																			The Company has entered into Founders Agreements with certain Fortress Companies. Pursuant to each Founders Agreement, in exchange for the time and capital expended in the formation of each Fortress Company and the identification of specific assets the acquisition of which result in the formation of a viable emerging growth life science company, the Company will loan each Fortress Company an amount representing the up-front fee required to acquire assets. Each Founders Agreement has a term of 15 years, which upon expiration automatically renews for successive one-year periods unless terminated by the Company or a Change in Control (as defined in the Founders Agreement) occurs. In connection with each Founders Agreement the Company receives 250,000 Class A Preferred shares (except for that with Checkpoint, in which the Company holds Class A Common Stock). The Class A Preferred Stock (Class A Common Stock with respect to Checkpoint) is identical to common stock other than as to voting rights, conversion rights and the PIK Dividend right (as described below). Each share of Class A Preferred Stock (Class A Common Stock with respect to Checkpoint) is entitled to vote the number of votes that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A) the shares of outstanding common stock and (B) the whole shares of common stock into which the shares of outstanding Class A Preferred Stock (Class A Common Stock with respect to Checkpoint) are convertible and the denominator of which is the number of shares of outstanding Class A Preferred Stock (Class A Common Stock with respect to Checkpoint). Thus, the Class A Preferred Stock (Class A Common Stock with respect to Checkpoint) will at all times constitute a voting majority. Each share of Class A Preferred Stock (Class A Common Stock with respect to Checkpoint) is convertible, at the holder’s option, into one fully paid and nonassessable share of common stock of such Fortress Company, subject to certain adjustments. The holders of Class A Preferred Stock (and the Class A Common Stock with respect to Checkpoint), as a class, are entitled receive on each effective date or “Trigger Date” (defined as the date that the Company first acquired, whether by license or otherwise, ownership rights to a product) of each agreement (each a “PIK Dividend Payment Date”) until the date all outstanding Class A Preferred Stock (Class A Common Stock with respect to Checkpoint) is converted into common stock or redeemed (and the purchase price is paid in full), pro rata per share dividends paid in additional fully paid and nonassessable shares of common stock (“PIK Dividends”) such that the aggregate number of shares of common stock issued pursuant to such PIK Dividend is equal to two and one-half percent (2.5%) of such Fortress Company’s fully-diluted outstanding capitalization on the date that is one (1) business day prior to any PIK Dividend Payment Date. The Company has reached agreements with several of the Fortress Companies to change the PIK Dividend Interest Payment Date to January 1 of each year – a change that has not and will not result in the issuance of any additional Fortress Company common stock beyond that amount to which the Company would otherwise be entitled absent such change(s). The Company owns 100% of the Class A Preferred Stock (Class A Common Stock with respect to Checkpoint) of each Fortress Company that has a Founders Agreement with the Company. As additional consideration under the Founders Agreement, each Fortress Company with which the Company has entered into a Founders Agreement will also: (i) pay an equity fee in shares of the common stock of such Fortress Company, payable within five (5) business days of the closing of any equity or debt financing for each Fortress Company or any of its respective subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when the Company no longer has majority voting control in such Fortress Company’s voting equity, equal to two and one-half (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to four and one-half percent (4.5%) of such Fortress Company’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a Change in Control, each such Fortress Company will pay a one-time change in control fee equal to five (5x) times the product of (A) net sales for the twelve (12) months immediately preceding the change in control and (B) four and one-half percent (4.5%).
Founders Agreement [Member] | Caelum Convertible Notes [Member]
Related Party Transaction [Line Items]
Other Fee Percentage																	2.50%
Stock Issued During Period, Shares, Conversion of Convertible Securities																	218,000
Stock Issued During Period, Value, Conversion of Convertible Securities																	$ 200,000
OPPM [Member]
Related Party Transaction [Line Items]
Payments for Rent																			$ 24,000	2,100,000
Percentage of Rentable Area											10.00%					20.00%
Operating Leases, Rent Expense																$ 500,000
Lease Improvement Cost Associate With Lease																			5,100,000
Due from Related Parties, Current																			$ 6,600	500,000
Executives Vice Chairman [Member]
Related Party Transaction [Line Items]
Interest own in percent by principal stockholder or director																			15.20%		14.80%
Mustang [Member] | Chord Advisors, LLC [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party											$ 7,500
Avenue [Member]
Related Party Transaction [Line Items]
Payments For Underwriter Fees							$ 2,300,000
Avenue [Member] | Chord Advisors, LLC [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party															$ 5,000				$ 64,700	15,000	$ 0
Avenue [Member] | Founders Agreement [Member]
Related Party Transaction [Line Items]
Other Fee Percentage						2.50%	2.50%
Stock Issued During Period, Shares, New Issues							158,000
Stock Issued During Period, Value, New Issues							$ 900,000
Desk Share Agreements [Member]
Related Party Transaction [Line Items]
Payments for Rent																			2,400,000	1,000,000
Shared Services Agreement [Member] | TG Therapeutics, Inc [Member]
Related Party Transaction [Line Items]
Proceeds from Related Party Agreement																			1,000,000	800,000
Due from Related Parties, Current																			$ 900,000	$ 71,800

Income Taxes - components of th

Income Taxes - components of the income tax provision (benefit) (Detail) - USD ($) $ in Thousands	3 Months Ended				12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Current
Federal					$ 1,074	$ 0
State					439	0
Deferred
Federal					0	0
State					0	0
Total	$ 1,513	$ 0	$ 0	$ 0	$ 1,513	$ 0	$ 0

Income Taxes - Significant Comp

Income Taxes - Significant Components of Company's Deferred Taxes Consist (Detail) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets:
Net operating loss carryforwards	$ 71,616	$ 76,486
Amortization of license fees	13,648	7,277
Amortization of in-process R&D	557	742
Stock compensation	10,682	10,899
Accruals and reserves	5,166	4,025
Tax credits	7,376	6,305
Start up costs	75	98
Unrealized loss on investments	0	1,095
Total deferred tax assets	109,120	106,927
Less: valuation allowance	(101,645)	(94,687)
Net deferred tax assets	7,475	12,240
Deferred tax liabilities:
Unrealized gain/loss on investment	(685)	0
Intangibles	(3,321)	(4,450)
Basis in subsidiary	(3,469)	(7,790)
Total deferred tax assets, net	$ 0	$ 0

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Statutory Tax Rates and Effective Tax Rates (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Percentage of pre-tax income:
U.S. federal statutory income tax rate	35.00%	35.00%	35.00%
State taxes, net of federal benefit	8.00%	3.00%	5.00%
Credits	1.00%	2.00%	1.00%
Non-deductible items	(2.00%)	(4.00%)	0.00%
Provision to return	1.00%	2.00%	0.00%
Stock based compensation shortfall	(1.00%)	(2.00%)	(1.00%)
Change in federal rate	(43.00%)	0.00%	0.00%
Change in state rate	2.00%	0.00%	0.00%
Intercomapny elimination adjustments	(3.00%)	0.00%	0.00%
Change in fair value of warrants	3.00%	0.00%	0.00%
Change in valuation allowance	(7.00%)	(33.00%)	(44.00%)
Change in subsidiary basis	4.00%	(3.00%)	3.00%
Other	0.00%	0.00%	1.00%
Effective income tax rate	(2.00%)	0.00%	0.00%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Line Items]
Deferred Tax Assets, Valuation Allowance		$ 101,645	$ 94,687
Operating Loss Carryforwards, Valuation Allowance		$ 101,600,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		35.00%	35.00%	35.00%
Deferred Income Tax Expense (Benefit)		$ 0	$ (73,000)	$ 0
Income Tax Credits and Adjustments		7,500,000
Scenario, Plan [Member]
Income Tax Disclosure [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%
National Holdings Corporation [Member]
Income Tax Disclosure [Line Items]
Deferred Tax Assets, Valuation Allowance			$ 8,800,000
Operating Loss Carryforwards, Valuation Allowance		259,000,000
Business Acquisition, Percentage of Voting Interests Acquired			56.00%
State and Local Jurisdiction [Member]
Income Tax Disclosure [Line Items]
Deferred Tax Assets, Valuation Allowance		$ 7,000,000

Net Capital Requirements of B98

Net Capital Requirements of Broker-Dealer Subsidiaries - Additional Information (Detail)	Sep. 30, 2017USD ($)
Minimum [Member]
Ratio of Indebtedness to Net Capital	1
Maximum [Member]
Ratio of Indebtedness to Net Capital	15
National Securities [Member]
Net Capital	$ 9,200,000
Excess Net Capital at 1000 Percent	9,000,000
Minimum Net Capital Required for Broker-Dealer Subsidiary	250,000
Vfinance Investments [Member]
Net Capital	1,400,000
Excess Net Capital at 1000 Percent	400,000
Minimum Net Capital Required for Broker-Dealer Subsidiary	$ 1,000,000
Vfinance Investments [Member] | Minimum [Member]
Ratio of Indebtedness to Net Capital	8
Vfinance Investments [Member] | Maximum [Member]
Ratio of Indebtedness to Net Capital	1

Segment Information - Operating

Segment Information - Operating Results by Reportable Segment (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Net Revenue									$ 187,584	$ 16,480	$ 863
Direct cost of goods									(3,658)	(790)	0
Sales and marketing costs									(10,410)	(5,774)	(2,850)
Research and development									(52,486)	(35,134)	(29,810)
General and administrative									(40,487)	(28,229)	(18,734)
National expenses									288,792	82,190	51,394
Segment loss from operations	$ (73,154)	$ (79,489)	$ (73,890)	$ (62,259)	$ (32,217)	$ (17,180)	$ (17,042)	$ (15,571)	(101,208)	(65,710)	(50,531)
Segment assets	245,950				170,731				245,950	170,731	118,610
Dermatology Products Sales [Member]
Segment Reporting Information [Line Items]
Net Revenue									15,520	3,587	273
Direct cost of goods									(3,658)	(790)	0
Sales and marketing costs									(10,410)	(5,774)	(2,850)
Research and development									0	0	0
General and administrative									(1,140)	(1,474)	(1,682)
National expenses									0
Segment loss from operations									312	(4,451)	(4,259)
Segment assets	9,644				4,469				9,644	4,469	1,965
Pharmaceutical And Biotechnology Product Development [Member]
Segment Reporting Information [Line Items]
Net Revenue									1,725	2,570	590
Direct cost of goods									0	0	0
Sales and marketing costs									0	0	0
Research and development									(52,486)	(35,134)	(29,810)
General and administrative									(39,347)	(26,755)	(17,052)
National expenses									0
Segment loss from operations									(90,108)	(59,319)	(46,272)
Segment assets	187,941				115,145				187,941	115,145	116,542
National [Member]
Segment Reporting Information [Line Items]
National expenses										(12,263)
Consolidated [Member]
Segment Reporting Information [Line Items]
National expenses										(12,263)
Financial Service Activities [Member]
Segment Reporting Information [Line Items]
Net Revenue									170,339	10,323	0
Direct cost of goods									0	0	0
Sales and marketing costs									0	0	0
Research and development									0	0	0
General and administrative									0	0	0
National expenses									(181,751)
Segment loss from operations									(11,412)	(1,940)	0
Segment assets	$ 48,365				$ 51,117				$ 48,365	$ 51,117	$ 0

Segment Information - Additiona

Segment Information - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2017	Sep. 30, 2016
Segment Reporting Information [Line Items]
Accounts Receivable, Net				$ 5.2	$ 5.4
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Segment Reporting Information [Line Items]
Concentration Risk, Percentage			100.00%
Customer One [Member]
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Gross	$ 10.8	$ 1.9
Accounts Receivable, Net	1.9	1.1
Customer Two [Member]
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Gross	7.7	1.1
Accounts Receivable, Net	1.5	0.5
Customer Three [Member]
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Gross	5.4	$ 0.7
Accounts Receivable, Net	$ 0.9

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Mar. 08, 2018	Sep. 14, 2016	Feb. 28, 2018	Oct. 31, 2017	Jun. 26, 2017	Sep. 18, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Mar. 16, 2018
Subsequent Event [Line Items]
Stock Issued During Period, Value, New Issues								$ 53,000
Payments of Stock Issuance Costs							$ 2,804	$ 0	$ 0
Stock Issued During Period, Shares, New Issues				43,292		10,000
Debt Instrument, Interest Rate, Stated Percentage							28.00%
Debt Instrument, Maturity Date, Description							May - 2018
Proceeds from issuance of Common stock					$ 34,200
Opus Credit Facility [Member]
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		12.00%
DebtInstrument Expiration period		Sep. 14, 2018
Subsequent Event [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount			$ 6,500
Cash fee Rate			8.00%
Maximum Cash Fee Expenses			$ 300
Debt Instrument, Interest Rate, Stated Percentage			8.00%
Line of Credit Facility, Maximum Borrowing Capacity			$ 30,000
Debt Instrument, Maturity Date, Description			Each Note matures on the 24 month anniversary of issuance, provided that the Company may extend the maturity date for two six-month periods.
DebtInstrument Expiration period			Mar. 31, 2018
Subsequent Event [Member] | Checkpoint [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Value, New Issues	$ 23,000
Payments of Stock Issuance Costs	$ 2,000
Stock Issued During Period, Shares, New Issues	4,600,000
Shares Issued, Price Per Share	$ 4.35
Payment Of Placement Agent Fee			$ 500
Proceeds from Issuance of Long-term Debt			$ 6,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	690,000
Proceeds from issuance of Common stock	$ 21,000
Subsequent Event [Member] | Opus Credit Facility [Member]
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Stated Percentage										12.00%

Selected Quarterly Financial102

Selected Quarterly Financial Data (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Quarterly Financial Information [Line Items]
Total Revenue	$ 45,319	$ 46,886	$ 50,697	$ 44,682	$ 14,405	$ 975	$ 2,230	$ 660	$ 187,584	$ 16,480	$ 863
Operating expenses	(73,154)	(79,489)	(73,890)	(62,259)	(32,217)	(17,180)	(17,042)	(15,571)	(101,208)	(65,710)	(50,531)
Other income/(expense)	3,330	(3,704)	244	3,015	(2,065)	(710)	(1,253)	(1,552)
Net loss attributable to common stockholders	(10,413)	(27,116)	(17,365)	(11,982)	(17,431)	(12,981)	(12,478)	(12,205)	(66,876)	(55,095)	(48,428)
Income tax expense	1,513	0	0	0					1,513	0	0
Non controlling interests	$ 15,605	$ 9,191	$ 5,584	$ 2,580	$ 3,871	$ 3,975	$ 3,911	$ 4,438	$ (32,960)	$ (16,195)	$ (5,455)
Basic and diluted net loss per common share	$ (0.25)	$ (0.67)	$ (0.43)	$ (0.30)	$ (0.43)	$ (0.32)	$ (0.31)	$ (0.31)	$ (1.61)	$ (1.38)	$ (1.24)